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1
1. Hematopoiesis 
1.1 Introduction 
Hematopoietic stem cells (HSCs), which reside in the fetal liver during embryonic 
development and in the bone marrow after birth, give rise to all mature cell types of the 
blood and immune system. They are defined by their self-renewal capacity and consist 
of two functionally distinct populations, long-term and short-term HSCs (LT-HSCs and 
ST-HSCs). The LT-HSCs have extensive self-renewing potential and give rise to ST-
HSCs with more restricted self-renewing capacity [1]. The latter further differentiate 
into multipotent progenitors (MPPs), which have only limited self-renewal ability but 
are capable of differentiating into multiple lineages [2]. At this stage, lineage restriction 
occurs, and MPPs are directed into either the myeloid or the lymphoid lineage [3]. The 
myeloid potential is suppressed during the differentiation of lymphoid-primed multipotent 
progenitors (LMPPs) into common lymphoid progenitors (CLPs) (Figure 1) [4]. These 
CLPs differentiate towards a diversity of cell types, including B- and T-cells, as well 
as innate lymphoid cells, including NK cells, while granulocytes, megakaryocytes and 
erythrocytes derive from the common myeloid progenitors (CMP) (Figure 1) [5, 6]. For the 
generation of B-cells, CLPs initiate a B-cell gene expression program and differentiate 
via the pre-pro B cell stage to pro-B cells. Pro-B cells subsequently develop into pre-B 
cells by undergoing IgH rearrangements. These pre-B cells express the pre-B cell 
receptor (pre-BCR) and undergo Ig light chain rearrangements to further differentiate 
into immature B-cells. These pre-B cells subsequently migrate from the bone marrow 
to the spleen, where they develop into various mature B-cell subtypes [7, 8]. 
1.2 Transcriptional networks controlling  B-cell differentiation
HSC differentiation and self-renewal are strictly regulated by transcription factors 
and controlled by several feedback mechanisms that maintain homeostasis of the 
hematopoietic system [10, 11]. For instance, the process of B-lineage specification and 
commitment requires the coordinated action of signaling cascades and transcription 
factor networks that initiate B-cell specific transcription factors and repress alternative 
lineage determinants. Differentiation of lymphoid progenitors towards the B-cell lineage 
involves the sequential activation of key B-cell transcription factors including IKZF1, 
E2A, early B cell factor (EBF1), FOXO1 and PAX5 [12, 13]. Deregulation of these 
important determinants of B-cell development contributes to the formation of B-cell 
malignancies, including B-cell precursor ALL (BCP-ALL) (Chapter 2) [14].
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2. B-lymphoid malignancies 
2.1 Introduction
The majority of neoplasms derived from the lymphoid cell lineage involves B-cell 
malignancies, which can occur at various stages of B-cell development [15]. B-cell 
progenitor acute lymphoblastic leukemia (BCP-ALL) represents the most immature 
subtype and arises from pro-B and pre-B cells within the bone marrow compartment 
[16]. As these rapidly proliferating precursor B-cells undergo heavy- and light-chain 
 
Figure 1. Lineage specification and differentiation during hematopoiesis. Differentiation from 
hematopoietic stem cells into different lineages is tightly controlled by various transcription factors. Dependent 
on the cell lineage, progenitor cells maturate into specialized lymphoid or myeloid cells. (Adapted from 
He et al.) [9].
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gene rearrangements through recombination activating gene (RAG)-mediated 
recombination, inappropriate targeting of RAG proteins can give rise to gene lesions 
such as chromosomal translocations, mutations and deletions that contribute to 
leukemic transformation [17-19]. Off-target RAG-mediated recombination can occur 
as a spontaneous event during lymphocyte differentiation, due to prolonged RAG 
activity in leukemic blasts, or as a consequence of persistent infections [18]. Also 
stimulation of activation-induced cytidine deaminase (AID) by repeated exposure to 
inflammatory cytokines, for instance due to chronic infections, may contribute to the 
development of childhood BCP-ALL [19]. In addition, several types of lymphomas, 
which are derived from more differentiated subsets of mature B-cells in secondary 
lymphoid organs, like the marginal zone and the germinal center, can arise due to off-
target recombination and mutational events [15]. Many of the oncogenic events that 
occur in BCP-ALL and B-cell lymphomas disrupt molecular pathways that regulate 
B-cell differentiation, proliferation and apoptosis [20].
2.2. Pediatric BCP-ALL
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, 
which in 85% of the cases involves BCP-ALL. The remaining 15% are T-lineage 
leukemias (T-ALL). Refinements in multi-agent chemotherapy treatment regimens for 
ALL, combined with improved risk stratification and better supportive care, have resulted 
in long-term event-free survival rates exceeding 80%. However, still approximately 20% 
of children suffer from relapse, which is associated with a much higher probability of 
therapy failure. BCP-ALL is genetically characterized by distinct genetic aberrations such 
as chromosomal alterations, including hyper- and hypodiploidy, recurrent chromosomal 
rearrangements that commonly involve genes such as MLL, CRLF2 or c-MYC, as well 
as translocations leading to ETV6-RUNX1, TCF3-PBX1 and BCR-ABL1 fusion proteins 
[21]. Moreover, recent genome-wide profiling efforts have led to the identification of a 
wide diversity of submicroscopic lesions affecting genes involved in key cellular pathways 
including cell cycle regulation and tumor suppression (CDKN2A/CDKN2B, PTEN, RB1, 
TP53), lymphoid development (IKZF1, EBF1, PAX5, LMO2), transcriptional regulators 
and co-activators (TBL1XR1, ETV6, ERG, NR3C1) as well as epigenetic regulators 
(CTCF, CREBBP) [16, 22-24]. Some of these copy number alterations (CNAs) are 
strongly associated with disease progression and outcome [25-28]. Overall, genetic 
alterations that disrupt cell cycle regulation and/or give rise to a block in B-lymphoid 
development are considered obligatory steps in the pathogenesis of ALL (Figure 2).
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2.3 BTG1 deletions in pediatric BCP-ALL
One of the genes frequently affected in BCP-ALL is the transcriptional co-regulator 
BTG1, the focus of this thesis. We and others have found that focal monoallelic deletions 
affecting the B-cell translocation gene 1 (BTG1) occur in about 9% of pediatric BCP-
ALL patients, but not in T-lineage ALL [22, 23]. Deletions affecting BTG1 are unevenly 
distributed among cytogenetic subgroups. For instance, BTG1 deletions are enriched 
in ETV6-RUNX1 (19%) and BCR-ABL1 (26%) positive BCP-ALL, while virtually absent 
in other cytogenetic subgroups such as MLL-rearranged leukemia (Chapter 2 and 
5) [18, 22, 23, 29, 30]. The t(12;21)(p13;q22) translocation, giving rise to the ETV6-
RUNX1 fusion protein, is the most common chromosomal aberration in pediatric 
BCP-ALL, comprising about 25% of all pediatric BCP-ALL cases. Importantly, ETV6-
Pro-B /Pre-B cellLymhpoid progenitor Mature B cell
ALL diagnosis ALL relapse
Initiation
Initiating lesions
e.g ETV6-RUNX1, 
TCF3-PBX1, 
MLL rearrangement
Predisposition
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e.g IKZF1, CEBPE, 
ARID5B, CDKN2A
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Alteration in B cell transcription 
factor genes IKZF1, EBF1, PAX5
Lesion generation
Aberrart RAG activity
Cooperating events
* Cell cycle/ tumor suppressors (CDKN2A, RB1, TP53)
* Cytokine receptors/kinases (CRLF2, JAK1/2, ABL1, PDGFRB)
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* Mutations in epigentic regulators (CREBBP, EP300)
Selective pressure (chemotherapy)
Genetic aberrations that confer 
resistance to therapy, e.g. IKZF1, 
CREBBP, NT5C2, TP53
Figure 2. Pathogenesis of BCP-ALL. This scheme outlines the nature and incidence of various genetic 
aberrations that contribute to the development of BCP-ALL. Chromosomal translocations are acquired as 
an early genetic event during leukemogenesis, predisposing cells to secondary genetic lesions. These 
lesions disrupt normal lymphoid development and result in the accumulation of immature cells. Additional 
cooperating events, targeting various pathways including cell cycle and kinase signaling, are required to 
develop overt leukemia. Therapy-induced selection of minor sub-clones may confer resistance to therapy 
and promote relapse (Adapted from Mullighan et al.) [16].
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RUNX1 translocations arise prenatally and can persist for many years before overt 
leukemia develops, arguing that additional cooperating genetic events, including loss 
of BTG1 function, are required [23, 31-34]. Within ETV6-RUNX1 positive leukemias, 
BTG1 deletions were found to occur independently in different ALL subclones from the 
same patient, suggesting a role for BTG1 deletions in clonal selection and outgrowth 
[18]. We identified at least eight different recurrent deletion breakpoints downstream 
of the BTG1 locus, which share their telomeric breakpoint with the tightly clustered 
breakpoint within the second exon of BTG1 (Figure 3). Moreover, we established that 
deletions in BTG1 are most likely caused by off-target RAG-mediated recombination 
and that these deletions result in read-through transcripts giving rise to highly unstable 
truncated BTG1 protein variants [18]. In contrast, BTG2 deletions were not found in 
BCP-ALL patients. 
A
B Figure 3. BTG1 deletions cluster tightly and 
disrupt the BTG1 open reading frame. (A) The 
BTG1 gene, located on the antisense strand of 
chromosome 12q22, is exclusively disrupted by 8 
different deletions (indicated by black bars), ranging 
from 101 to 557 kb in size. The deletion breakpoints 
cluster tightly within exon 2. Colored triangles indicate 
the position of the breakpoints in different patients. 
Light blue represents the breakpoint of deletion I, grey 
deletion II, blue deletion III, pink deletion IV, purple 
deletion V, green deletion VI, red deletion VII and 
orange deletion VIII, respectively. (B) Overview of 
the eight distinct deletions of which deletion III was 
the most prevalent (49% of the cases). Adapted from 
Waanders et al. [18].
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Similar to BTG1, deletions or mutations affecting the early lymphoid transcription 
factor IKZF1 are frequently observed in BCP-ALL (Chapter 2 and 6) [35]. Although 
we and others have shown that IKZF1 aberrations are a strong predictor of relapse 
in childhood BCP-ALL [25, 28, 36-38], the effects of IKZF1 aberrations on outcome 
appear to be determined by the presence or absence of additional genetic lesions 
(Chapter 6). In this context, we observed that BTG1 deletions are relatively frequent in 
IKZF1-deleted ALL, while the combined (single copy) loss of these two genes identifies 
a patient group with extremely poor outcome (Chapter 6).
2.4 BTG1 and BTG2, potential tumor suppressors in B-cell malignancies
Genomic alterations affecting the BTG1 gene have also been identified in diffuse large 
B-cell lymphoma (DLBCL) [39, 40]. Similarly, the closely related BTG2 gene was found 
to be subject to mutations in DLBCL as well as Burkitt and follicular lymphoma, although 
deletions have not been identified for this gene in BCP-ALL [39-42]. The functional 
consequences of BTG1/BTG2 aberrations in DLBCL are still unknown, although the 
occurrence of two adjacent mutations on different alleles, observed in some patients, 
suggests a loss-of-function mechanism [39].
In vivo studies with Stat5b-CA x Ebf1+/- mice showed rapid induction of ALL and 
downregulation of Btg1 and/or Btg2 in these leukemic cells [43], suggesting that loss 
of Btg1 and Btg2 function contributes to the leukemia development in these animals. 
These findings suggest that altered expression or function of BTG1 or BTG2, in 
cooperation with other recurrent genetic aberrations, may lead to the occurrence of 
B-cell malignancies. Furthermore, BTG1 was identified as a target of c-MYC in B-cell 
lymphomas, where its expression is directly suppressed by c-MYC, which involves a 
microRNA known as miR-17-92. Hence, suppression of BTG1 by miR-17-92 retains 
these B-cell lymphoma cells in a neoplastic state. To the converse, overexpression 
of BTG1 was sufficient to reverse the c-MYC oncogenic phenotype [44]. Interestingly, 
both Btg1 and Btg2 are highly expressed at various stages of B-cell development in 
mouse bone marrow [45], and both genes were identified as a target of the key B-cell 
transcription factor PAX5, although their exact roles during B-cell differentiation remain 
to be elucidated [46].
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3. Molecular function of BTG1 and BTG2  
The BTG1 gene was originally identified as a translocation partner of the c-MYC 
gene in a case of B-cell chronic lymphocytic leukemia and belongs to the mammalian 
BTG/Tob family of antiproliferative genes (BTG1-BTG4, TOB1 and TOB2) [47]. BTG1 
and its close relative BTG2 are known to directly interact with transcription factors 
and modulators involved in the regulation of important cellular processes including 
apoptosis, proliferation and differentiation [48-50].
BTG/Tob proteins share two conserved stretches (Box A and Box B) at their NH2-
terminus (Figure 4), which together have been termed the APRO (AntiPROliferative) 
or BTG domain [47, 51]. In contrast to the other members of this gene family, BTG1 
and BTG2 also harbor a conserved Box C domain, which allows these two proteins 
to interact with protein arginine methyltransferase I (PRMT1) (Figure 4). The human 
BTG1 gene is located on chromosome 12q22 and consists of two exons that encode 
171 amino acids [52, 53]. BTG2, which is located on chromosome 1q32, shows 74% 
identity in protein sequence to BTG1, suggesting that they may fulfill overlapping 
functions. The BTG2 transcript encodes 158 amino acids divided over two exons 
[48]. Both BTG1 and BTG2 show instability of their mRNA transcripts as well as the 
proteins which they encode. BTG1 and BTG2 proteins are both targets for degradation 
by the Skp1-Cdc53/Cullin 1-F-box protein (SCF) complex [54, 55]. Both full-length 
and N-terminally truncated forms of BTG1 and BTG2 proteins were found to be highly 
unstable, whereas truncation of the C-terminus was reported to confer increased stability 
to these proteins [54, 56]. This is in contrast with our own observations indicating 
that intragenic BTG1 gene deletions, as they are found in BCP-ALL, yield C-terminal 
deletions of the BTG1 protein that are highly unstable [18].
The subcellular localization of BTG1 is controlled by the so-called Box B, C- and 
N-terminal domains [57]. Moreover, BTG proteins are subject to different forms of 
post-translational modifications, such as phosphorylation, that may also regulate their 
function [58, 59].  
BTG1 and BTG2 predominantly function as transcriptional coactivators. Both proteins 
were shown to enhance the transcriptional activity of HoxB9 [60], which belongs to 
the HOX gene family. In addition, BTG2 can associate with receptor regulated SMAD 
proteins SMAD1 and SMAD8, thereby activating bone morphogenic gene (BMP)-
dependent transcription [61]. Both BTG1 and BTG2 contain two copies of the LXXLL 
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motif, which permits interaction with nuclear receptors, like TR1α, ERα and RARα, 
which enhances their transcriptional activity [62-64].
The BTG1 and BTG2 proteins show no intrinsic enzymatic activity and more likely 
act by recruiting other cofactors that regulate transcription. They associate with, and 
positively modulate the activity of PRMT1 via the Box C domain [65, 66]. PRMT1 act 
as a global regulator of gene expression by mediating asymmetric dimethylation of 
histone H4 Arg3 (H4R3me2a). Consistent with these findings, BTG2 promotes PRMT1 
participation in the RARα protein complex [63], while we have demonstrated that BTG1, 
in association with PRMT1, acts as a positive regulator of glucocorticoid receptor 
(GR) mediated gene expression in leukemia cell lines (Chapter 3) [67]. Moreover, 
we identified the BTG1/PRMT1 complex as a new modifier of ATF4 mediated stress 
responses, which in case of sustained stress induces apoptosis [68].
In addition to regulating gene expression, BTG1 and BTG2 play a role in the regulation 
of mRNA abundance by binding to the RRM domain of poly(A)-binding proteins (PABPC) 
of the Ccr4-Not deadenylase complex [49, 51, 58, 64, 69-71]. Hence, some of the 
effects of BTG1 and BTG2 on gene expression could be mediated through interaction 
with Ccr4-Not complex [64].  
A B CNH2 COOH
NES
LXXLL
Ser159
0 bp 171 bp
NH2 COOH
NES
Ser147/149
0 bp 158 bp
LXXLL
LXXLL LXXLL
Hydrophobic residues
Hydrophobic residues
BTG1
BTG2
BA C
APRO domain
APRO domain
Figure 4. Domain structure of BTG1 and BTG2 proteins. The BTG/Tob proteins share two conserved 
homology regions, Box A and Box B (APRO domain) located at the N-terminus. BTG1 and BTG2 also have 
a Box C domain and two LXXLL motifs required for interaction with nuclear receptors.
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4. Biological functions of BTG1 and BTG2 
4.1 Regulation of cell cycle
The function of BTG2 in proliferation, differentiation and apoptosis has been more 
extensively studied than that of BTG1. The expression of BTG1 and BTG2 is high at 
the quiescent G0/G1 phase of the cell cycle, while their expression is down-regulated 
as the cell enters the cell cycle [53, 72]. BTG1 was found to induce G0-G1 cell cycle 
arrest in breast cancer cells by inhibition of cyclin B1 and cyclin D1 cell cycle related 
proteins [73]. Similarly, in cerebellar granule precursors (GCPs) BTG1 negatively 
regulates the cell cycle by controlling cyclin D1 expression [74].
Originally, BTG2 was identified as a p53-inducible gene, but BTG2 expression 
appears to be also regulated by NF-κB through a p53-independent mechanism [48, 
75]. Moreover, expression of BTG2 can be induced by growth factors, and it has a role 
during the G1 phase of the cell cycle as well as during DNA damage induced G2/M 
cell cycle arrest [48, 76]. Activation of BTG2 induces G2/M-cell cycle arrest and cell 
death, accompanied by inhibition of cyclin B1 and Cdc2 kinase activity, resulting in 
accumulation of cyclin A and cyclin B1 [77]. In addition, induction of BTG2 levels in 
response to growth arrest stimuli, such as DNA damage, was shown to mediate G1 
arrest, by inhibition of cyclin D1 (CCND1) transcription. This impairs the ability of cyclin 
D1/CDK4 to phosphorylate pRb, thereby preventing inactivation of pRb and entry into 
G1 [78]. In absence of functional pRb, p53 and cyclin D1, BTG2 was shown to inhibit 
G1 to S phase progression by reducing cyclin E levels [79]. Altogether, BTG2 triggers 
cell cycle arrest via different mechanisms, dependent on the cellular context, of which 
inhibition of CCND1 is a preferred, but not an exclusive mechanism.
4.2 Regulation of apoptosis
BTG1 overexpression results in increased apoptosis of several cell types including 
murine fibroblast cells, microglia and myoblasts [53, 80, 81]. Furthermore, BTG1 was 
identified as a target of the anti-apoptotic protein Bcl-2, which negatively regulates 
BTG1 expression. In breast cancer cells, BTG1 appears to act as a Bcl-2 regulated 
mediator of apoptosis and its induction contributes to antisense Bcl-2 mediated cell 
death [73, 82]. BTG2 expression can be induced by various cellular stresses, such 
as UV radiation, reactive oxygen species (ROS) and other DNA damaging agents. 
This is consistent with the notion that BTG2 may be involved in DNA repair, as more 
double strand breaks were found upon loss of BTG2 [83]. 
Chapter 1
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4.3 Control of cell differentiation and proliferation
Both BTG1 and BTG2 are broadly expressed in various organs and tissues, with 
higher levels of BTG1 and BTG2 in hematopoietic tissues, lung, kidney, prostate and 
moderate expression in intestine and pancreas [72]. BTG2 is also expressed in the 
mammary gland, where its expression declines during pregnancy [75]. Moreover, BTG2 
expression is observed in neuroepithelial cells that give rise to postmitotic neurons 
and in the hippocampus in proliferating and differentiating progenitor cells [84]. In 
vitro and in vivo studies have revealed that BTG2 is involved in differentiation and 
proliferation of neuronal precursor cells by activation of PRMT1 during development 
[85-88]. Similarly, BTG1 is expressed in the developing and adult brain [89] where 
it is required for the development of the cerebellum, maintenance and generation of 
progenitor cells and new neurons of the hippocampus and subventricular zone. In 
these tissues, BTG1 acts primarily by regulating cell cycle progression and survival. 
Hence, the main role of Btg2 expression in the adult hippocampus is to drive terminal 
differentiation, while Btg1 is responsible for the control of self-renewal and quiescence 
of the pool of stem and progenitor cells [74, 90-92]. In line with these findings, our 
data indicate that Btg1 promotes progenitor B-cell proliferation and/or acts to inhibit 
apoptosis, while Btg2 seems to be more involved in regulation of lineage specification 
and differentiation (Chapter 4).
Finally, Btg2, like Btg1, is required for the development of normal axial vertebrae 
(Chapter 7). Btg2-deficient mice, similar to Btg1-/- mice, display posterior homeotic 
transformation, which has been attributed to impaired bone morphogenetic protein 
(BMP) signaling [61]. Posterior homeotic transformation, as observed in Btg1- and 
Btg2-deficient mice shows similarity to the phenotype observed in mice deficient for 
polycomb group (PcG) genes, which are required to maintain repression of HOX genes 
[93-96]. It remains to be established whether deregulation of HOX gene expression, 
by loss of Btg1 or Btg2, also contributes to this phenotype. In summary, BTG1 and 
BTG2 exert both unique and overlapping functions in the regulation of cell proliferation, 
differentiation and apoptosis in a variety of tissues and organ systems (Figure 5).
4.4 The role of BTG1 and BTG2 during hematopoiesis
High expression of BTG1 is observed both during myeloid differentiation as well at 
various stages of B-cell development, suggesting a role for this transcriptional coregulator 
in hematopoietic cell differentiation [97, 98]. In line with these findings, we observed 
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Figure 5. Unique and Overlapping interactions of BTG1 and BTG2 proteins. More interactions with 
the BTG2 protein are shown since BTG1 has been less well studied. Solid lines indicate direct physical 
interactions, while dotted lines indicate transcriptional regulation.
that Btg1 knockout mice show reduced B-cell numbers at various stages of B-cell 
development, while myeloid differentiation is not affected in these mice (Chapter 4).
BTG2 appears to be involved in the regulation of T-cell differentiation, where it inhibits 
the expansion of the double negative thymocyte stage and β-selected thymocytes. 
Moreover, BTG2 was identified as a negative regulator of hematopoietic progenitor 
expansion in response to 17β-estradiol (E2) [63, 99]. We find however that Btg2 knockout 
mice show normal myeloid and T-cell development in the thymus, although a minor 
increase in CD4+ and CD8+ peripheral T-cells is observed in the spleen (Chapter 4).
Expression of both BTG1 and BTG2 is induced by Foxo3a during erythroid 
differentiation, whereas stem cell factor (SCF) suppresses their function. BTG1 
expression in primary mouse bone marrow cells negatively regulates the outgrowth 
of erythroid progenitors, which requires association with the arginine methyl transferase 
PRMT1 [100]. 
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5. Role of the tumor suppressor proteins BTG1 and BTG2 in solid cancers 
In addition to their suspected roles in B-cell malignancies, both BTG1 and BTG2 have 
also been implicated in the formation and/or progression of solid tumors. For instance, a 
number of studies have demonstrated that reduced expression of BTG1 correlates with 
the pathogenesis and progression of hepatocellular carcinoma, breast, ovarian, gastric, 
kidney and non-small cell lung cancer (NSCLC) [101-106]. Similarly, deregulation of 
BTG2 is an important step in the development, proliferation and metastasis of various 
cancers, including breast, prostate, clear cell renal carcinoma and medulloblastoma 
[75, 90, 107-110]. Low expression of BTG1 in breast and non-small cell lung cancer 
(NSCLC) and reduced BTG2 expression levels in breast and prostate cancer have 
been correlated with poor prognosis, providing evidence for their tumor suppressive 
function [101, 111-115]. Inactivation of tumor suppressor genes BTG1 or BTG2 may 
represent an important step in tumor development since they affect cell cycle regulation, 
apoptosis and growth regulatory proteins. In vitro studies in human breast cancer 
cell lines have identified BTG1 and BTG2 as potential therapeutic targets as they 
suppress the outgrowth of breast cancer cells by induction of cell cycle arrest and 
apoptosis [82, 116-118]. These in vitro studies suggest that induction or stabilization 
of BTG1 or BTG2 expression might be an effective anti-tumor strategy, although more 
research is required to elucidate which drugs positively affect expression of these 
tumor suppressor genes.
 
6. Outline of this thesis 
In order to reduce toxicity of current therapies, more selective targeted therapies for 
children with BCP-ALL are warranted. To achieve this goal, a better understanding 
of the transcriptional hierarchies that regulate normal as well as malignant B-cell 
development, and how these affect tumor cell behavior, is needed. Transcription factors 
involved in B-lineage specification and commitment are frequent targets of genetic 
alterations in B-cell neoplasms. The presence of gene lesions affecting the function of 
the transcriptional coregulators BTG1 and BTG2 in different B-cell malignancies suggest 
that these genes are important regulators of normal B-cell development. In this thesis 
we have studied the roles of Btg1 and Btg2 both during normal (B-cell) development 
and how aberrations in particularly BTG1 contribute to the development of ALL. 
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In chapter 2, we review the importance of various key transcription factors for B-cell 
development and cooperating gene lesions required for leukemia development. In 
chapter 3 we report that the BTG1/PRMT1 complex regulates GR-mediated gene 
expression and demonstrate that loss of BTG1 expression contributes to glucocorticoid 
therapy resistance in ALL cell line models. In chapter 4, we address the roles of 
Btg1 and Btg2 during normal B-cell development in mice. BTG1 deletions frequently 
occur in ETV6-RUNX1-positive BCP-ALL. In chapter 5 we describe a mechanism by 
which BTG1 promotes ETV6-RUNX1-induced self-renewal. In Chapter 6 we report 
the co-occurrence of BTG1 and IKZF1 deletions in BCP-ALL and demonstrate that 
the combined loss of BTG1 and IKZF1 predicts a very poor outcome in patients 
with BCP-ALL. Moreover we demonstrate cooperative effects of Btg1-deficiency on 
leukemia development in Ikzf1 haplodeficient mice, firmly establishing BTG1 as a 
tumor suppressor in ALL. Previous studies identified posterior vertebral transformations 
in Btg2-null mice. In chapter 7 we demonstrate that Btg1 deficiency, either alone or 
intercrossed with Btg2-null mice, affects vertebral patterning. In Chapter 8, the results 
of this thesis will be summarized and discussed.
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Abstract  
Differentiation of hematopoietic stem cells into B-lymphocytes requires the concerted 
action of specific transcription factors, such as RUNX1, IKZF1, E2A, EBF1 and PAX5. 
As key determinants of normal B-cell development, B-lineage transcription factors are 
frequently deregulated in hematological malignancies, such as B-cell precursor acute 
lymphoblastic leukemia (BCP-ALL), and affected by either chromosomal translocations, 
gene deletions or point mutations. However, genetic aberrations in this developmental 
pathway are generally insufficient to induce BCP-ALL, and often complemented by 
genetic defects in cytokine receptors and tyrosine kinases (IL-7Rα, CRLF2, JAK2, 
c-ABL1), transcriptional co-factors (TBL1XR1, CBP, BTG1), as well as regulatory 
pathways that mediate cell cycle control (pRB, INK4A/B). Here, we provide a detailed 
overview of the genetic pathways that interact with these B-lineage specification factors, 
and describe how mutations affecting these master regulators together with cooperating 
lesions drive leukemia development.
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Introduction 
 
Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children 
characterized by a block in lymphoid differentiation, leading to accumulation of immature 
progenitor cells in the bone marrow, peripheral blood and occasionally the central 
nervous system. Although ALL cure rates are approaching 90%, it remains the leading 
cause of cancer-related mortality in children and young adults. The most prevalent 
form of childhood ALL is B-cell precursor ALL (BCP-ALL), which represents about 
85% of the cases, while the remaining 15% of the cases involves T-lineage ALL 
(T-ALL). In BCP-ALL two variants of aneuploidy, namely hyperdiploidy of more than 
50 chromosomes and hypodiploidy, as well as a collection of recurrent chromosomal 
rearrangements give rise to distinct genetic subtypes. These rearrangements include 
commonly affected genes, such as MLL, CRLF2 or c-Myc, fused to a diverse range 
of different partner genes or regulatory elements, and uniquely defined chromosomal 
translocations, such as BCR-ABL1, ETV6-RUNX1 and TCF3-PBX1. Some of these 
genetic subtypes, such as ETV6-RUNX1 and hyperdiploidy, which together include 
about 50% of the cases, correlate with a favorable outcome, while others, like the 
MLL-rearrangements, BCR-ABL1 and hypodiploidy, covering about 13% of the cases, 
are associated with a poor treatment response [1].
Many of these chromosomal rearrangements constitute “driver” mutations and 
can be detected in both diagnosis and relapse samples. However, it is evident from 
experimental mouse models and through extensive genomic profiling of patient samples 
that these genetic driver lesions are usually insufficient to induce leukemia and require 
cooperating events. Both single-nucleotide polymorphism (SNP) arrays as well as 
deep-sequencing of genomes and transcriptomes have provided important new 
insights into the different cellular pathways that are commonly affected by recurrent 
point mutations, focal gene deletions and rearrangements [2-4]. In general, BCP-
ALL harbors gene lesions that affect transcription factors and signaling molecules 
implicated in lymphoid differentiation, such as IKZF1, RUNX1, TCF3, EBF1, PAX5, 
VPREB1, RAG1/RAG2, as well as proteins that control cell survival and proliferation, 
including ABL1, NRAS/KRAS, JAK2, IL7R and CRLF2 (Table 1). Mutations in these 
two common pathways are often combined with genetic defects in transcriptional 
co-regulators, such as TBL1XR1, CREBBP, BTG1 and well known tumor suppressor 
genes involved in regulation of the cell cycle, such as RB1, CDKN2A, CDKN2B and 
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TP53. Surprisingly however, many of the BCP-ALL genetic subtypes display a rather 
unique pattern of specific cooperating gene lesions.
In this review we will focus on the key hematopoietic transcription factors targeted in 
BCP-ALL, describing their role in normal and malignant hematopoiesis, and summarizing 
cooperating gene lesions and critical transcriptional targets/pathways that drive leukemia 
formation. Specifically, we describe in detail the post-translational modifications and 
co-factors that are associated with these transcription factors regulating their activity 
and protein stability. A more precise understanding of the regulatory pathways that 
control these transcription factor functions and their cooperating signaling molecules 
may hold the key to development of novel targeted therapies aimed at specific BCP-
ALL subtypes.
Pathways# Genes
Lymphoid differentiation
RUNX1, ERG1, IKZF1, IKZF2, IKZF3, TCF3, TCF4, TCF12, 
EBF1, PAX5, LEF1, TCF7L2, ETV6, SPI1, MEF2C, IRF8, 
C-MYC, NR3C1, NR3C2, RAG1, RAG2, VPREB1, CD200/BTLA
Proliferation and cell survival
ABL1, JAK1, JAK2, JAK3, KRAS, NRAS, IL7R, CRLF2, FLT3, 
PTPN11, NF1 
Cell cycle regulation CDKN2A, CDKN2B, RB1, TP53
Transcriptional cofactors TBL1XR1, BTG1, CREBBP, NCOR1, BCOR, CTCF, ARID5B 
Others FHIT, C20orf94, ASMTL, MUC4, ADARB2, ADD3, ARPP21, DMD
Table 1. Functional classification of the genes affected in BCP-ALL. #In BCP-ALL, most of the genes 
that are affected by chromosomal rearrangements, focal gene deletions and point mutations in diagnosis 
and relapse samples can be classified into four different genetic pathways [1-4].
RUNX1
One of the most frequently mutated genes in leukemia is RUNX1 (encoding the AML1 
protein), which belongs to the Runt-related family of transcription factors, together with 
RUNX2 (AML3) and RUNX3 (AML2). The RUNX proteins together with the common 
core binding factor-beta (CBFβ) make up the heterodimeric CBF transcription factors, 
which play important roles in hematopoiesis and bone development. The RUNX proteins 
directly bind DNA via an N-terminal runt homology domain (RHD) that also mediates 
heterodimerization with CBFβ, which is required for efficient binding to the RUNX 
consensus site and results in activation or repression of target genes. The human 
RUNX1 gene generates three alternatively spliced variants, giving rise to RUNX1a, 
RUNX1b and RUNX1c, each of which possesses the DNA-binding domain, while 
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RUNX1a lacks the C-terminal transcriptional regulatory domain. RUNX1 can recruit 
a variety of transcriptional co-activators, such as the lysine acetyl transferases MOZ 
and p300/CBP [5, 6], the transcriptional regulator YAP1, and the protein subunits 
BRG1 and INI1, which are components of the ATP-dependent SWI/SNF chromatin 
remodeling complex [7]. Transcriptional repression by RUNX1 is mediated through direct 
binding to the histone deacetylases HDAC1 and HDAC3, the histone methyltransferase 
SUV39H1 and recruitment of the SIN3A and TLE/Groucho co-repressor complexes via 
the C-terminal region [8, 9]. In addition, RUNX1 can interact in a cooperative manner 
with several tissue-specific transcription factors, such as GATA1, ETS1, MYB, C/
EBPα, PU.1 and STAT5, thereby able to modulate the expression of a broad range 
of transcriptional target genes.
RUNX1 can be modified through phosporylation by the MAP kinases ERK1/2 [10], 
which results in enhanced transactivation by RUNX1. In addition, cyclin-dependent 
kinases (CDKs) are able to phosphorylate RUNX1 on multiple sites thereby regulating 
different aspects of AML1 function, including its degradation during G2/M-phase of the 
cell cycle by the anaphase-promoting complex [11], and the interaction with HDAC1 
and HDAC3 [12]. The DNA-binding affinity of RUNX1 is enhanced by p300-mediated 
acetylation at two lysine residues (K24 and K43 in RUNX1b) [6]. In contrast, both 
DNA-binding and transactivating properties of RUNX1 are abrogated through lysine 
methylation by SUV39H1 [13], while arginine methylation of residues R206 and R210 by 
protein arginine methyltransferase 1 (PRMT1), disrupts SIN3A-mediated transcriptional 
repression of RUNX1 [14]. RUNX1 function is also modulated by PRMT4/CARM1, 
which induces R223 methylation and binding of the zinc-finger protein DPF2 resulting 
in differential target gene regulation [15]. Furthermore, PRMT5, in complex with its 
co-factor COPR5, regulates nuclear export of RUNX1 through R142 methylation [16].
RUNX1 and CBFβ are essential for all lineages of definitive hematopoiesis in mouse 
fetal liver, including the formation of erythroid cells, granulocytes, macrophages and 
lymphoid cells [17, 18]. In particular, mouse Runx1 expression is required for the 
emergence of hematopoietic stem cells (HSCs) from the vascular endothelium in the 
midgestation embryo (Figure 1). In contrast, conditional gene-targeting experiments 
have revealed that the Runx1 gene is not essential for the maintenance of adult long-
term HSCs (LT-HSCs) during definitive hematopoiesis. Rather, Runx1-deficiency blocks 
megakaryopoiesis and lymphocyte development, while at the same time expands 
multipotent and myeloid progenitors in the bone marrow [19] (Table 2). The identification 
of RUNX1 target genes has provided some insight into its function during hematopoiesis. 
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Runx1-insufficiency suppresses apoptosis and delays cell cycle progression in the 
stem/progenitor cell fraction, which is accompanied with altered expression of the 
anti-apoptotic protein Bcl2 and the polycomb ring finger oncoprotein Bmi1 [20]. The 
PU.1 (Sfpi1) gene is an essential target of RUNX1 expression in all three major 
hematopoietic lineages. In myeloid and T-lymphoid cell lineages, RUNX1 regulates 
the Il3, Csf2, Csf1r, Cd4 and Tcrδ  genes, while in B-lineage differentiation RUNX1 
is essential for Ebf1 expression (Figure 2) [21]. Mouse models have demonstrated 
that both RUNX1 gain-of-function and loss-of-function predisposes to hematological 
malignancies. Enhanced or deregulated expression of Runx1 due to integration of 
murine leukemia virus (MLV) is a recurrent event upon proviral tagging of lymphoma-
prone mice, and RUNX1-transgene expression accelerates the onset of B- and T-cell 
lymphomas of Eµ-Myc transgenic mice [22]. On the other hand, conditional or chimeric 
Runx1-deficient mice develop thymic lymphomas [23, 24], and are predisposed to 
leukemia development upon retroviral insertional mutagenesis [25]. 
CLP Pre-BPro-BPre-Pro B
IKZF1 E2A
EBF1
PAX5
RUNX1
ERG
Mesoderm
Primitive 
HSC
Definitive 
HSC
Figure 1. Schematic overview of the normal function of the different B-lineage transcription factors 
affected in BCP-ALL. B-lineage transcription factors affected in BCP-ALL often act at different stages of 
hematopoietic development, but their earliest critical function in hematopoiesis as revealed by gene knockout 
mouse studies is indicated. RUNX1 is required for the emergence of primitive hematopoietic stem cells (HSCs) 
during embryonic development, while ERG is essential for definitive HSC maintenance. IKZF1 expression 
is necessary for the formation of common lymphoid progenitors (CLP), and E2A and EBF1 are essential to 
generate pro-B cells. PAX5 fulfils a critical role in maintaining B-cell identity and its expression is required 
to generate functional pre-B cells. LEF1 mainly regulates early B-cell survival signaling and proliferation. 
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Transcription 
factor (gene)
Phenotype of knockout mouse 
models
Lymphoid malignancies in mouse 
models
RUNX1 (Runx1)
Runx1-/-: embryos die around E12.5; no 
primitive and definitive hematopoiesis 
[17]
Runx1 conditional KO: impaired 
megakaryopoiesis and lymphocyte 
development; expansion of myeloid 
progenitors [19]
ETV6-RUNX1 knock-in: expansion of 
HSCs, block in B-cell development, no 
B-cell malignancies  [33]
Runx1 conditional KO: develop T-cell 
malignancies [24]
ERG (Erg)
ErgMld2/Mld2: embryos die at E11.5-12.5; no 
definitive hematopoiesis [36-38]
ErgMld2/+: defective stress-induced HSC 
function, impaired B-cell development 
and megakaryopoiesis [36-38]
Erg transgenic: develop T-ALL [40]
IKZF1 (Ikzf1)
IkarosL/L: absence of pDCs and a 
reduction in pre-pro-B cells [52]
Ikaros-null-/-: mild reduction in HSCs and 
absence of B-, NK- and fetal T-cells [53-
54]
Ikaros-DN-/-: strong reduction in HSCs 
and no B-, T-, NK-cells and DCs [56]
Ikaros-Plastic-/-: embryos die around 
E16.5; block in erythropoiesis and 
lymphopoiesis [57]
Ikaros-null+/-: develop thymic 
lymphomas with a low incidence
Ikaros-DN+/-: develop thymic 
lymphomas
Ikaros-Plastic+/-: develop thymic 
lymphomas 
E-box binding 
proteins E2A 
(E12/E47) (Tcf3/
Tcfe2a)
E2-2 (Tcf4)
HEB (Tcf12)
Tcf3-/-: impaired T-lymphopoiesis and 
block at the pre-pro-B cell stage [78-79] 
E47-/-: block at the pre-pro-B cell stage 
[79]
E12-/-: impaired B-cell differentiation [79]
Tcf3-/-: develop T-cell lymphomas [80]
TCF3-PBX1: develop T-cell 
lymphomas and myeloid leukemias
TCF3-HLF: develop T-cell lymphomas
Tcf4-/-: are born with extremely low 
frequency and die around birth. Mild 
reduction in the number of pro-B cells 
and no pDCs [81-83]
Tcf12-/-: die within 2 weeks after birth. 
Mild reduction in the number of pro-B 
cells [81]
Tcf4-/-: no lymphoma/leukemia 
Tcf12-/-: no lymphoma/leukemia
EBF1 (Ebf1)
Ebf1-/-: block at the pre-pro-B cell stage 
[99]
Ebf1+/-: reduction in the number of pro-B 
and splenic B-cells [99]
 
Ebf1+/- and Ebf1-/-: no spontaneous 
hematological malignancies 
PAX5 (Pax5)
Pax5-/-: early block in B-cell differentiation 
during fetal hematopoiesis. In adult bone 
marrow block at the pro-B cells stage 
with no VH-DJH recombination [116-117]
Pax5 conditional KO: conversion of 
mature B-cells into functional T-cells 
through dedifferentiation to uncommitted 
progenitors [122]
 
Pax5 transgenic: develop T-cell 
lymphomas
Pax5 conditional KO: Develop 
progenitor B-cell lymphomas [122]
LEF1 (Lef1)
Lef1-/-: reduced proliferation and 
enhanced apoptosis of pro-B cells; no 
defect in B-cell differentiation [135]
Lef1+/- and Lef1-/-: no spontaneous 
hematological malignancies
 
 Table 2. Phenotype of mice harboring altered function of B-lineage transcription factors
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In humans, deregulation of RUNX1 expression through chromosomal translocations, 
mono- and bi-allelic deletions, point mutations as well as gene amplification is observed 
in multiple hematopoietic malignancies, including AML, ALL, CML and MDS. In addition 
to somatic mutations, germline point mutations in RUNX1 are responsible for an 
autosomal-dominant platelet disorder with a propensity to develop leukemia (FPD-
AML) [26]. The most prevalent translocations involving the RUNX1 gene located on 
chromosome 21q22.12 are RUNX1-MTG8 (encoding the AML1-ETO protein), which 
occurs in about 15% of AML cases, and ETV6-RUNX1 (encoding the TEL-AML1 protein) 
that represents the most common genetic subtype in pediatric BCP-ALL, present in 
25% of the cases. While the ETV6-RUNX1 translocation is associated with a favorable 
outcome, intrachromosomal amplification of chromosome 21 (iAMP21) leading to 
RUNX1 gene amplification predicts an increased risk of relapse and is present in 
about 2% of childhood BCP-ALL cases [27]. The ETV6-RUNX1 translocation arises 
most often in utero, generating a preleukemic clone that can persist for years before 
overt leukemia develops, and which requires additional cooperating events. These 
include deletions in the CDKN2A locus, and copy number alterations (CNAs) in genes 
regulating B-cell differentiation, such as PAX5 (28%) and EBF1 (10%), but not IKZF1 
[3]. Furthermore, there is a very strong enrichment for cooperating gene deletions 
in NR3C1, NR3C2, BTG1 and TBL1XR1 (Figure 3A) [3], which encode components 
and regulators of nuclear receptors and together are present in ~45% of the ETV6-
RUNX1 cases. In addition, 70% of the ETV6-RUNX1-positive leukemias harbor focal 
deletions in the pre-B cell receptor gene VPREB1. Another characteristic feature of 
ETV6-RUNX1-positive leukemias is the high frequency of ETV6 deletions affecting 
the other non-translocated ETV6 allele in about three-quarters of BCP-ALL cases, 
arguing that loss of TEL function cooperates with ETV6-RUNX1 in leukemogenesis.
The ETV6-RUNX1 fusion protein has retained the N-terminal non-DNA binding 
region of TEL containing the oligomerisation pointed domain (PNT) as well as the 
central repression (CR) domain, together with all functional domains of RUNX1 (Figure 
4A). The prevailing notion is that ETV6-RUNX1 binds RUNX1 target sequences, and 
acts as a constitutive inhibitor of transcription through recruitment of SIN3A- and 
NCoR1-containing co-repressor complexes by the ETV6 part of this fusion protein. 
ETV6-RUNX1 has been shown to promote B-cell differentiation and enhance the 
self-renewal of multipotent and B-cell progenitors in culture [28, 29], which requires 
DNA- and CBFβ-binding of the RHD of RUNX1 [29]. Furthermore, ETV6-RUNX1 
interferes with apoptosis through regulation of Survivin via the microRNAs miRNA-494 
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Figure 2. Gene regulatory interactions of B-lineage transcription factors at the early stages of B-cell 
development. B-lineage specification starts at the lymphoid-primed multipotent progenitors (MLPP) stage, 
and continues in the common lymphoid progenitor (CLP) and pro-B cell stage. B-cell differentiation is regulated 
by several transcription factors, including RUNX1, IKZF1, EBF1, E2A and PAX5 that cross regulate each 
other at the transcriptional level. Furthermore, the B-lineage transcription factors induce expression of the 
critical cytokine receptors FLT3 and IL7R, as well as target genes that are important for VDJ recombination, 
pre-B cell receptor signaling and B-lineage commitment. Transcriptional targets that fulfill no active role in 
signaling/transcription regulation at the specified stage are indicated in Italic and light gray, while cytokine 
receptors are boxed to distinguish them from B-lineage transcription factors.
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and miRNA-320a. Other specific pathways affected by ETV6-RUNX1 expression 
include the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin 
(mTOR) and TGF-β pathways [30, 31]. An ETV6-RUNX1 knock-in allele or transgenic 
expression of ETV6-RUNX1 is insufficient to induce leukemia in mice [32, 33], but 
may predispose ETV6-RUNX1 mice to carcinogen-induced T-lineage malignancies 
[33]. Similarly, transplantation of fetal liver-derived progenitor cells expressing ETV6-
RUNX1 into lethally irradiated recipient mice yields no leukemia, but confers a selective 
advantage on hematopoietic repopulation [28]. Hence, future experiments will need 
to identify the key cooperating events that drive ETV6-RUNX1-induced progenitor 
B-cell leukemia development. One promising candidate is the tumor suppressor gene 
CDKN2A, which has been shown to promote ETV6-RUNX1-induced leukemogenesis 
in a bone marrow transplantation assay [34]. 
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ERG
The ERG gene encodes a member of the E-twenty-six (ETS) family of transcription 
factors, which are characterized by an ETS-domain encoding a winged helix-turn-
helix structure for DNA-binding and a pointed (PNT) protein interaction domain. The 
ERG gene encodes six different protein isoforms, due to distinct transcriptional start- 
and termination-sites as well as alternative splicing events. The ERG subfamily also 
includes ETS family members FLI1 and FEV, both of which have been implicated in 
different forms of cancer. Many ETS proteins are phosphorylated in response to growth 
factor stimulation and cellular stress, but the exact residues modified in ERG as well 
as the responsible kinase(s) remain to be identified and investigated in more detail. 
By employing high-throughput sequencing of ERG binding sites in hematopoietic 
progenitor cells after chromatin immunopreciptation (ChIP-Seq), it has become evident 
that ERG binds not only to canonical ETS-sites, but also shows direct and indirect 
cooperative interactions with other transcriptional regulators, including GATA2, SCL, 
LYL1, RUNX1, LMO1 and FLI1 [35].
The ErgMld2/Mld2 mouse mutant harboring a loss-of-function Erg allele, which fails to 
induce target gene expression, has revealed that ERG fulfills a critical role in sustaining 
definitive hematopoiesis [36, 37] (Figure 1). During early embryonic hematopoietic 
development, Erg is not required for the initial hematopoietic lineage specification from 
the mesoderm, which coincides with the essential function of Runx1 in HSC emergence. 
However, at the second wave of hematopoietic development, which involves HSC 
maintenance, ERG is essential to drive expression of Runx1 and Gata2 and to prevent 
stem cell exhaustion [37]. ErgMld2/+ mice show adequate steady-state HSC maintenance, 
but display defective HSC renewal during stress-induced hematopoiesis, as well as 
defective megakaryopoiesis and B-cell development in competitive repopulation 
assays [38]. Retroviral expression of ERG in progenitor cells appears to promote 
megakaryopoiesis, increase the frequency of myeloid progenitors and induce expansion 
of T-, pro-B and erythroid cells. Moreover, enforced ERG expression can induce 
megakaryoblastic leukemia and T-ALL in mice, but not B-lineage leukemia [39, 40].
Deregulation of ERG function is observed both in solid tumors such as prostate 
cancer, Ewing’s sarcoma and primitive neuroectodermal tumors as well as hematological 
malignancies [41]. In leukemia, ERG expression can be downregulated through miR-
196a and miR-196b. The chromosomal translocation FUS-ERG is detected in AML and 
BCP-ALL [41, 42], while overexpression of ERG is associated with poor prognosis in 
T-ALL, cytogenetically normal adult AML, and MLL-rearranged childhood AML. ERG 
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has also been implicated in the development of transient myeloproliferative disorder 
and acute megakaryocytic leukemia (DS-AMKL) in Down syndrome patients, as ERG 
is located on chromosome 21q22.2 [43]. This is supported by a mouse model for 
Down syndrome-induced myeloproliferation, where the Erg+/Mld2 allele corrects the 
hematological features of this malignant disorder [44].
Childhood BCP-ALL is characterized by the presence of ERG point mutations and 
mono-allelic gene deletions, which are predicted to produce a truncated ERG protein 
[3]. Recent studies have defined ERG gene deletions as a separate genetic subtype 
present in childhood ALL (±7%) associated with a unique gene expression cluster, which 
correlates with a good treatment outcome [45, 46], although gain of ERG mutations 
have been described in relapsed BCP-ALL cases. This gene expression cluster is 
characterized by a high frequency of NRAS gene mutations. ERG is a transcriptional 
regulator of the non-canonical WNT11 gene [47] and the serine/threonine protein 
kinase PIM1 [48], but it remains to be established which gene targets of ERG are 
critical in BCP-ALL.
IKZF1 
Since its discovery as a key regulator of lymphopoiesis, the transcription factor 
IKZF1(Ikaros) and its family members, encoded by the genes IKZF1-IKZF5, have 
been the subject of intense study in the field of immunology [49]. These transcription 
factors are characterized by an N-terminal conserved zinc finger domain that mediates 
DNA binding, and an C-terminal zinc finger domain required for homo- and/or hetero-
dimerization with IKZF family members. Alternative splicing of the IKZF1 gene can 
generate thirteen different isoforms that vary in the number of N-terminal zinc fingers 
and often display compromised DNA binding, giving rise to dominant negative (DN) 
isoforms. Like the RUNX1 protein, IKZF1 is known to act both as a repressor as well 
as an activator of transcription. IKZF1 represses target genes through recruitment 
of HDAC-dependent (SIN3A and Mi-2β/NuRD complexes) and HDAC-independent 
(CtIP and CtBP) co-repressors [50]. Transcriptional activation by IKZF1 involves 
interaction with BRG1-containing SWI/SNF chromatin remodeling complexes, and 
through transcription elongation via recruitment of the P-TEFb component Cdk9 [50, 
51]. IKZF1 function can be modified through several posttranslational modifications. 
Phosphorylation of IKZF1 protein by Casein Kinase 2 (CK2) at multiple sites affects DNA 
binding, localization to pericentromeric heterochromatin, and controls degradation via 
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the ubiquitin pathway [50]. Furthermore, SUMOylation of IKZF1 at two lysine residues 
(K58 and K241) disturbs its function as transcriptional repressor [50].
IKZF1 plays a critical role at the early stages of hematopoiesis and lymphoid 
commitment as shown in different mouse models. Mice homozygous for a hypomorphic 
Ikzf1 allele (IkarosL/L) harboring a beta-galactosidase reporter within the Ikzf1 gene, 
display a mild phenotype with absence of peripheral plasmacytoid dendritic cells (pDCs) 
and a reduction in pre-pro-B cells, but relatively normal numbers of mature, polyclonal 
B-cells [52]. On the other hand, Ikaros-null-/- mice show a 30-fold decrease in HSC 
activity and are completely deficient in B-, natural killer (NK)- and fetal T-cells [53, 54]. 
Postnatally, a reduced number of T-cells differentiate in the thymus, but these T-cells 
display defects in CD4 versus CD8 lineage differentiation and pre-T-cell receptor (pre-
TCR) and TCR selection [55]. A more severe phenotype is observed in mice expressing 
a dominant-negative isoform, which lacks a functional DNA-binding domain but still 
contains an intact dimerization motif allowing it to homo-or heterodimerize (Ikaros-DN). 
Ikaros-DN mice display a more than 100-fold reduction in HSC activity and a complete 
lack of B-, T-, NK-cells, and all types of DCs [56]. The most severe phenotype has been 
described for mice with a single amino acid change (His191Arg) in the third zinc-finger 
of the DNA-binding domain, called Ikaros-Plastic, which interferes with the function of all 
IKZF family members. Mice homozygous for this mutation die between embryonic day 
15.5 (E15.5) and E17.5 due to an additional block in erythroid differentiation resulting 
in severe anemia [57]. In contrast, Ikaros-null+/- mice show rather normal lymphoid 
differentiation, and especially the Ikaros-DN+/- and Ikaros-Plastic+/- animals are highly 
susceptible to develop T-cell malignancies. Consistent with these observations, the 
Ikzf1 gene is frequently subject to genetic alterations in various types of mouse T-cell 
lymphomas, including mutations, deletions and inactivating retroviral insertions [58]. 
The essential role of IKZF1 in hematopoiesis is demonstrated by the fact that IKZF1 
primes lymphoid development in the HSC by activating transcription of lymphoid-
associated transcription factors (Ebf1) and signaling molecules (Flt3 and IL7r) (Figure 
2), while simultaneously suppressing myeloid-associated transcription factors (Sfpi1 
and Gfi1). Secondly, IKZF1 shuts down gene transcription programs in the lymphoid-
primed multipotential progenitors (LMPPs) that correlate with stemness (e.g. Gata2, 
Thy1) and multipotency (e.g. Gata1). IKZF1 controls expression of Cd3δ and Cd8 
genes within the T-cell lineage, while it directs early B-cell development by the induction 
of Rag gene expression and IgH rearrangements, allelic exclusion of the Igκ locus, 
and negative regulation of the Igll1 and Dntt promoters, thereby terminating pre-BCR 
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signaling [50]. Furthermore, IKZF1 controls pre-B cell proliferation by decreasing c-Myc 
expression in these cells [59]. Beyond the pre-B stage, IKZF1 controls the function of 
B-cells at later stages of development by increasing the activation threshold for mature 
B-cells, and regulating the isotype selection during class-switch recombination [60].
Although mouse knockout models for IKZF1 revealed its potential role as a tumor 
suppressor, only with the emergence of genome-wide screening methods, IKZF1 
was identified as a bona-fide leukemia suppressor gene in childhood ALL. It has now 
been established hat mono-allelic deletions and point mutations of the IKZF1 gene 
on chromosome 7p12.2 are a common event in childhood ALL and occur in about 
10-15% of BCP-ALL and 4% of T-ALL cases [2, 3] (Figure 4B). These deletions may 
affect the complete IKZF1 gene, giving rise to haploinsufficiency, or result in intragenic 
deletions generating DN-isoforms due to ∆4-6 and Δ4-7 deletions. Furthermore, single 
nucleotide sequence polymorphisms (SNPs) at the IKZF1 gene correlate with an 
increased risk to develop ALL [61, 62]. Gene deletions and point mutations are also 
detected in the IKZF3 gene in about 2% of the BCP-ALL cases [3]. Interestingly, IKZF1 
deletions are present at a much higher frequency in high-risk BCR-ABL1-positive 
BCP-ALL (85%) [63], while in chronic myeloid leukemia (CML) IKZF1 deletions are 
predominantly present in lymphoid blast crises (~20%). In line with these observations, 
Ikzf1 haploinsufficiency accelerates the onset of B-cell leukemia in p190BCR-ABL1 
transgenic mice [64]. IKZF1 gene deletions also frequently occur in another subclass of 
high-risk childhood leukemia patients, characterized by activating JAK2 point mutations 
that often harbor high expression of the CRLF2 cytokine receptor as a result of CRLF2 
gene rearrangements [65]. A large fraction of the remaining IKZF1-mutated BCP-
ALL cases also display a BCR-ABL1-like gene expression signature, and are often 
characterized by other variants of ABL1 and JAK2 translocations or gene lesions in 
IL7R as identified by transcriptome analyses [66] (Figure 3B). Notably, deletions and 
mutations of IKZF1 are associated with a poor clinical outcome and act as a strong 
predictor of relapse [67, 68]. 
The pathways downstream of IKZF1 that play a critical role in the onset of BCP-
ALL and altered therapy response largely remain to be identified. In mouse T-cell 
leukemogenesis, aberrant Notch receptor activation is a critical key event upon loss 
of IKZF1 function [69]. Whether IKZF1-dependent deregulated expression of Notch or 
any of its other cancer-related targets, such as CDK-inhibitor p27Kip1 (CDKN1B) [70], 
c-Myc [59], or phospho-STAT5 [71], contribute to the pathogenesis of BCP-ALL is still 
an open question. There is compelling evidence that disruption of p19ARF (CDKN2A 
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gene) is a strong cooperating event together with IKZF1 gene alterations in Ph+-ALL, 
and both represent the predominant complementation groups in the BCR-ABL1 subtype 
of BCP-ALL [3, 63]. However, in these leukemia samples there is still selection for the 
presence of additional genetic aberrations in other transcription factors in about 60% 
of the cases, including PAX5, EBF1 and ETV6, arguing that mono-allelic IKZF1 gene 
deletions are not sufficient to block B-lymphoid differentiation and probably regulate 
additional signaling pathways.
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Figure 3. Differential requirement for distinct cooperating events in specific genetic subtypes of BCP-
ALL. (A) ETV6-RUNX1-positive leukemias display a selective enrichment for gene lesions in transcriptional 
cofactors BTG1 (19% versus 5% in the remaining BCP-ALL subtypes) and TBL1XLR1 (13% versus 1% in 
the remaining BCP-ALL subtypes) together with genetic aberrations in nuclear hormone receptors, mainly 
the glucocorticoid receptor (GR), encoded by the gene NR3C1 (13% versus 2% in the remaining BCP-
ALL subtypes), as well as the mineralocorticoid receptor, encoded by the gene NR3C2 (11% versus 1% 
in the remaining BCP-ALL subtypes) [3]. (B) Focal gene deletions and point mutations affecting the tumor 
suppressor IKZF1 frequently co-occur with gain-of-function mutations in tyrosine kinases, such as BCR-
ABL1, JAK2 and cytokine receptors CRLF2 and IL-7Rα. Solid lines indicate direct physical interactions, 
while dotted lines indicate genetic interactions, i.e. cooperation in leukemogenesis [63, 65-66].
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E-box binding proteins
Transcriptional regulators of the E-box binding protein family play important roles in 
neuronal, muscle cell and lymphoid differentiation. E proteins E12 and E47, generated 
through alternative splicing of the E2A (TCF3) gene, constitute the class I helix-loop-
helix (HLH) transcription factors, together with E2-2 (TCF4) and HEB (TCF12). These 
HLH transcription factors are characterized by a basic region that mediates DNA 
binding to the E-box recognition site, and a HLH-domain essential for dimerization. 
E proteins also share two N-terminal transcriptional activation domains, AD1 and 
AD2, where the AD1 domain modulates transcription through recruitment of lysine 
acetyltransferases CBP/p300 and p/CAF, the SAGA-complex and members of the 
ETO family [72-74]. The DNA binding activity of E proteins is abrogated upon binding 
to members of the class IV HLH proteins comprising ID1-ID4, which contain the HLH 
dimerization motif, but lack a functional DNA-binding domain. Within the hematopoietic 
compartment, the E2A proteins form heterodimers with the basic-HLH protein SCL, an 
essential regulator of hematopoietic development. Proteomic studies have revealed 
that E47 also interacts with lysine demethylase LSD1, co-repressor CoREST and 
members of the 14-3-3 scaffolding proteins [75]. Furthermore, HEB and E2A bind in 
a cooperative manner to SMAD2 and SMAD3 transcription factors, effectors of TGFβ 
signaling. E12 and E47 are degraded by the ubiquitin-proteosome system through 
binding to ubiquitin-conjugating enzyme mUbc9 and via Notch-induced association 
with E3 ubiquitin ligase SCFSKP2. E2A function is regulated through lysine acetylation 
by p300/CBP on residue K34 within the AD1 domain, which potentiates transcriptional 
activation [72]. Phosphorylation of E12/47 by p38-MAPK interferes with transcription 
activation [76], while phosphorylation on residues S514 and S529 by CKII and protein 
kinase A (PKA) inhibits E47 homodimerization [77]. In addition, human E47 harbors 
an AKT phosphorylation site (S529) [75], but the functional implication remains to be 
established.
The Tcfe2a/Tcf3 gene is required to maintain the HSC pool under stress conditions, 
and to promote the development of LMPPs, common lymphoid precursors (CLPs), 
early thymocyte progenitors (ETPs), pre-pro-B cells and all subsequent stages of B-cell 
differentiation [78, 79]. A partial block at the earliest stages of T-cell differentiation in 
Tcfe2a-/- mice precedes the development of T-cell lymphomas in these mice [80]. E2A 
directs B-cell fate determination by activating Foxo1 gene expression, which, together 
with E2A, PU.1 and IL-7R-activated STAT5, induce Ebf1 expression. At the same time, 
E2A represses myeloid/erythroid-lineage-specifying genes, including Gata1, Csf1r and 
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EpoR. E47 homodimers are the major E proteins in pro-B lymphocytes, consistent 
with the specific requirement for E2A proteins at this stage of B-cell differentiation. 
HEB- and E2-2-deficient lymphocytes develop normally, showing a mild reduction 
in the number of pro-B cells [81, 82]. Compound heterozygous Tcf4+/-;Tcf12+/- and 
Tcf4+/-;Tcfe2a+/- mice show a more severe phenotype compared to the single knockout 
animals, arguing that total levels of E proteins, rather than the activity of a specific 
E-box binding protein is important for B-cell development [82]. In contrast, E2-2 fulfills 
a unique and essential role in the development of plasmacytoid dendritic cells (pDCs) 
[83]. In addition to Ebf1, other E protein targets important for B-lymphoid differentiation 
include Rag1, Rag2, Dntt, Igll1, Vpreb1 and CD79a, as well as VH-DJH recombination 
at the IgH locus and Igk rearrangements. Additionally, E2A contributes to activate 
expression of the Pax5 locus in concerted action with EBF1, FOXO1, IRF4 and IRF8 
[84]. In peripheral activated B-cells, E47 functions to induce Aicda expression and 
immunoglobulin class-switch recombination [85], while E2-2 influences follicular versus 
marginal zone fate determination [81].
The human E protein-encoding genes TCF3, TCF4 and TCF12 are implicated in 
several different types of hematological malignancies. Recurrent focal gene deletions 
and point mutations affecting TCF4 (chromosome 18q21.1) and TCF12 (chromosome 
15q21.3) occur at low frequency in pediatric BCP-ALL [2, 4]. TCF3 loss-of-function 
genetic alterations on chromosome 19p13.3 include heterozygous gene deletions, 
which are found in about 70% of the patients suffering from Sezary syndrome, a 
cutaneous subtype of T-cell lymphomas [86]. At much lower frequencies, chromosomal 
translocations TCF3-HLF (1%) and TCF3-PBX1 (5%) are found in childhood BCP-
ALL (Figure 4C), both of which are associated with a poor treatment outcome. These 
oncogenic fusion proteins combine the transcriptional activation domains of E2A with 
the DNA binding domains of HLF and PBX1, respectively. Both TCF3-HLF and TCF3-
PBX1 are thought to interfere with normal E-box binding/HLH protein function through 
recruitment of transcriptional co-activators via the AD1 domain of E2A to PBX1 and 
HLF target genes. Notably, inhibition of E2A/HEB function is an important mechanism 
for the frequently occurring gain-of-function alterations in HLH protein-encoding genes 
TAL1/SCL and LYL1 in T-ALL. In general, TCF3-PBX1-positive leukemias display 
a rather limited amount of cooperating gene deletions, including PAX5 (40%) and 
CDKN2A (35%) [3]. These leukemias are also characterized by almost an obligatory 
deletion of the other non-translocated TCF3 allele (95%) [3].
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TCF3-PBX1 is a regulator of BMI1 expression, thereby alleviating part of the 
requirement for CDKN2A gene deletions in BCP-ALL [87]. TCF3-PBX1 induces the 
expression of Wnt16, which may affect survival signaling and N-cadherin-dependent 
adhesion [88, 89]. Experimental mouse models for TCF3-PBX1-induced leukemia 
show collaboration with Hox gene overexpression in lymphoid malignancies [90]. The 
oncogenic fusion protein TCF3-HLF suppresses Runx1 transcription and activates 
expression of Lmo2 and several Groucho-related genes, as well as anti-apoptotic 
genes Slug and Bcl2 [91-93]. Furthermore, TCF3-HLF mediates overexpression of 
ATP-dependent drug transporter ABCB1 (MDR1) [94], which may contribute to the 
poor treatment outcome of leukemias harboring a TCF3-HLF translocation. Thus, 
TCF3-PBX1 and TCF3-HLF seem to regulate different target genes, but may employ 
similar mechanisms of ectopic recruitment of transcriptional co-activators, like CBP/
p300 and components of the SAGA-complex, which are important for the oncogenic 
properties of these leukemia-associated fusion proteins.
EBF1
The early B-cell factor (EBF) transcription factors EBF1-EBF4 play an important role in 
the development of a number of specialized cell types, including neurons, adipocytes 
and lymphocytes. EBF proteins are composed of a highly conserved N-terminal DNA-
binding domain (DBD), an IPT/TIG (immunoglobulin, plexins, transcription factors-
like/transcription factor immunoglobulin) domain, an atypical helix-loop-helix-loop-
helix (HLHLH) motif, and a less conserved C-terminal domain, which contributes to 
transcriptional activation. EBF proteins bind DNA as homo- or heterodimers via a unique 
motif specific for the EBF family, termed the “zinc knuckle” located within the DBD [95, 
96]. EBF1 interacts with transcriptional co-activator CBP, but surprisingly inhibits its 
lysine acetyltransferase activity [97]. Two related large zinc-finger proteins, ZFP423 
and ZFP521, can bind EBF1, and are capable of recruiting Mi-2β/NuRD complexes. 
Gene silencing of Mi-2β subunit seems to potentiate EBF1-mediated gene activation 
[98]. Furthermore, EBF1 inhibits DNA methylation of specific target genes (e.g. Cd79a), 
which is counteracted by Mi-2β/NuRD. On the other hand, EBF1 requires the BRG1 
and BRM-containing SWI/SNF complex to activate target genes [98].
The essential role of EBF1 in B-cell lineage commitment has become evident from 
various mouse studies. Mice deficient for Ebf1 show an absolute block in differentiation 
at the pre-pro-B cell stage [99]. Forced expression of EBF1 in E2A-deficient cells 
rescues B-cell differentiation, arguing that EBF1 acts downstream of E2A in B-cell 
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development [100]. EBF1 is essential for the rearrangement of IgH and IgL loci and 
expression of genes essential for B-lineage specification and commitment, including 
Cd79a, Cd79b, Vpreb1, Igll1, Foxo1 and Pax5. EBF1 and PAX5 positively cross-
regulate each other promoters at early stages of B-cell development, thereby providing 
an auto-regulatory loop critically important for B-cell specification. EBF1 antagonizes 
the expression of Cebpα, Sfpi1, Id2, Id3 and several NK-cell-specific genes [101, 
102]. EBF1 also appears to be a critical regulator of proliferative expansion and 
survival of pro-B cells by activating expression of c-Myb, and controlling Akt- and 
canonical B-cell receptor (BCR) signaling [103]. Genome-wide ChIP-Seq analyses 
have revealed the identification of several new EBF1 target genes, including Hlx, Ctla4 
and Gfi1b [104]. Ectopic EBF1 expression in hematopoietic progenitor cells forces 
B-cell development at the expense of myeloid cell fates [101, 105]. At later stages of 
B-cell differentiation, EBF1 is essential for the development of B1- and marginal zone-B 
cells, and maintenance of follicular and germinal center B-cells [103, 106]. Ebf1+/- mice 
display a 50% decrease in pro-B cells and a 10-30% reduction in splenic B-cells, but 
are not prone to develop spontaneous leukemia. However, combining a constitutive 
active transgenic STAT5 allele with Ebf1 haploinsufficiency yields progenitor B-cell 
leukemias with a penetrance of 100% [107]. 
In human ALL, mono-allelic deletions affecting the EBF1 gene on chromosome 
5q33.3 have been reported in a small fraction of the total BCP-ALL cohort (4%) [3]. 
These deletions are variable in size, but frequently affect a large portion of the EBF1 
open reading frame, suggesting a loss-of-function phenotype (Figure 4D). Genetic 
aberrations affecting EBF1 are more prevalent in high-risk leukemia patients, including 
BCR-ABL1-positive cases (14%) and in a novel defined cluster (38%) characterized 
by a high frequency of TP53/RB1 and JAK mutations, together with other B-cell 
pathway gene deletions [45]. Notably, EBF1 haploinsufficiency occurs more frequently 
in combination with BTG1 gene deletions (26%) suggesting that these tumor suppressor 
genes may cooperate in leukemogenesis [108].
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PAX5 
The guardian of B-cell identity PAX5, also known as B-cell specific activator protein 
(BSAP), is one of nine PAX transcription factors, but the only one expressed within the 
hematopoietic system. A characteristic feature of PAX protein family is the conserved 
paired domain, which functions as a bipartite DNA-binding region and consist of an N- 
and C-terminal subdomain. Each subdomain binds to a distinct half-site of a degenerate 
consensus recognition sequence. PAX5 displays cooperative DNA-binding with other 
transcription factors, such as MYB and ETS1, and has been shown to repress PU.1 
transactivation through direct binding [109]. Besides the paired domain, PAX5 harbors 
two interaction domains for Groucho co-repressors [110], a partial homeodomain that 
serves as a binding domain for pRb [111], and a potent C-terminal transactivation domain 
that interacts with the SAGA-complex and lysine acetyltransferases CBP/p300, which 
induce lysine acetylation of the PAX5 DNA-binding domain [112]. Alternative splicing 
of the Pax5 gene generates multiple protein isoforms that differ in the C-terminal 
transactivation domain, but their individual functions remain to be established. The death-
domain-associated protein DAXX has been shown to bind PAX5, thereby modulating 
its transcriptional activity [113]. Proteomic studies have demonstrated that PAX5 can 
also recruit the TBP, TAF4 and TAF6 subunits of the basal transcription factor complex 
TFIID, the SWI/SNF chromatin remodeling components BRG1, BAF57 and BAF170, 
Figure 4. Overview of the type of genetic lesions that affect B-lineage transcription factors. (A) The 
RUNX1 gene comprises of nine exons and an open reading frame (ORF) of 1359 base pairs (bp). The 
chromosomal translocation ETV6-RUNX1 confers RUNX1 into a constitutive transcriptional repressor, which 
is dependent on the Runt homology domain (RHD) for DNA binding. The transcriptional regulatory domain 
(TRD) of RUNX1 still contributes to the recruitment of co-repressor proteins. (B) The IKZF1 gene, which 
consists of eight exons, is targeted by point mutations generating frameshift (fs) or missense mutations, as 
well as mono-allelic deletions affecting a larger portion of the gene (Δ4-8) without producing a functional 
protein ( ), and intragenic deletions ( ) generating dominant negative (DN) isoforms (Δ4-6 and 
Δ4-7). These DN-isoforms lack the DNA binding domain that comprises of four zinc-fingers (ZF), but 
retain the dimerization domain, which consists of two ZF. (C) The TCF3 gene encoding the E2A protein 
consists of 19 exons. The chromosomal translocations TCF3-PBX1 and TCF3-HLF retain the transcriptional 
activation domains (AD) of E2A, but harbor the DNA binding domain of PBX1 and HLF, respectively. The 
helix-loop-helix (HLH) domain of E2A is not present in the oncogenic fusion proteins. (D) The EBF1 gene, 
which consists of 16 exons, is exclusively affected by focal gene deletions that cover a large portion of 
the coding region including the ATG ( ), or generate truncated proteins ( ) encoding a part of 
the DNA binding domain (DBD), but lack the IPT/TIG and helix-loop-helix-loop-helix motif. (E) The PAX5 
gene, which consists of 10 exons, is affected by different gene lesions, including missense and frameshift 
mutations, intragenic deletions often giving rise to truncated proteins that lack the paired domain (PD) 
required for DNA binding, as well as translocations. These translocations with multiple partner genes 
produce oncogenic PAX5 fusion proteins that still harbor the PD domain, but may lack the octapeptide 
(O) involved in Groucho-binding, the homeodomain-like region (H), and transcriptional regulatory domain 
(TRD), depending on the breakpoint of the translocation.
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the RbBP5 subunit of the MLL-containing H3K4 methyltransferase complex, and 
co-repressor NCoR1 [114]. Thus, PAX5 is able to regulate target genes through its 
interplay with different epigenetic modifiers in a context-dependent manner.
During B-lymphopoiesis, Pax5 expression starts at the pro-B cell stage acting 
downstream of E2A and EBF1 in the B-cell differentiation pathway, and its levels 
are maintained until plasma cell differentiation occurs. At the early stages of B-cell 
development, the Pax5 gene is subject to allele-specific regulation, with only one allele 
being transcribed, whereas it switches to bi-allelic expression in immature B-cells 
[115]. During the initial phase of fetal hematopoiesis, Pax5-deficiency results in a block 
before the appearance of B220+ progenitors, while in adult Pax5-deficient mice B-cell 
development proceeds until the c-Kit+B220+ pro-B cell stage [116, 117]. Specifically, 
Pax5-deficient bone marrow cells are halted at the stage of VH-to-DJH rearrangement. 
However, Pax5-/- pro-B cells are not yet fully committed to the B-cell lineage, since 
these cells remain pluripotent and are able to differentiate into functional macrophages, 
granulocytes, dendritic cells, osteoclasts and natural killer cells in the presence of the 
appropriate cytokines [118]. Enforced expression of PAX5 in multipotent progenitors 
results in the production of biphenotypic myeloid/B-lymphoid cells with extensive 
self-renewal capacity [119].
PAX5 fulfills a dual role as master regulator of lineage commitment by repressing 
non-B-lineage genes (Notch1, Csf1r, Csf1, CD28) and differentiation-stage inappropriate 
genes (Flt3, Sca1, Blimp1), while activating (pro-) B-cell specific genes, including 
components of receptor signaling (Cd79a, Cd19, Blnk, Cd72, Igk) and genes encoding 
transcriptional regulators (Ebf1, Lef1, Tcf4, Ikzf3, Id3, Bach2, Irf4, Irf8). In addition, 
PAX5 permits accessibility of the immunoglobulin heavy chain locus through binding to 
PAX5-activated intergenic repeat (PAIR) elements [120]. PAX5 expression is enhanced 
in activated B-cells and essential for class-switch recombination, by activating Aid 
expression. However, PAX5-target genes in early and late B-lymphopoiesis appear to be 
quite distinct [121]. PAX5 remains required for maintaining the B-cell gene expression 
program, as conditional Pax5 gene inactivation results in the conversion of mature 
B-cells into functional T-cells by dedifferentiation to uncommitted progenitors in the 
bone marrow [122, 123]. In addition, complete loss of PAX5 in mature B-cells leads 
to the development of aggressive progenitor-B cell lymphomas in these mice [122]. In 
vivo studies have shown that constitutive active STAT5 expression in combination with 
Pax5 haploinsufficiency drive ALL development [107]. On the other hand, ectopic PAX5 
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expression in the T-cell lineage induces immature lymphoblastic T-cell lymphomas in 
IgH-PAX5 transgenic mice.
The PAX5 gene located on chromosome 9p13.2 is deregulated in a small fraction 
of diffuse large B-cell lymphomas, which results from translocations involving the IgH 
enhancer (Eµ) and correlate with elevated PAX5 levels [124]. In addition, aberrant 
ectopic expression of PAX5 has been reported in AML [125]. On the other hand, 
PAX5 loss-of-function genetic lesions have been identified in a high percentage of 
childhood and adult BCP-ALL cases (±35%), which include predominantly mono-allelic 
deletions that sometimes involves a larger segment of chromosome 9p, and point 
mutations, as well as some chromosomal translocations generating a large variety of 
distinct chimeric PAX5-fusion proteins (Figure 4E). PAX5 mutations have also been 
identified in splenic marginal zone lymphomas and diffuse large B-cell lymphomas 
[126]. Recurrent translocations in BCP-ALL include PAX5-ETV6, PAX5-C20orf112, 
PAX5-FOXP1 and PAX5-PML that predominantly act to suppress PAX5 target genes 
[3, 127]. PAX5 CNAs are detected in virtually all BCP-ALL genetic subtypes, but 
occur more frequently in BCR-ABL1- (50%) and TCF3-PBX1-positive cases (41%) [3, 
128]. The frequent concurrent deletion of PAX5 and CDKN2A suggests that they are 
cooperating events in the pathogenesis of BCP-ALL [3, 129]. There is no significant 
association between clinical outcome and PAX5 status, despite the finding that PAX5 
is commonly mutated in ALL [68].
LEF1
Deregulation of the canonical Wnt/β-catenin signaling pathway has been identified as 
a hallmark of multiple cancers, including hematological malignancies. This pathway is 
activated via ligation of secreted Wnt proteins to their receptors and inhibition of the 
Ser/Thr kinase GSK-3β. As a consequence, the transcriptional co-activator β-catenin 
is stabilized allowing it to translocate to the nucleus and bind to the T-cell factor (TCF)/
lymphoid enhancer factor (LEF) transcription factors TCF7, TCF7L1, TCF7L2 and LEF1. 
This results in a transcriptional switch from repression to activation, through recruitment 
of co-activator complexes, including BRG1, p300/CBP, the ATAC acetyltransferase 
complex, BCL9 and the chromatin remodeling factors Pygo1/Pygo2 [130-133]. Another 
level of complexity is introduced by the expression of distinct isoforms for each of the 
TCF/LEF family members, where alternative splicing generates four different LEF1 
isoforms. Moreover, there is a natural occurring LEF1-antisense transcript located at 
the 5’ end of the gene, which has not yet been studied in great detail. LEF1 contains 
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a DNA-binding domain that shows homology to members of the high mobility group 
(HMG) proteins, and binds DNA as a monomer inducing a sharp bend in the DNA. In 
the absence of Wnt signaling, LEF1 predominantly acts as a transcriptional repressor 
by assembling CtBP, TLE/Groucho and HDAC molecules to its target genes [132].
The Wnt/β-catenin signaling pathway controls the proliferation, survival and 
differentiation of hematopoietic cells. Self-renewal of HSCs coincides with activation 
of β-catenin pathway, and high levels of constitutively activated β-catenin in HSCs 
confer myeloid potential on lymphoid progenitors [134]. Mice deficient for Lef1 display 
reduced proliferation and enhanced apoptosis of pro-B cells, but no defect in B-cell 
differentiation [135], while ectopic LEF1 expression promotes myeloid at the expense 
of lymphoid development [136]. Moreover, enforced LEF1 expression in bone marrow 
progenitor cells results in myeloid and lymphoid malignancies upon transplantation 
into lethally irradiated recipient mice [136]. In human CD34+ cells, inhibition of LEF1, 
but not of β-catenin, affects proliferation and apoptosis of these cells, suggesting 
that LEF1 may fulfill β-catenin-independent functions in early human progenitor cells 
[137]. Furthermore, these studies have demonstrated a role of LEF1 in neutrophil 
differentiation, which correlates with regulation of the ELA2 gene by LEF1 together 
with CBFα.
Enhanced activation and strong nuclear localization of β-catenin has been 
demonstrated in CML, ALL, AML, mantle cell and cutaneous lymphoma. One way this 
pathway can be modulated is through epigenetic gene silencing of Wnt antagonists, 
as observed in AML and ALL [138, 139]. In addition, overexpression of LEF1 has been 
observed in CLL, ALL, AML and lymphomas and associated with enhanced survival 
properties of CLL cells and poor treatment outcome in adult BCP-ALL patients [140, 
141]. On the other hand, recurrent inactivating mono-allelic and bi-allelic microdeletions, 
and truncating point mutations of the LEF1 gene, located on chromosome 4q25, have 
been reported in pediatric T-ALL (17%) and BCP-ALL (2%) [3, 142]. Somatic mutations 
in TCF7L2 have also been described in BCP-ALL [143]. Deficiency for LEF1 function 
has been linked to enhanced c-MYC and FAS expression [135, 142], but whether 
these LEF1 target genes critically contribute to human leukemogenesis remains to 
be determined.
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Concluding remarks 
Genomic profiling by SNP arrays and genomic sequencing have led to the identification 
and characterization of novel genetic lesions that not only contribute to the pathogenesis 
of BCP-ALL, but in some cases also predict therapy response. It is evident that the 
B-lineage transcription factors described in this review play a central role in the 
differentiation and survival of lymphocyte progenitor cells. However, for many of these 
factors it remains to be established how they contribute to leukemia development 
or which cooperating events are required to develop the disease. In addition, the 
observation that both gain-of-function and loss-of-function genetic lesions that 
affect proteins, such as AML1, ERG, PAX5 and LEF1, may contribute the oncogenic 
transformation of hematopoietic cells, calls for a more detailed understanding of the 
distinct signals regulated by these transcription factors. Extensive network structure 
analyses will provide additional insight into the key target genes that are regulated by 
these mutated transcription factors [144]. The next step will be to translate this knowledge 
into improved therapy modalities for the patient. These may include drugs that interfere 
with the action of epigenetic regulators recruited by oncogenic fusion proteins, such 
as ETV6-RUNX1 and TCF3-PBX1. It can be expected that such developments will 
lead the way from standard (chemo-) therapy to personalized medicine for patients 
with BCP-ALL.
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Abstract 
Resistance to glucocorticoids (GCs) is a major clinical problem in the treatment of 
acute lymphoblastic leukemia (ALL), but the underlying mechanisms are not well 
understood. Although mutations in the glucocorticoid receptor (GR) gene can give 
rise to therapy resistance in vitro, acquired somatic mutations in the GR are rarely 
encountered in patients. Here we report that the protein encoded by the BTG1 gene, 
which is frequently deleted in (pediatric) ALL, is a key determinant of GC responsiveness. 
Using RNA interference, we show that loss of BTG1 expression causes GC resistance 
both by decimating GR expression and by controlling GR-mediated transcription. 
Conversely, re-expression of BTG1 restores GC sensitivity by potentiating GC-induced 
GR expression, a phenomenon known as GR autoinduction. In addition, the arginine 
methyltransferase PRMT1, a BTG1-binding partner and transcriptional coactivator, 
is recruited to the GR gene promoter in a BTG1-dependent manner. These results 
implicate the BTG1/PRMT1 complex in GR-mediated gene expression and reveal that 
deregulation of a nuclear receptor coactivator complex can give rise to GC resistance. 
Further characterization of this complex as part of the GR regulatory circuitry could 
offer novel opportunities for improving the efficacy of GC-based therapies in ALL and 
other hematologic malignancies.
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Introduction 
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. 
Although cure rates are exceeding 80%, therapy resistance and associated disease 
relapse remain a significant clinical problem. Pediatric ALL is a genetically heterogeneous 
disease characterized by chromosomal abnormalities, including translocations, 
aneuploidies, and deletions. Molecular analysis of the most common chromosomal 
alterations in ALL has allowed classification into different subtypes that are associated 
with distinct clinical outcome. In addition to these chromosomal abnormalities, prognosis 
is determined by blast count at diagnosis, lineage (B- or T-cell), and the initial response 
to therapy [1]. Despite these advances in the molecular pathology of pediatric ALL, 
little is known about the mechanisms that contribute to relapse or therapy resistance 
in the patient.
Synthetic glucocorticoids (GCs) are essential drugs in the treatment of pediatric 
ALL, as they effectively induce apoptosis in leukemic blasts. GCs exert their effects by 
binding to the glucocorticoid receptor (GR), a ligand-activated receptor and member 
of the nuclear receptor family. Activation of the GR by GCs leads to recruitment of GR 
to large transcription regulatory complexes that modulate expression of GC response 
genes, which leads to the induction of apoptosis in lymphoblasts. Resistance to GCs is 
a major clinical problem predictive of poor therapy outcome [2]. In most in vitro models, 
resistance to GCs appears to occur at the level of the receptor, either by mutations in 
the GR or by the inability of cells to up-regulate the GR in response to GC exposure, 
a phenomenon known as GR autoinduction [3]. However, mutations in the GR are 
rarely seen in (relapsed) ALL [4], and it remains unclear to what extent differences in 
GR expression affect therapy response in the patient [5, 6]. 
Through genome-wide profiling using single nucleotide polymorphism (SNP)-based 
array comparative genomic hybridization, we and others recently identified several 
novel submicroscopic lesions that may either contribute to the development of ALL 
or determine the response to therapy [7, 8]. Focal microdeletions, often smaller than 
0.5 Mb and containing single genes, were identified with a relatively high frequency. 
The genes most frequently affected by these microdeletions are implicated in B-cell 
differentiation, cell survival, or cell-cycle progression [7, 8]. A novel recurrent single-
gene lesion observed in pediatric pre-B ALL involves the B-cell translocation 1 gene 
(BTG1) [7-9]. This gene was originally identified as a translocation partner of the 
c-MYC gene in a case of B-cell chronic lymphocytic leukemia and belongs to a family 
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of antiproliferative genes that also includes BTG2, BTG3, TOB, and TOB2 [10, 11]. 
Proteins encoded by members of this gene family have been implicated in the induction 
of growth arrest or apoptosis in a variety of cell systems [12]. Overexpression of BTG1 
was found to block proliferation during normal erythroid differentiation [13] and to 
induce growth arrest in a B-cell lymphoma model [14]. The BTG1 protein has no proven 
intrinsic enzymatic activity, but the presence of several protein interaction domains 
suggests that BTG1 functions either as an adaptor molecule or as a cofactor involved 
in transcriptional regulation. For instance, BTG1 was identified as coactivator of the 
homeobox transcription factor HoxB9 [15] and the transcriptional regulator CAF1 [16]. 
Moreover, BTG1 was shown to stimulate the activity of several myogenic transcription 
factors as well as nuclear receptors during muscle cell differentiation [17]. 
BTG1 interacts with and regulates the activity of the arginine methyltransferase 
PRMT1 [10, 18]. Members of this enzyme family, including PRMT1, are considered 
global regulators of gene expression that act as transcriptional coregulators by arginine 
methylation of histone tails and critical transcriptional regulators [19]. PRMT1 was shown 
to act as a histone H4 Arg-3–specific methyltransferase involved in transcriptional 
activation of several nuclear receptors [20-22]. However, a role for either BTG1 or 
PRMT1 in GR activation has not been investigated. In the present study, we identify 
BTG1 as a critical determinant of GC-induced therapy responses in vitro, which acts by 
controlling GR autoinduction as well as by regulating GR-mediated gene expression. 
Moreover, we demonstrate that PRMT1 is recruited to the GR promoter in a BTG1-
dependent manner.
Material and Methods 
Collection of leukemia samples and maintenance of ALL cell lines
Lymphoblast samples of patients treated according to the current clinical protocol were 
obtained with informed consent in accordance with the Declaration of Helsinki and with 
the approval and supervision of the Medical Ethics Committee of the Radboud University 
Nijmegen Medical Center. ALL-derived cell lines RS4;11, REH, and SUP-B15 were 
purchased from ATCC. Primary lymphoblasts, RS4;11, and REH cells were maintained 
in RPMI 1640 with L-glutamine (Invitrogen) supplemented with 10% fetal bovine serum 
(FBS; Greiner Bio-One) and 100 units/mL penicillin/streptomycin (Invitrogen), whereas 
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SUP-B15 cells were maintained in Iscove modified Dulbecco medium with L-glutamine, 
20% FBS, and 100 units/mL penicillin/streptomycin.
MLPA and sequence analysis
Nine Multiplex Ligation-dependent Probe Amplification (MLPA) probes covering the 
BTG1 gene (supplemental Table 1; supplemental Figure 1A, available on the Blood 
Web site; see the Supplemental Materials link at the top of the online article) were 
combined in one MLPA assay along with 4 standard control probes in 3 different 
genes, ie, VIRP2, MRPL41, and KIAA0056, according to guidelines of MRC-Holland. 
Amplification products were quantified and identified by capillary electrophoresis on 
an ABI 3730 genetic analyzer (Applied Biosystems). Normalization of the data was 
performed by dividing the peak area of each probe by the average peak area of the 
control probes. This normalized peak pattern was divided by the average peak pattern 
of all the samples in the same experiment. The resulting values were approximately 
1.0 for every wild-type peak, 0.5 for heterozygous deletions, and 1.5 for heterozygous 
duplications.
Lentiviral knockdown in ALL cell lines 
shRNAs were introduced using the BLOCK-iT U6 RNAi Entry Vector in combination 
with the pLenti6/BLOCK-iT DEST vector according to the manufacturer's protocol 
(Invitrogen). Two shRNA sequences were directed against BTG1 mRNA (NM_001731.1): 
5′-gctctctgtacatttgctagc-3′ (shRNA1) and 5′-gctgctggcagaacattataa-3′ (shRNA2). A 
nonfunctional shRNA (5′-gctacaagagaaaccaaatct-3′), originally designed to target 
myosin X, which is not expressed in lymphocytes, was used as a negative control. 
The individual vectors were cotransfected with packaging vectors into the 293FT cells 
according to the manufacturer's instructions. Virus was produced in Dulbecco modified 
Eagle medium containing Glutamax (Invitrogen) supplemented with 10% FBS and 
100 units/mL penicillin/streptomycin and collected from tissue culture supernatant 48 
hours after transfection. Tissue-culture plates were coated with retronectin (Takara), 
and virus supernatant was cocultured with ALL cell lines for 8 hours. Transduced cells 
were selected with 4 μg/mL blasticidin (Invitrogen). 
Retroviral transduction and Western blot analysis
A BTG1 expression construct was generated by polymerase chain reaction (PCR; 
forward primer: 5′-gcgaattcgaccatggcttacccatacgatgttcc-agattacgctcatcccttctacacccg
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gg-3′; reverse: 5′-gcctcgagttaacctgatacagtcatcatattg-3′), cloned into pLZRS-Neo, and 
verified by sequencing. pLZRS-HA-BTG1 and pLib-T7-MSC2-IRESpuro-hGR (obtained 
from Prof Dr R. Kofler, Innsbruck, Austria) were transfected into Phoenix amphotropic 
producer cells to generate retrovirus-containing supernatants. Cells were transduced 
in retronectin-coated tissue-culture dishes, and transduced cells were selected using 
400 μg/mL G418 (Invitrogen) and 1 μg/mL puromycin. Antibodies directed against the 
GR (Santa Cruz Biotechnology), α-tubulin (Sigma-Aldrich), and the HA epitope, clone 
3F10 (Roche Diagnostics) were used in immunoblot assays using standard procedures.
Cytotoxicity assays
Cell viability was determined using the CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay (MTS; Promega). A total of 1×105 cells were seeded in a 96-well 
culture plate and treated with increasing amounts of prednisolone (5×10−3 to 5×103 
μg/mL; Organon) or dexamethasone (5×10−4 to 5×102 μg/mL; Centrafarm) for 72 
hours (RS4;11 cells) or 48 hours (REH cells). Apoptosis induction was measured 
using the annexin V–PE Apoptosis Detection Kit I (BD Biosciences) according to 
the manufacturer's protocol and analyzed on a FACSCalibur flow cytometer (BD 
Biosciences).
Microarray analysis and quantitative real-time RT-PCR
Total RNA was isolated using the RNeasy Mini kit (QIAGEN) according to the 
manufacturer's instructions, and RNA quality was tested using the Agilent 2100 
Bioanalyzer. A total of 1 μg of total RNA from each sample was used to perform 
hybridizations on the GeneChip Human Exon 1.0 ST Array (Affymetrix) in duplicate 
according to the Affymetrix GeneChip Expression Analysis Technical Manual. Probe 
set intensities were summarized into transcript intensities by taking the mean of 
corresponding probe sets. Mean expression of 2 independent experiments was 
calculated. Analysis of variance was applied comparing the log2 intensities of BTG1 
shRNA1 knockdown cells to the empty vector-transduced cells. The resulting P values 
were corrected for multiple testing using the Benjamini-Hochberg False Discovery Rate. 
The data discussed in this publication have been deposited in the National Center for 
Biotechnology Information Gene Expression Omnibus and are accessible through Gene 
Expression Omnibus Series accession number GSE18027. For reverse-transcribed 
(RT)–PCR, cDNA was generated with the iScript cDNA synthesis kit (Bio-Rad) and 
analyzed by quantitative real-time PCR using SYBR Green technology on a 7500 Fast 
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Real-Time PCR System (Applied Biosystems). Expression levels were normalized 
against the housekeeping gene TATA box-binding protein (TBP). Primer sequences 
used in RT-PCR experiments are depicted in supplemental Table 2.
ChIP assays
Chromatin immunoprecipitations (ChIP) were performed as described elsewhere [23], 
using 2 μg of anti-PRMT1 ab3768 (Abcam) or 07-404 (Upstate Biotechnology) or anti-
TBP (TBPCSH-100; Diagenode Epigenetics; positive control) antibody. Efficacy of 
both anti-PRMT1 antibodies in ChIP was compared on control RS4;11 cells. Because 
ab3768 gave the most reproducible results (supplemental Figure 2), it was used 
in all further experiments. Primer sequences used in real-time PCR experiments 
were: 5′-ccgtgcagcaccctttatagt-3′ forward, 5′-atggtgcgatattcggattg-3′reverse (BTG1), 
5′-tcctccttgggaatgagaaa-3′ forward, 5′-atcaagcaggtgccagaaaa-3′ reverse (NR3C1). 
Primers were designed to detect the genomic area around the transcription initiation 
site of all genes. All ChIP experiments were performed at least 3 times, and the real-
time PCR reactions were performed in duplicate.
Luciferase reporter assays
The mouse mammary tumor virus promoter cloned upstream of the luciferase gene 
(MMTV-Luc) contains multiple GC-responsive elements, located between positions −202 
and −79 upstream of the RNA start site, and was originally described by Hollenberg 
and Evans [24]. 293FT cells were seeded in 24-well plates (2×105 cells/well). Six 
hours later, each well was transfected with 60 ng of MMTV-Luc, 20 ng pCMV-HA-GR, 
2 ng of pRL-CMV (Promega), and increasing concentrations of pcDNA3.1-HA-BTG1 
using linear polyethylenimine (Polysciences). The DNA amount was supplemented 
with pcDNA plasmid to a total of 300 ng. The next day, prednisolone (3.6 μg/mL) or 
medium control was added to the wells and 16 hours later cells were harvested and 
analyzed with a Dual-Luciferase Reporter Assay according to the supplier's instructions 
(Promega). Firefly luciferase values were normalized with Renilla luciferase values, 
which served as an internal control.
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Results 
BTG1 copy number loss occurs frequently in pediatric precursor-B ALL
By high-resolution genomic profiling of childhood ALL, we and others recently identified 
a recurrent microdeletion on the q-arm of chromosome 12 affecting the BTG1 locus 
in approximately 10% of precursor-B (pre-B) ALL cases (Figure 1) [7-9]. In our study, 
copy number losses of the BTG1 gene were found in 4 of 33 cases examined. MLPA 
was used to confirm the presence of these microdeletions (supplemental Figure 
1). Because these BTG1 microlesions appeared to be monoallelic, we performed 
exon sequencing to determine whether loss of function mutations in BTG1 could be 
observed in the other allele. Sequencing of the BTG1 gene was also performed in 
the remaining 29 cases to reveal the potential presence of smaller lesions or point 
mutations. However, in none of the cases showing a single-copy loss of BTG1 or in the 
other leukemia samples, additional mutations in BTG1 were found. The reported role 
of BTG1 as a regulator of differentiation, proliferation, and cell survival [12] suggests 
that BTG1 haploinsufficiency contributes to ALL development, preferentially through 
focal microdeletions. However, it remains to be established how BTG1 contributes to 
ALL development. 
Figure 1. BTG1 copy number loss is observed in approximately 10% of pediatric pre-B ALL cases. 
Genomic profiles of the chromosome 12q21.31-23.1 segment in 4 pre-B ALL cases. Indicated is a region 
of less than 300 kb in size containing the BTG1 gene, with the positions of the 2 hypothetical proteins 
FLJ30877 and BC044741 and the SNPs represented on the array.
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shRNA-mediated knockdown of BTG1 leads to GC resistance
BTG1 expression and function have been linked to the inhibition of cell growth and the 
induction of apoptosis in a variety of model systems [12]. Moreover, with one exception 
[25], several studies have identified BTG1 as one of many genes up-regulated in 
clinical isolates of ALL cells in response to synthetic GCs [26-28]. Similarly, we detected 
a 3-fold induction of BTG1 mRNA expression after exposure of primary pre-B ALL 
cells, primary T-ALL cells, or the pre-B ALL cell line RS4;11 to 1 mg/mL prednisolone 
for 8 hours (Figure 2A). Next, we determined to what extent BTG1 expression could 
be involved in the induction of GC-induced cell death. Using a lentiviral vector, we 
expressed shRNAs targeting different areas of the BTG1 gene in RS4;11 pre-B ALL 
cells. With either of these shRNA constructs, BTG1 mRNA expression was reduced 
to less than 10% compared with cells transduced to express an irrelevant shRNA 
control (Figure 2B). Prednisolone treatment had only a minor effect on BTG1 levels, 
which remained low in BTG1 knockdown cells (Figure 2B).
The BTG1 knockdown cells showed a marked increase in growth rate compared with 
shRNA control cells (Figure 2C), consistent with the observation that overexpression 
of BTG1 leads to a cessation of growth in other cell types [12]. Subsequently, a role for 
BTG1 in GC-induced apoptosis was examined by exposing control shRNA cells and 
BTG1 knockdown cells to increasing concentrations of prednisolone and assessing in 
vitro toxicity after 3 days of exposure using an MTS cell viability assay. Whereas vector 
control-transfected RS4;11 cells were highly sensitive to prednisolone exposure, with 
a 50% inhibitory concentration (IC50) of 2.1×10−2 μg/mL prednisolone at 72 hours, 
BTG1 knockdown cells had become largely refractory (IC50 of 1.6×103 and 0.6×103 μg/
mL for shRNA1 and shRNA2, respectively) to the cytotoxic effects of this drug (Figure 
2D). During these 3 days of exposure to prednisolone, BTG1 mRNA levels continued 
to increase in the control cells; whereas in the BTG1 knockdown cells, the expression 
level remained low (supplemental Figure 3A). Similar to prednisolone, BTG1 knockdown 
cells also acquired resistance to the synthetic GC dexamethasone (IC50 of 2.8×10−4, 
2.3×102, and 1.9×102 μg/mL for control shRNA, shRNA1, and shRNA2, respectively; 
Figure 2E). The protective effect of BTG1 knockdown on GC-induced cytotoxicity was 
confirmed using a flow cytometry–based apoptosis assay, which measures exposure 
of annexin-V and 7-amino-actinomycin D (supplemental Figure 4A-B). These results 
demonstrate that loss of BTG1 expression is sufficient to induce GC resistance in vitro.
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Figure 2. BTG1 expression is essential for the induction of GC-mediated cell death. (A) Quantitative 
RT- PCR analysis of BTG1 in total mRNA of primary pre-B and T ALL and RS4;11 cell line after exposure to 
1 mg/ml prednisolone dissolved in medium or medium alone for 8 hours. Expression values were normalized 
for TBP. Titration of the prednisolone concentration revealed that efficient induction of BTG1 mRNA, after 
8-hour exposure to prednisolone, could be observed at concentrations as low as 5.0·10-1 µg/ml (supplemental 
Figure 3B). (B) Quantitative PCR analysis of BTG1 mRNA in RS4;11 cell lines transduced with control or 
either of 2 independent shRNAs targeting different regions of the BTG1 gene (shRNA1 and shRNA2). Cells 
were exposed to 1 mg/ml prednisolone for up to 8 hours. (C) The relative increase in cell number of the 
RS4;11 control, BTG1 shRNA 1, and BTG1 shRNA 2 cell lines was determined during 4 days of culture. 
(D-E) Determination of relative viability of RS4;11 control, BTG1 shRNA 1, and BTG1 shRNA 2 cell lines 
as determined by an MTS-based cytotoxicity assay after 3 days of exposure to increasing concentrations 
of prednisolone (D) or dexamethasone (E). Relative survival is determined as relative compared with 
the medium control. Data are mean ± SEM of triplicate experiments. Statistical significance was tested 
with 2-sided Student t test. (A) *Significant change  compared with control cells (P<0.05). (B) *Significant 
change compared with mock-treated control cells (P<0.05). (C-E) *Significant change in both shRNA 1 and 
2 compared with control cells that had received similar treatment (P<0.05).
Loss of BTG1 expression effectively interferes with GR autoinduction and GC-induced 
gene expression
Having identified BTG1 as a critical determinant of GC-induced apoptosis, microarray 
expression analysis was used to compare GC-regulated transcript levels in RS4;11 
control shRNA cells versus BTG1 knockdown cells. In the (GC-sensitive) RS4;11 
control shRNA cells, we found that 951 genes were up- or down-regulated at least 
2-fold after exposure to prednisolone (Figure 3A; supplemental Table 3). In contrast, 
in the BTG1 knockdown cells, only 38 genes were differentially expressed in response 
to prednisolone (Figure 3A; supplemental Table 4). Of the top 200 ranked genes most 
strongly up- or down-regulated by prednisolone in control cells, the majority had become 
unresponsive to prednisolone in the BTG1 knockdown cells (Figure 3B; supplemental 
Table 3). Expression of 3 representative genes induced by GC exposure was confirmed 
by quantitative RT-PCR (Figure 3C). Notably, one of the genes strongly affected 
by BTG1 knockdown was the NR3C1 gene, which encodes the GR. Expression of 
the GR was reduced more than 10-fold in the BTG1 knockdown cells relative to the 
RS4;11 control cells, as determined by quantitative PCR (Figure 3C) and confirmed 
at the protein level by Western blotting (Figure 3D). These findings suggested that 
the inability of the BTG1 knockdown cells to respond to GCs could be the result of 
severely reduced expression of the GR. To address whether and how BTG1 would 
also affect expression of other GR-regulated genes, we complemented expression 
of the GR in the BTG1 knockdown cells by retroviral transduction of a GR transgene. 
GR expression levels obtained in these cells were than those in the control RS4;11 
cells, as determined by Western blotting (Figure 3E).
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Even though GR expression was restored to endogenous levels in these cells, 
expression of GR-target genes in response to GCs could not be induced (supplemental 
Figure 5), although no reversal of prednisolone resistance was seen (Figure 3F). These 
results demonstrate that GR expression per se is not sufficient to restore therapy 
responses but requires the presence of additional regulatory protein complexes. We 
similarly tried to restore expression of BTG1 in the shRNA1 knockdown cells, by 
retroviral transduction of an HA-BTG1 transgene (resistant to shRNA1). However, 
despite multiple attempts, we observed that enforced expression of HA-BTG1 in these 
cells was not tolerated. 
BTG1 and GR synergize to reverse therapy responses in GC resistant REH pre-B 
ALL cells
To further define a role for BTG1 in controlling GC responsiveness, we made use of 
the GC-resistant REH pre-B ALL cell line, which carries a single copy deletion of the 
BTG1 gene [29]. Expression of the BTG1 mRNA could still be detected in these cells, 
albeit at a reduced level compared with RS4;11 cells (supplemental Figure 6A). In 
contrast, expression of the GR was almost undetectable in REH cells (supplemental 
Figure 6B), suggesting that also in these cells GC resistance may be the result of 
lack of GR expression. To determine whether BTG1 haploinsufficiency in REH cells 
was directly linked to reduced GR mRNA levels, we complemented BTG1 expression 
by retroviral transduction of an HA-BTG1 transgene. In contrast to RS4;11 cells, 
expression of the HA-BTG1 transgene was readily detected in these cells (Figure 
4A). Indeed, expression of (HA-tagged) BTG1 resulted in a marked up-regulation 
Figure 3. BTG1 knockdown in RS4;11 cells impairs GC-induced gene expression because of loss of 
GR expression. (A) Venn diagram summarizing microarray expression analysis in prednisolone-treated (8-
hour) control RS4;11 and BTG1 knockdown (shRNA1) RS4;11 cells. The number of genes with a significant 
(2-fold change) in expression is indicated. (B) Heat map of the 200 genes with highest differential expression 
after prednisolone exposure in control cells. For comparison, expression changesin BTG1 shRNA1 cells are 
shown in the right column. (C) mRNA expression of the GR and the GC-regulated genes SGK1 and VDR 
were analyzed by quantitative RT-PCR and normalized for TBP after exposure to 1 mg/ml prednisolone for 
up to 8 hours in RS4;11 control and BTG1 shRNA1 cells. (D) Immunoblot showing GR expression in control 
RS4;11 cells and in BTG1 knockdown cells in response to prednisolone treatment for up to 8 hours. (E) 
Immunoblot showing GR expression in RS4;11 cells transduced with a control shRNA, BTG1 shRNA1, or 
BTG1 shRNA1 with a GR overexpression construct. (F) MTS assay determining relative viability of RS4;11 
cells transduced with a control shRNA, BTG1 shRNA1, or BTG1 shRNA1 with a GR overexpression construct 
after prednisolone treatment. Error bars represent the SEM of triplicate experiments. Statistical significance 
(P<0.05) was assessed with the Student t test compared with untreated control cells. 
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of the GR mRNA, as determined by quantitative PCR, particularly after exposure 
to prednisolone (Figure 4B). This phenomenon of GC-induced GR expression (GR 
autoinduction) is considered to contribute to the apoptosis-inducing effects of GCs 
in leukemic blasts [5, 30]. Despite increased GR autoinduction, expression of GR 
mRNA in the HA-BTG1–expressing REH cells still remained approximately 20-fold 
lower compared with the (GC-sensitive) RS4;11 cells (supplemental Figure 6C). As 
a consequence, we were not able to detect the GR protein in these cells (Figure 4A; 
results not shown). In agreement with these observations, only a partial reversal of 
GC resistance was observed; IC50 value was reduced from 4.8 μg/mL in control cells 
to 2.8×10−1 μg/mL in HA-BTG1 cells (Figure 4C). Similarly, raising GR expression 
levels by retroviral transduction of a GR transgene was not sufficient to fully restore 
GC responses in the REH cells (IC50 was reduced to 2.7×10−1 μg/mL). However, 
when expression of HA-BTG1 and the GR was combined, a further 10-fold increase 
in sensitivity to GCs was observed (IC50 reduced to 3.0×10−2 μg/mL; Figure 4C), 
consistent with a role for BTG1 as a limiting cofactor in GR-mediated gene regulation. 
In REH cells expressing HA-BTG1, this recombinant protein migrated as a single band 
of approximately 20 kDa. When expression of HA-BTG1 was combined with that of 
the GR, several discrete products representing HA-BTG1 were observed (Figure 4A), 
suggesting that, under these conditions, the BTG1 protein is subject to modification. 
The nature of this modification is currently under investigation.
To further explore a functional interaction between BTG1 and the GR, we analyzed 
expression of the GR-target genes TSC22D3/GILZ and ZFP36L2/TIS11D, both of 
which have been linked to the antiproliferative effects of GCs in leukemic cells [26, 
31]. Despite the low GR expression in parental REH cells, a moderate induction of 
these genes was observed in response to prednisolone, which was further enhanced 
in the presence of the GR transgene (Figure 4D). Expression of HA-BTG1 only slightly 
increased GC-induced expression of TSC22D3/GILZ and ZFP36L2/TIS11D; however, 
combined expression of HA-BTG1 and the GR resulted in a significantly larger induction 
(Figure 4D). Together, these results strongly suggest that BTG1 and the GR synergize 
in the induction of GC-mediated gene expression and apoptosis. 
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Figure 4. A BTG1 transgene rescues GR expression and GC therapy response in REH pre-B ALL 
cells. (A) Western blot showing protein expression of HA-BTG1 and GR protein obtained after retroviral 
transduction of REH cells with the vectors indicated at the top. (B) Expression of GR mRNA analyzed by 
quantitative RT-PCR and normalized for TBP in REH control vector versus REH HA-BTG1-transduced 
cells, after exposure to prednisolone or mock treatment. (C) Determination of relative viability of REH 
control vector-transduced cells compared with REH cells transduced with HA-BTG1, GR or HA-BTG1 
and GR retroviral constructs using an MTS-based cytotoxicity assay after exposure to prednisolone for 
3 days. (D) Quantitative RT-PCR of GR target gene TSC22D3/GILZ and ZFP36L2/TIS11D in REH cells 
after exposure to 1 mg/ml prednisolone or mock treatment for 8 hours. Error bars represent the SEM of 
triplicate experiments. (C) *Statistical significance (P<0.05) was assessed with Student t test compared with 
control vector-transduced cells that received the same treatment. (B,D) *Statistical significance (P<0.05) 
was assessed with Student t test compared with control vector-transduced cells that were mock treated.
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PRMT1 is recruited to GC-responsive promoter elements
Several studies have demonstrated that BTG1 associates with and regulates the 
activity of PRMT1 [10, 18]. Moreover, this arginine methyltransferase was shown to 
regulate transcription mediated by several nuclear receptors, but a functional interaction 
between PRMT1 and the GR has not been established. Therefore, we examined by 
ChIP analysis whether BTG1, in complex with PRMT1, may control GR autoinduction. 
To this end, 2 independent PRMT1 antibodies were tested (supplemental Figure 2). 
By doing so, a specific association between PRMT1 and the promoter regions of 
BTG1 and NR3C1 (GR) could be observed in response to GC exposure (Figure 5A; 
supplemental Figure 2). These results establish PRMT1 as a novel GR coactivator. 
Importantly, this association was no longer present in the BTG1 knockdown cells 
(Figure 5A). As the loss of BTG1 expression in the knockdown cells is accompanied by 
a loss of GR expression, the lack of association between PRMT1 and these promoters 
could be the result of either reduced BTG1 expression or reduced GR expression, or 
a combination of the two.  
BTG1 directly affects GR-mediated gene expression
To more directly implicate BTG1 in GR-mediated transcriptional regulation, we studied 
the effects of BTG1 on a MMTV-LUC reporter plasmid by transient transfection of 
293FT cells. This GC-responsive reporter plasmid, which contains the mouse mammary 
tumor (MMTV) promoter cloned upstream of the luciferase gene, harbors multiple GC-
responsive elements [24]. When this reporter was transfected in combination with low 
amounts of recombinant GR, we observed a robust (15-fold) activation of this promoter 
in response to prednisolone (Figure 5B). Importantly, titration of increasing amounts 
of HA-BTG1 resulted in a dose-dependent increase in GR-induced transcriptional 
activation (Figure 5B). Based on these findings, we propose that BTG1, possibly in 
association with the arginine methyltransferase PRMT1, promotes GR-mediated gene 
expression, whereas loss of BTG1 function contributes to GC resistance. This type 
of therapy resistance appears to involve both defective GR autoregulation as well as 
reduced activation of GR target genes (Figure 5C). 
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Figure 5. Involvement of BTG1 and PRMT1 in GC-dependent target gene regulation. (A) Association 
of PRMT1 with the promoter regions of BTG1 and GR in response to GC exposure is dependent on 
BTG1 expression. Quantitative ChIP analysis of PRMT1 binding to promoter sequences of BTG1 and 
NR3C1 in RS4;11 control vector-transduced cells versus BTG1-shRNA1 cells treated with either 1 mg/ml 
prednisolone or mock treated for 8 hours. Error bars represent the SEM of 2 independent experiments. 
*Statistical significance (P<0.05) was assessed with the Student t test compared with mock-treated cells. 
(B) Luciferase reporter assays were performed using MMTV-Luc in the presence of 20 ng of exogenous GR 
and increasing concentrations of HA-BTG1 (3-200 ng), with or without prednisolone treatment. Luciferase 
activity was normalized to Renilla values. Error bars represent the SEM of 2 independent experiments. 
*Statistical significance (P<0.05) was assessed with the Student t test compared with cells without HA-
BTG1 expression. (C) Schematic representation explaining how BTG1 regulates expression of the GR 
and that of GR-target genes. 
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Discussion  
Although GCs are essential drugs in the treatment of ALL and other lymphoid 
malignancies, the molecular mechanisms that lead to GC resistance in the patient 
remain unclear [2, 5]. It is evident, mostly from in vitro studies, that GC resistance can 
occur at the level of the GR, either by loss-of-function mutations in the GR [32-34] or by 
defective GR autoinduction [34]. However, acquired somatic mutations in the GR are 
rarely found in the patient and not related to GC resistance in vivo [35]. Moreover, in 
a recent study comparing GC-resistant with GC-sensitive ALL, no correlation between 
GR expression in patient samples and therapy response was seen [6]. These studies 
indicate that GR expression alone does not accurately predict therapy response but 
rather that GC sensitivity is highly dependent on cellular context, such as the metabolic 
state of the cell [36] or the presence of specific genetic changes.
In this study, we identify BTG1, a gene recurrently deleted in pre-B ALL, as a 
novel determinant of GC-induced apoptosis that acts by regulating GR-mediated 
gene expression. Reduced expression of BTG1, either induced by shRNA-mediated 
knockdown or by (single copy) deletion of the BTG1 gene, as observed in the REH 
cells, renders pre-B ALL cells refractory to the apoptosis-inducing effects of GCs. 
This acquired GC resistance appears to be, at least in part, the result of defective GR 
autoinduction. In RS4;11 cells, shRNA-mediated knockdown of BTG1 leads to a more 
than 10-fold reduction in GR expression, whereas restoration of BTG1 expression in 
BTG1-haploinsufficient REH cells promotes GR autoinduction. However, the effects 
of BTG1 on GR-mediated gene expression and associated therapy responses cannot 
be explained simply by increased GR expression levels. Restoring GR expression in 
RS4;11 BTG1 knockdown cells could not restore therapy responses in these cells. 
Similarly, in the REH cells, which show reduced expression of BTG1 coincident with 
a single copy loss of BTG1, retroviral transduction of the GR only partially rescued 
GR-mediated gene transcription and associated therapy response. This suggests 
that, in both leukemia cell lines, expression of BTG1 might be a rate-limiting factor. 
Indeed, combined expression of BTG1 and the GR further enhanced GC-induced 
gene expression in the REH cells and consequently the induction of apoptosis. Similar 
to GR, elevating BTG1 expression in the REH cells was not sufficient to fully restore 
therapy response. Apparently, GR expression levels need to exceed a certain threshold 
before proper activation by BTG1 can take place. As BTG1 expression also increases 
in response to GC stimulation and GR autoinduction is dependent on BTG1, we 
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conclude that BTG1 and the GR are part of a potent feed-forward autoregulatory loop 
that enhances the apoptosis-inducing effects of GCs in ALL cells.
Similar to other nuclear receptors, GR-mediated transcription involves the sequential 
recruitment of transcriptional coregulators into multiprotein complexes. Components 
of these complexes include acetyltransferases and methyltransferases that modify 
transcription factors present in the complex and bring about specific combinations 
of histone modifications at these promoter sites [37, 38]. In this context, the arginine 
methyltransferase PRMT1 has been identified as a coactivator of the nuclear receptors 
HNF4 [20, 39], ER [40], and FXR [21]. Activation of the nuclear receptor HNF4-α by 
PRMT1 involves a 2-step process. Initially, PRMT1 methylates the receptor, thereby 
facilitating binding to the target promoter element, after which PRMT1 can bind to the 
receptor complex and locally methylate histone tails to further enhance transcription [20]. 
Hence, PRMT1 functions as a global regulator of gene expression, and it was shown 
that disruption of normal PRMT1 function can contribute to leukemia formation [41]. As 
BTG1 was found to interact with PRMT1 [42], we postulated that the effects of BTG1 
knockdown on GR-mediated gene expression might be the result of a failure to recruit 
PRMT1 to GC-responsive promoter elements. Consistent with such a model, ChIP 
assays using PRMT1 antibodies revealed that on GC exposure PRMT1 associates with 
the promoter regions of both BTG1 and the GR (NR3C1) in a BTG1-dependent manner. 
As ChIP grade antibodies for BTG1 are not available, we could not establish a direct 
association of BTG1 with these promoter elements by this method. Instead, luciferase 
reporter assays using the GC-responsive MMTV promoter were used to demonstrate 
that expression of recombinant HA-BTG1 enhances prednisolone-induced activation 
of this promoter in a dose-dependent manner. Because BTG1 and PRMT1 appear to 
cooperate in GC-mediated gene expression, shRNA-mediated knockdown of PRMT1 
was expected to similarly affect GC responsiveness. Lentiviral knockdown of PRMT1 
in RS4;11 cells, however, induced massive cell death within days after transduction 
(results not shown), which probably reflects other important nonredundant functions 
of PRMT1. The latter may be explained by the fact that PRMT1 is responsible for 
approximately 80% of all arginine methylation activity within the cell [43].
Although our leukemia cell models provide valuable insights into how BTG1 and 
GR synergize in the control of GR-mediated gene expression, these results cannot 
be directly translated to the clinical situation. For instance, a near-complete loss of 
GR expression, as found in the REH cells, is not observed in primary ALL. Hence, 
it remains to be established to what extent BTG1 copy number losses contribute to 
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therapy resistance in the patient. Assessment of our small patient cohort (33 cases) 
revealed that a single copy loss of BTG1 at the time of diagnosis was not necessarily 
associated with a poor therapy response. Indeed, in none of the patients was a poor 
therapy response to initial GC therapy observed. We therefore suspect that the effect 
of BTG1 copy number loss on GC responsiveness is highly dependent on the genetic 
and cellular context in which the lesion occurs. For instance, BTG2, which shows 
overlapping expression patterns and functions with BTG1 [14], may compensate for 
the effects of BTG1 copy number loss. Consistent with such a compensatory role, GC-
sensitive SUP-B15 pre-B ALL cells, which exhibit a BTG1 copy number loss, showed 
high expression of BTG2, particularly after stimulation with prednisolone; whereas in 
GC-resistant REH cells, which also lack one copy of the BTG1 gene, expression of 
BTG2 was undetectable (supplemental Figure 6D). A first clue that deletions in BTG1 
may influence therapy outcome was recently provided by Mullighan et al [44]. They 
showed that (therapy-induced) selection of malignant subclones, often already present 
at the time of diagnosis, may result in a therapy-resistant relapse. In one of the cases 
examined, a BTG1 lesion not present at diagnosis appeared in the relapse [44]. In 
addition, 4 other relapse samples were found to contain single copy deletions of the 
NR3C1 gene, which were not present at diagnosis. These results suggest that the GC 
therapy may have contributed to the selective outgrowth of these clones.
In the present study, we show that loss of BTG1 expression, either induced by deletion 
or by shRNA-mediated knockdown, is sufficient to induce GC resistance in the defined 
context of 2 model cell lines. It will be important to determine to what extent BTG1 
or other members of the BTG/TOB family modulate GC-induced therapy responses 
in the patient. As GC-based therapies are used in a variety of medical conditions, a 
detailed understanding of these novel regulators of GR signaling may provide more 
rational approaches to overcoming GC resistance.
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Supplementary Appendix 
Supplemental Tables
Forward Reverse
Probe 1 CAAATTGGGGCACAACGAACTTAAG GAATGCCTTAAGACTGCC
ACTGGTAAGTAACAGGGGTTAATTA 
GAACCCCACAGTGAGGGT
Probe 2 TCCAGCTACGCCACTTCCTTTTC GTGGCACTATAAAGGGTGCTGCA
Probe 3 CACTCTGGGTTGACCCCTATGAAGT GTCCTACAGAATTGGAGAGGATGGC
Probe 4 AGACACTGTCTCAACTGTGGTGTTAG CAC CAGCCAGCTCTCTGTACATTTGCTAGCTT
Probe 5 TGTCATCTCCCACTAGTTTCTAGCACA CGGGCT
ACACACTCACTGGCCCACTTACCCTC 
TATTCTG
Probe 6 GAGTGCTTCCTCTGATTACTCTGGATTT GTTGGTG
CGTAATTTTAAAGTGGGGCTCTGTGGTT 
TCCCCAT
Probe 7 CGGAAAGATATAGTGGAGGGAAGATGTC CATGGCAGGGATG
TTGGAGGCACTGTGTCCAAACACGTTG 
GTAGGCTAGTACTG
Probe 8 CACCATGGACAGCAGGGCTGTATTTAT TACC
ATCCTAATGGCAAGTCATTCAGTGAGC 
CGCA
Probe 9 CTGTCAATGCCATCTTCGAGTGGTC CAGTGTTCTGATTT
GGGTGAGTGGGATGCAGTTTCTCTT 
TACCTACCTTACTT
 
Gene Primer
BTG1-Fwd 5’-tgacgagcgagcgacagctgca-3’
BTG1-Rev 5’-gcatggcttttctgggaaccagtg-3’
NR3C1/GR-Fwd 5’-ctggggactctgaacttccctg-3’
NR3C1/GR-Rev 5’-ctgttgttgctgttgaggagctgg-3’
SGK1-Fwd 5’-accttctgtggcacgccgga-3’
SGK1-Rev 5’-ctgtgtttcggctataaaaaggc-3’
VDR-Fwd 5’-aactccagacacactcccagc-3’
VDR-Rev 5’-gattggagaagctggacgagtcc-3’
TSC22D3/GILZ-Fwd 5’-ccagcgtggtggccatagac-3’
TSC22D3/GILZ-Rev 5’-ggatctgctccttcaggatctcca-3’
ZFP36L2/TIS11D-Fwd 5’-cacacttctgtccgccttcta-3’
ZFP36L2/TIS11D-Rev 5’-gcatgttgttcaggttgaggt-3’
BTG2-Fwd 5’-cgtgagcgagcagaggctt-3’
BTG2-Rev 5’-agcccttggacggcttttcg-3’
TBP-Fwd 5’-gcacaggagccaagagtgaa-3’
TBP-Rev 5’-acatcacagctccccaccat-3’
Table S2. For quantitative RT-PCR experiments the following primer-sets were used.
Table S1. Probes used in MLPA analysis of copy-number changes of the BTG1 locus.  
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Table S3. Prednisolone treatment of RS4;11 affects expression (2-fold up- or downregulation) of 
951 genes
Symbol Annotation
Control 
 Fold change         direction 
shRNA1 
 Fold change         direction
SGK1 NM_005627 24,88 up 1,17 up
LILRA1 NM_006863 24,68 up 1,13 up
P2RY14 NM_001081455 16,87 up 1,12 up
RASSF4 NM_032023 13,33 up 1,12 down
OGFRL1 NM_024576 12,65 up 1,10 up
NDRG2 NM_201540 11,39 up 1,00 down
PRICKLE1 NM_153026 11,01 down 1,06 down
IL6ST NM_002184 10,29 up 1,17 down
TIPARP NM_015508 10,03 up 1,03 down
IL1B NM_000576 9,14 down 1,16 up
PIK3IP1 NM_052880 9,11 up 1,66 up
LONRF1 NM_152271 8,77 up 1,26 up
MAP3K5 NM_005923 8,70 up 1,11 down
DFNA5 NM_004403 8,67 up 1,07 up
SLA NM_001045556 8,57 up 1,58 down
SHISA2 NM_001007538 8,39 up 1,21 up
SLC7A11 NM_014331 7,94 up 6,62 up
FBXW7 NM_033632 7,91 up 1,24 down
SPRY1 NM_005841 7,85 up 1,07 up
TMEM2 NM_013390 7,73 up 1,04 up
PARP15 NM_001113523 7,72 up 1,07 up
DAAM1 NM_014992 7,69 up 1,05 down
MST150 NM_032947 7,66 up 1,12 up
SORT1 NM_002959 7,48 up 1,33 down
NFIL3 NM_005384 7,46 up 1,09 up
RIN2 NM_018993 7,43 up 1,04 up
ELL2 NM_012081 7,07 up 1,03 up
MAP3K6 NM_004672 6,86 up 1,29 up
SLC44A1 NM_080546 6,67 up 1,14 up
CHRNA1 NM_001039523 6,62 up 1,23 up
IRAK3 NM_007199 6,59 up 1,01 down
FKBP5 NM_004117 6,50 up 1,26 up
SESN1 NM_014454 6,48 up 1,02 up
TSC22D3 NM_198057 6,37 up 1,98 up
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KIR3DX1 NM_001047605 6,22 up 1,13 up
SDHC NM_003001 6,12 up 2,51 down
CLIC5 NM_001114086 6,08 up 1,18 up
INPP1 NM_002194 6,07 up 1,12 up
KLF7 NM_003709 5,78 up 1,13 up
ITGA9 NM_002207 5,64 up 1,15 up
XPR1 NM_004736 5,57 up 1,32 down
FMO5 NM_001461 5,55 up 1,09 up
LOC652968 CR456449 5,53 up 1,02 down
DDIT4 NM_019058 5,49 up 1,92 up
NCOA7 NM_181782 5,42 up 1,29 up
DOK4 NM_018110 5,39 up 1,10 up
FGD2 NM_173558 5,34 up 1,14 up
MYRIP NM_015460 5,07 up 1,18 up
WDR91 NM_014149 5,03 up 1,02 down
KIAA1257 NM_020741 5,02 up 1,22 up
MT1X NM_005952 5,01 up 1,33 up
PAG1 NM_018440 4,95 up 1,25 up
FAM86C NM_018172 4,93 down 1,49 down
GJA5 NM_005266 4,93 up 1,19 up
KRCC1 NM_016618 4,89 up 1,10 down
AMY2B NM_020978 4,88 up 1,01 down
RNF146 NM_030963 4,77 up 1,22 up
B4GALT4 NM_212543 4,64 up 1,32 down
RASA2 NM_006506 4,62 up 1,19 down
PLAUR NM_002659 4,58 down 1,03 up
RPS27L NM_015920 4,55 up 1,00 up
UBL3 NM_007106 4,47 up 1,08 up
LASS6 NM_203463 4,39 up 1,22 down
METTL7A NM_014033 4,33 up 1,11 up
PDGFRB NM_002609 4,27 down 1,20 up
CD109 NM_133493 4,24 up 1,01 down
SLC31A2 NM_001860 4,24 up 1,06 down
SEPT7 NM_001788 4,22 up 1,60 down
GLDC NM_000170 4,21 down 1,10 up
UNQ6493 AY358234 4,15 up 1,16 up
NFKBIA NM_020529 4,12 up 1,02 down
ZC3H6 NM_198581 4,11 up 1,12 up
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ID3 NM_002167 4,10 down 1,25 down
LGR5 NM_003667 4,09 down 1,02 down
IFNGR1 NM_000416 4,05 up 1,10 down
CD180 NM_005582 4,03 down 1,03 up
SNX6 NM_021249 4,01 up 1,00 down
TXNIP NM_006472 4,00 up 1,48 down
KANK2 NM_015493 4,00 down 1,05 up
TGFA NM_003236 3,97 up 1,15 up
FBXO32 NM_058229 3,96 up 1,21 up
ARHGAP18 NM_033515 3,96 up 1,10 up
TFAP4 NM_003223 3,95 down 1,12 down
ZNF364 NM_014455 3,94 up 1,27 down
NEK7 NM_133494 3,92 up 1,23 down
FLJ34077 AK091396 3,92 down 1,21 down
CSPG4 NM_001897 3,80 down 1,11 up
TXLNB NM_153235 3,78 up 1,11 up
GNAZ NM_002073 3,77 down 1,24 up
TSKU NM_015516 3,75 down 1,10 up
TARSL2 NM_152334 3,74 up 1,12 down
GNA12 NM_007353 3,72 up 1,00 up
SMAP2 NM_022733 3,72 up 1,12 up
PRICKLE2 NM_198859 3,70 down 1,06 up
YPEL5 NM_016061 3,69 up 1,15 up
TSNAX NM_005999 3,68 up 1,14 down
TRAK2 NM_015049 3,67 up 1,21 down
DEPDC1 NM_001114120 3,66 up 1,40 down
DNMT3B NM_006892 3,64 up 1,16 down
VAV3 NM_006113 3,64 up 1,43 down
TMEM65 NM_194291 3,63 up 1,10 up
GNPTAB NM_024312 3,62 up 1,01 down
TCP11L2 NM_152772 3,61 up 1,12 up
POT1 NR_003102 3,61 up 1,13 down
C5orf41 AY139008 3,59 up 1,22 up
FJX1 NM_014344 3,59 down 1,03 down
P2RX5 NM_002561 3,59 up 1,10 up
TRAF4 NM_004295 3,56 down 1,07 up
PSCD3 NM_004227 3,54 up 1,06 up
ISG20 NM_002201 3,53 up 1,36 up
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CCND3 NM_001760 3,53 down 1,14 down
SLC4A7 NM_003615 3,53 up 1,10 down
HSD17B11 NM_016245 3,52 up 1,33 down
AP3S1 NM_001284 3,50 up 1,20 down
TM6SF1 NM_023003 3,48 up 2,10 up
PER1 NM_002616 3,48 up 1,13 down
USP53 NM_019050 3,48 up 1,14 down
MAP7 NM_003980 3,48 up 1,17 up
SMAD3 NM_005902 3,46 up 1,46 up
LBH NM_030915 3,46 down 1,15 up
HIST1H2BB NM_021062 3,45 up 1,06 down
BTG2 NM_006763 3,45 up 1,12 up
MAP1A NM_002373 3,44 up 1,18 up
CLN8 NM_018941 3,43 up 1,02 up
SOCS1 NM_003745 3,43 up 1,06 up
CHKA NM_001277 3,42 up 1,27 down
DDIT3 NM_004083 3,41 up 1,15 up
PARP9 NM_031458 3,40 up 1,26 down
ERV3 NM_001007253 3,39 up 2,07 down
HSH2D ENST00000253680 3,38 down 1,04 down
RLBP1L1 NM_173519 3,36 down 1,22 up
PTPLB NM_198402 3,36 up 1,13 down
LCE1D NM_178352 3,32 down 2,80 up
EIF4B ENST00000328474 3,31 up 1,10 down
GRASP NM_181711 3,30 up 1,25 up
PXDNL NM_144651 3,28 up 1,21 up
BCAP29 NM_001008407 3,28 up 1,33 down
CLK4 NM_020666 3,27 up 1,02 down
CCPG1 NM_004748 3,27 up 1,01 down
SPIB NM_003121 3,27 down 1,14 up
CHMP2B NM_014043 3,26 up 1,51 down
PICALM NM_007166 3,26 up 1,10 up
GSN NM_000177 3,26 up 1,03 up
PLD1 NM_002662 3,25 up 1,11 up
HS3ST3B1 NM_006041 3,25 up 1,04 down
SIT1 NM_014450 3,24 down 1,33 down
ID2 NM_002166 3,23 up 1,17 up
C6orf72 AY358952 3,22 up 1,40 down
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GABBR2 NM_005458 3,22 down 1,12 up
UGT3A2 NM_174914 3,22 down 1,18 up
LOC201164 BC031263 3,21 down 1,03 down
RWDD4A NM_152682 3,21 up 1,84 down
HMMR NM_012484 3,19 up 1,48 down
SLC25A24 NM_213651 3,19 up 1,12 down
RCAN1 NM_004414 3,19 up 1,03 up
C1orf103 NM_018372 3,19 up 1,50 down
AHDC1 NM_001029882 3,18 up 1,04 down
PCNP NM_020357 3,17 up 1,05 up
GPR19 NM_006143 3,17 up 1,45 up
ZMYM1 NM_024772 3,17 up 1,06 down
NDUFA5 NM_005000 3,17 up 1,17 down
KLF16 NM_031918 3,17 down 1,18 up
RECK NM_021111 3,17 up 1,01 down
NDRG1 NM_006096 3,15 up 1,26 up
RHOBTB3 NM_014899 3,15 up 1,26 down
RCN1 NM_002901 3,14 up 1,16 up
PPRC1 NM_015062 3,14 down 1,08 down
ALOX5AP NM_001629 3,14 up 1,06 up
PTPN3 NM_002829 3,14 up 1,01 up
CD58 NM_001779 3,12 up 1,03 down
PGGT1B NM_005023 3,12 up 1,08 up
RPS6KA2 NM_021135 3,12 up 1,49 up
HIST1H2AJ NM_021066 3,11 up 1,08 up
FAM91A1 NM_144963 3,11 up 1,29 down
GCLM NM_002061 3,11 up 1,24 up
AP1S3 NM_001039569 3,10 up 1,01 down
AKR1C3 NM_003739 3,10 up 1,26 up
PMS2CL NR_002217 3,09 up 1,46 down
SMOC1 NM_001034852 3,08 down 1,01 up
DUSP19 NM_080876 3,08 up 1,08 up
PLEKHF2 NM_024613 3,08 up 1,16 down
GLUL NM_002065 3,07 up 1,44 up
C9orf5 NM_032012 3,07 up 1,04 down
GBA2 NM_020944 3,06 up 1,02 up
ZNF277 NM_021994 3,06 up 1,00 up
GTF2H5 NM_207118 3,03 up 1,30 down
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CNIH4 NM_014184 3,03 up 1,36 down
IFI30 NM_006332 3,03 down 1,19 down
HINT3 NM_138571 3,02 up 1,02 up
VDR NM_001017535 3,02 up 1,05 up
CD22 NM_001771 3,02 down 1,08 up
KLHL24 NM_017644 3,01 up 1,66 up
SAMHD1 NM_015474 3,01 down 1,02 up
RAB38 NM_022337 3,01 down 1,08 up
ATG12 NM_004707 3,00 up 1,04 down
SLC27A3 NM_024330 2,99 up 1,20 up
MYO10 NM_012334 2,99 up 1,17 up
IFT20 NM_174887 2,99 up 1,10 down
CD69 NM_001781 2,99 up 1,33 down
TMEM106B NM_018374 2,98 up 1,38 down
ZNF107 NM_016220 2,98 up 1,42 down
PTPN7 NM_080588 2,98 down 1,26 down
ASXL2 NM_018263 2,98 up 1,29 down
MFN1 NM_033540 2,97 up 1,35 down
CENPE NM_001813 2,96 up 1,64 down
DAPP1 NM_014395 2,96 up 1,05 up
HBP1 NM_012257 2,96 up 1,09 up
ZNF429 NM_001001415 2,95 up 1,52 down
WDR60 NM_018051 2,95 up 1,00 up
SOS2 NM_006939 2,95 up 1,09 up
ARRB1 NM_004041 2,95 down 1,10 down
LRRC1 NM_018214 2,94 up 1,06 down
IGF2BP2 NM_006548 2,93 up 1,09 up
LCE3A NM_178431 2,93 down 1,17 up
CD22 NM_001771 2,93 down 1,11 down
SERINC2 NM_178865 2,92 up 1,29 up
ZFYVE16 NM_001105251 2,92 up 1,19 down
NT5DC3 NM_016575 2,92 down 1,11 down
UBE2F NM_080678 2,92 up 1,11 down
TLE1 NM_005077 2,91 up 1,17 up
C3orf63 NM_001112736 2,90 up 1,23 down
DOCK7 NM_033407 2,90 up 1,19 down
ANGPTL2 NM_012098 2,90 down 1,06 up
RASGRP1 NM_005739 2,90 down 1,06 down
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RNF14 NM_004290 2,89 up 1,26 down
TAPT1 NM_153365 2,88 up 1,19 down
UACA NM_018003 2,88 up 1,01 down
BLNK NM_013314 2,88 down 1,04 up
TRIB1 NM_025195 2,88 down 1,42 up
PLXNA1 NM_032242 2,88 up 1,09 up
AMOT NM_133265 2,86 up 1,02 up
GALNT7 NM_017423 2,86 up 1,08 down
PLEKHO1 NM_016274 2,85 down 1,09 down
PRDM1 NM_001198 2,85 up 1,35 up
TLK1 NM_012290 2,85 up 1,19 down
TTLL12 NM_015140 2,85 down 1,06 down
WWC3 NM_015691 2,84 up 1,06 up
SPC25 NM_020675 2,84 up 1,63 down
BIRC2 NM_001166 2,83 up 1,02 down
SERINC1 NM_020755 2,82 up 1,09 down
OXR1 NM_181354 2,82 up 1,32 down
TP53INP1 NM_033285 2,82 up 1,85 up
REEP3 NM_001001330 2,81 up 1,06 down
ANKLE1 NM_152363 2,81 down 1,29 up
HYAL2 NM_033158 2,81 down 1,16 down
IER2 NM_004907 2,81 down 1,32 up
PXN NM_001080855 2,80 up 1,59 up
NCK2 NM_003581 2,79 up 1,08 down
SENP6 NM_015571 2,79 up 1,54 down
DOPEY1 NM_015018 2,79 up 1,17 down
FCHO1 NM_015122 2,79 down 1,01 up
CLK1 NM_004071 2,78 up 1,11 down
LMBRD1 NM_018368 2,77 up 1,74 down
SLC25A19 NM_001126121 2,77 down 1,11 down
SPATA13 NM_153023 2,76 up 1,01 up
NOG NM_005450 2,76 down 1,10 up
DNAJB4 NM_007034 2,76 up 1,07 up
LOC790955 NM_001085372 2,76 down 1,21 down
RASD1 NM_016084 2,76 up 1,15 up
FAM53B NM_014661 2,75 up 1,08 up
BMPR2 NM_001204 2,75 up 1,07 down
PDE7A NM_002603 2,75 up 1,40 up
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ITPKA NM_002220 2,75 down 1,11 up
CA2 NM_000067 2,75 up 1,03 up
SLC27A2 NM_003645 2,74 down 1,18 down
IQWD1 NM_018442 2,73 up 1,14 down
LOXL4 NM_032211 2,73 up 1,12 up
ELMO1 NM_014800 2,73 up 1,15 down
TACC1 NM_006283 2,73 up 1,33 down
RNASET2 NM_003730 2,73 up 1,10 down
DKFZp451A211 BX647655 2,73 up 1,06 up
--- 2,73 down 1,80 up
ATP11B NM_014616 2,73 up 1,11 down
REEP3 ENST00000298249 2,72 up 1,01 up
ARRDC3 NM_020801 2,72 up 1,32 up
FAM117A NM_030802 2,72 down 1,17 up
BBS7 NM_176824 2,71 up 1,17 down
EZR NM_003379 2,71 up 1,13 down
KIAA1712 NM_001040157 2,71 up 1,01 down
SUPT3H NM_181356 2,71 up 1,10 down
ZNF511 NM_145806 2,70 down 1,09 down
ZNF138 NM_006524 2,70 up 1,05 down
C5orf3 NM_018691 2,70 up 1,00 down
ERBB2IP NM_018695 2,70 up 1,28 down
CENPH NM_022909 2,70 up 1,57 down
PLEKHA3 NM_019091 2,70 up 1,05 up
RCN2 NM_002902 2,70 up 1,06 up
C14orf145 NM_152446 2,69 up 1,02 up
COMMD8 NM_017845 2,69 up 1,25 down
FAM44A NM_148894 2,69 up 1,15 down
TMF1 NM_007114 2,69 up 1,18 down
SCARNA4 NR_003005 2,69 up 1,41 down
ICAM2 NM_001099786 2,68 down 1,08 up
LCE1F NM_178354 2,68 down 1,17 up
SEC61G NM_014302 2,68 up 1,19 down
PRKAB2 NM_005399 2,68 up 1,09 down
KRTAP23-1 NM_181624 2,68 down 1,06 down
GLT8D3 NM_173601 2,67 up 1,19 down
C6orf81 BC033033 2,67 up 1,19 up
MGAT4A NM_012214 2,67 up 1,00 up
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C20orf59 NM_022082 2,67 down 1,05 up
LOC401152 NM_001001701 2,66 up 2,09 down
CCNG1 NM_004060 2,66 up 1,10 down
ALDH1B1 NM_000692 2,66 down 1,00 up
CASD1 NM_022900 2,66 up 1,14 down
CCDC111 NM_152683 2,65 up 1,57 down
VRK2 NM_006296 2,65 up 1,08 up
FAM89B NM_001098785 2,64 down 1,23 up
RTN4R NM_023004 2,64 down 1,05 up
PMAIP1 NM_021127 2,64 up 1,35 up
LOC339803 AK023856 2,64 up 1,06 up
EEF2K NM_013302 2,64 down 1,06 down
TPD52 NM_001025252 2,64 up 1,14 up
OR7A5 NM_017506 2,63 up 1,01 down
USP40 NM_018218 2,63 up 1,06 down
MAP3K7IP2 NM_015093 2,63 up 1,24 down
STK16 NM_003691 2,63 up 1,04 up
YWHAZ NM_145690 2,63 up 1,11 down
N4BP2 NM_018177 2,63 up 1,13 down
ORMDL1 NM_016467 2,63 up 1,39 down
YAF2 NM_005748 2,62 up 1,04 down
CRMP1 NM_001313 2,62 up 1,21 up
EZH1 NM_001991 2,62 up 1,03 up
REV3L NM_002912 2,62 up 1,23 down
CLIC4 NM_013943 2,62 up 1,19 up
RPS6KA4 NM_003942 2,61 down 1,00 up
RALB NM_002881 2,60 up 1,02 down
QPCTL NM_017659 2,60 down 1,28 up
PCTP NM_001102402 2,60 up 1,17 up
MND1 NM_032117 2,60 up 1,35 down
KRT33A NM_004138 2,60 down 2,01 up
STK17A NM_004760 2,60 up 1,35 down
CAPN7 NM_014296 2,60 up 1,22 down
TUBA4A NM_006000 2,60 up 1,14 up
CAMKK2 NM_006549 2,60 down 1,04 down
HLA-F NM_001098479 2,59 up 1,18 up
CYB5R4 NM_016230 2,59 up 1,37 down
CENTD1 NM_015230 2,59 up 1,11 down
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LAIR1 NM_002287 2,59 up 1,02 down
NQO1 NM_000903 2,59 up 1,45 up
NP NM_000270 2,58 down 1,19 down
COQ10B NM_025147 2,57 up 1,46 down
LRFN4 NM_024036 2,57 down 1,09 up
XRN1 NM_019001 2,57 up 1,23 down
SSR3 NM_007107 2,57 up 1,43 down
C5orf28 BC013351 2,57 up 1,04 up
WDFY1 NM_020830 2,57 up 1,24 down
MARCH7 NM_022826 2,56 up 1,44 down
SESN3 NM_144665 2,56 up 1,12 up
ZNF680 NM_178558 2,56 up 1,36 down
SLC10A7 NM_001029998 2,55 up 1,13 down
STK17B NM_004226 2,55 up 1,27 down
EFHC1 NM_018100 2,55 up 1,03 down
PARP8 NM_024615 2,55 up 1,10 up
TACC2 NM_206862 2,55 up 1,05 up
CPEB2 NM_182485 2,55 up 1,08 up
RYBP NM_012234 2,55 up 1,16 down
C12orf35 NM_018169 2,54 up 1,14 up
EIF2C4 NM_017629 2,53 up 1,00 down
IRAK4 NM_001114182 2,53 up 1,01 down
OLAH NM_018324 2,53 up 1,01 down
ZFAND1 NM_024699 2,53 up 1,12 down
COMMD6 NM_203497 2,53 up 1,12 down
C2orf25 AF131802 2,53 up 1,36 down
SC4MOL NM_006745 2,53 up 2,35 up
CCDC28A NM_015439 2,53 up 1,11 down
SP100 NM_001080391 2,52 up 1,13 down
PPFIBP1 NM_003622 2,52 down 1,04 down
TBC1D23 NM_018309 2,52 up 1,24 down
HMBS NM_000190 2,52 down 1,14 down
PIGV NM_017837 2,51 up 1,04 up
SLC35B3 NM_015948 2,51 up 1,01 up
SETD7 NM_030648 2,50 up 1,01 down
AKNA NM_030767 2,50 up 1,12 up
VAMP4 NM_003762 2,50 up 1,04 up
PUS7 NM_019042 2,50 down 1,60 down
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C17orf48 NM_020233 2,50 up 1,02 down
TMEM77 NM_178454 2,50 up 1,34 down
NMI NM_004688 2,50 up 1,29 down
INSR NM_000208 2,50 up 1,21 up
ZNF318 NM_014345 2,49 up 1,20 down
ETFDH NM_004453 2,49 up 1,33 down
MAD2L1 NM_002358 2,49 up 1,48 down
CCDC86 NM_024098 2,49 down 1,24 down
MRPS18C NM_016067 2,49 up 1,77 down
RPL35 NM_007209 2,48 down 1,37 up
CPNE8 NM_153634 2,48 up 1,05 up
MRPS17 NM_015969 2,48 down 1,75 down
SORBS1 NM_001034954 2,48 down 1,03 up
GSTTP1 NR_003081 2,48 down 1,13 up
ATP5E NM_001001977 2,48 down 1,22 up
STIM1 NM_003156 2,48 up 1,10 up
SYF2 NM_015484 2,48 up 1,21 down
CHD2 NM_001271 2,47 up 1,24 up
DHX33 NM_020162 2,47 down 1,01 up
FAM54A NM_001099286 2,47 up 1,43 down
SH2D2A NM_003975 2,47 down 1,05 down
SLC25A36 NM_001104647 2,47 up 1,17 down
C5orf34 BC036867 2,47 up 1,24 down
FAHD2A NM_016044 2,46 up 1,51 down
ZC3H11A NM_014827 2,46 up 1,34 down
ISY1 NM_020701 2,46 up 1,27 down
SENP7 NM_020654 2,46 up 1,45 down
KHK NM_000221 2,46 down 1,51 down
SKAP2 NM_003930 2,46 up 1,15 up
FKBP11 NM_016594 2,45 down 1,20 down
STX12 NM_177424 2,45 up 1,32 down
MR1 NM_001531 2,44 up 1,17 down
MTBP NM_022045 2,44 up 1,44 down
C12orf44 NM_021934 2,44 down 1,28 down
KIF3A NM_007054 2,44 up 1,21 down
ATP11B NM_014616 2,44 up 1,04 up
HTRA3 NM_053044 2,44 down 1,35 up
PLAG1 NM_002655 2,44 up 1,31 up
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PPID NM_005038 2,44 up 1,20 down
DNTT NM_004088 2,44 down 1,00 down
CORO1C NM_014325 2,44 up 1,01 down
RHOH NM_004310 2,43 up 1,31 down
UBXD2 NM_014607 2,43 up 1,15 down
SHANK1 NM_016148 2,43 down 1,06 up
CTSB NM_147780 2,43 up 1,27 down
ACBD6 NM_032360 2,43 up 1,38 down
SFXN3 NM_030971 2,43 down 1,04 up
CCDC53 NM_016053 2,43 up 1,04 up
TRAPPC6B NM_001079537 2,43 up 1,05 down
FAM123B NM_152424 2,43 down 1,15 down
PSAT1 NM_058179 2,42 up 2,71 up
ANKRD36B NM_025190 2,42 up 2,03 down
P2RY11 NM_002566 2,42 down 1,21 down
TTK NM_003318 2,42 up 1,61 down
RB1 NM_000321 2,42 up 1,16 down
SNX13 NM_015132 2,42 up 1,21 down
CCNC NM_005190 2,42 up 1,54 down
DCUN1D1 NM_020640 2,42 up 1,10 down
KIAA0265 D87454 2,41 up 1,76 down
SLC46A3 NM_181785 2,41 up 1,11 down
C10orf104 NM_173473 2,41 up 1,06 up
UBL4A NM_014235 2,41 down 1,03 down
ECT2 NM_018098 2,41 up 1,85 down
MARVELD1 BC004995 2,41 down 1,00 down
AAK1 NM_014911 2,41 up 1,19 down
MDM4 NM_002393 2,41 up 1,00 up
BET1 NM_005868 2,41 up 1,44 down
C12orf52 BC022092 2,40 down 1,03 down
TUBE1 NM_016262 2,40 up 1,10 up
MTHFD2 NM_001040409 2,40 up 1,64 up
SKIL NM_005414 2,40 up 1,05 up
CCDC14 NM_022757 2,40 up 1,47 down
ETS1 NM_005238 2,39 up 1,06 up
NAT8L NM_178557 2,39 down 1,21 up
KAZALD1 NM_030929 2,39 down 1,23 up
BTG1 NM_001731 2,39 up 1,60 up
BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia
97
3
A26C1A NM_001083538 2,39 down 1,09 up
SNX9 NM_016224 2,39 up 1,51 up
POLR3H NM_001018050 2,38 down 1,00 up
CCDC82 NM_024725 2,38 up 1,06 down
ZNF555 NM_152791 2,38 up 1,05 down
CEP350 NM_014810 2,38 up 1,27 down
MAP2K1 NM_002755 2,38 up 1,49 down
TMEM161B NM_153354 2,38 up 1,05 down
USP1 NM_003368 2,38 up 1,53 down
ZMYND19 NM_138462 2,38 down 1,07 down
ADAM17 NM_003183 2,37 up 1,10 down
APPBP2 NM_006380 2,37 up 1,09 down
LCN6 NM_198946 2,37 up 1,01 down
MYNN NM_018657 2,37 up 1,45 down
TMEM168 NM_022484 2,37 up 1,22 down
C1orf25 NM_030934 2,37 up 1,18 down
--- 2,37 down 1,43 up
PIK3C2B NM_002646 2,37 down 1,20 up
RIPK2 NM_003821 2,37 up 1,05 up
COMMD2 NM_016094 2,37 up 1,27 down
DHODH NM_001361 2,37 down 1,12 down
RAB18 NM_021252 2,37 up 1,25 down
CENPK NM_022145 2,37 up 1,45 down
RP3-377H14.5 ENST00000383511 2,36 up 1,15 up
FCHSD2 NM_014824 2,36 up 1,11 down
NTHL1 NM_002528 2,36 down 1,17 down
FAM62B NM_020728 2,36 up 1,11 down
SLU7 NM_006425 2,36 up 1,47 down
SEMA3A NM_006080 2,36 down 1,03 up
ARID4A NM_002892 2,35 up 1,01 down
FNBP1L NM_001024948 2,35 up 1,06 down
GABPA NM_002040 2,35 up 1,07 down
CBX2 NM_005189 2,35 down 1,17 down
DPYSL3 NM_001387 2,35 up 1,16 up
ZNF342 NM_145288 2,35 down 1,03 up
WWP2 NM_007014 2,35 up 1,05 up
LCN12 NM_178536 2,35 down 1,42 down
PIGK NM_005482 2,35 up 1,26 down
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ERBB2 NM_001005862 2,35 down 1,22 up
LOC100129395 AY459295 2,35 down 1,30 down
FXYD2 NM_001680 2,35 down 1,13 up
ST6GALNAC4 NM_175039 2,35 down 1,19 up
TMEM204 NM_024600 2,34 down 1,12 up
CHRNA5 NM_000745 2,34 down 1,03 down
KIAA1109 NM_015312 2,34 up 1,04 down
PICK1 NM_012407 2,34 up 1,05 up
KIAA0423 NM_015091 2,34 up 1,00 up
KATNAL1 NM_001014380 2,34 up 1,02 up
NLRP2 NM_017852 2,34 down 1,10 up
C4orf15 BC003648 2,34 up 1,12 down
C20orf91 BC131537 2,34 down 1,49 up
TLR10 NM_030956 2,34 down 1,05 up
CAPZA2 NM_006136 2,33 up 1,73 down
RHBDF2 NM_024599 2,33 up 1,07 up
AGPAT7 NM_153613 2,33 down 1,13 up
SLC25A22 NM_024698 2,33 down 1,01 up
LOC554203 BC071776 2,32 up 1,17 down
RBMS3 NM_001003793 2,32 up 1,08 up
USO1 NM_003715 2,32 up 1,26 down
THOC7 NM_025075 2,32 up 1,46 down
B3GALTL NM_194318 2,32 down 1,04 down
NIPSNAP3B NM_018376 2,32 up 1,02 up
DPY19L2P2 NR_003561 2,32 down 1,00 down
CSNK1G3 NM_004384 2,32 up 1,20 down
PRIM2 NM_000947 2,32 up 1,49 down
ALPK1 NM_025144 2,32 up 1,10 up
LCN10 NM_001001712 2,32 up 1,02 up
DZIP3 NM_014648 2,32 up 1,13 down
FKBP4 NM_002014 2,32 down 1,17 down
HSPA5 NM_005347 2,32 down 1,40 down
DCP2 NM_152624 2,31 up 1,32 down
NBR1 NM_031858 2,31 up 1,13 up
TIPRL NM_152902 2,31 up 1,51 down
TAX1BP1 NM_006024 2,31 up 1,26 down
FBXL3 NM_012158 2,31 up 1,00 up
FAM36A NM_198076 2,31 up 1,28 down
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UTX NM_021140 2,30 up 1,11 down
MEF2A NM_005587 2,30 up 1,12 down
PMPCB NM_004279 2,30 up 1,13 down
DUSP10 NM_007207 2,30 up 1,09 up
SCARB1 NM_005505 2,30 down 1,03 down
SLC38A9 NM_173514 2,30 up 1,16 down
LCK NM_005356 2,30 down 1,04 down
TMEM209 NM_032842 2,30 up 1,54 down
SLC17A5 NM_012434 2,29 up 1,13 up
C21orf96 AK024509 2,29 down 1,22 up
MFSD3 NM_138431 2,29 down 1,28 up
BICD1 NM_001714 2,29 down 1,33 up
CXorf21 BC020611 2,29 down 1,02 up
EMB NM_198449 2,29 up 1,20 down
PPIF NM_005729 2,29 down 1,06 up
BCL2L11 NM_138621 2,29 up 1,13 up
RALGPS2 NM_152663 2,29 up 1,12 up
KCTD3 NM_016121 2,29 up 1,31 down
ACAD11 NM_032169 2,29 up 1,12 up
SRP9 NM_003133 2,29 up 1,10 down
YIPF4 NM_032312 2,28 up 1,04 up
ZHX3 NM_015035 2,28 up 1,05 up
SGOL2 NM_152524 2,28 up 1,67 down
PTPN12 NM_002835 2,28 up 1,04 down
ZNF451 NM_001031623 2,28 up 1,17 down
IFT80 NM_020800 2,28 up 1,16 down
TMEM116 NM_138341 2,28 up 1,04 up
C12orf51 NM_001109662 2,28 up 1,02 down
SLC30A6 NM_017964 2,27 up 1,35 down
HS2ST1 NM_012262 2,27 up 1,29 down
SUCLG2 NM_003848 2,27 up 1,79 down
ANKRA2 NM_023039 2,27 up 1,07 up
C15orf39 NM_015492 2,27 down 1,03 down
LILRB1 NM_006669 2,27 up 1,01 up
SMC4 NM_005496 2,27 up 1,43 down
IQSEC1 NM_014869 2,27 up 1,08 up
RG9MTD2 NM_152292 2,27 up 1,09 down
JMJD1C NM_032776 2,26 up 1,05 down
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KIAA1033 NM_015275 2,26 up 1,16 down
EIF5A NM_001970 2,26 down 1,38 down
OPRS1 NM_005866 2,26 down 1,15 up
NLN NM_020726 2,26 down 1,47 down
SFXN5 NM_144579 2,26 up 1,02 up
TMEM63A NM_014698 2,26 up 1,18 up
SLC19A1 NM_194255 2,26 down 1,03 down
MOBKL1B NM_018221 2,26 up 1,46 down
RIT1 NM_006912 2,25 up 1,18 down
HERC4 NM_022079 2,25 up 1,05 down
ADARB1 NM_001033049 2,25 down 1,23 up
DKFZP564O0523 NM_032120 2,25 up 1,35 down
SEPT5 NM_002688 2,25 down 1,20 up
NUP43 NM_198887 2,25 up 1,10 down
SOS1 NM_005633 2,25 up 1,27 down
UBXD4 NM_181713 2,25 up 1,42 down
ZC3H7A NM_014153 2,25 up 1,01 up
MKLN1 NM_013255 2,25 up 1,29 down
RP5-
1022P6.2 NM_019593 2,25 up 1,23 up
SESN2 NM_031459 2,24 up 1,52 up
HACE1 NM_020771 2,24 up 1,19 down
TFDP2 NM_006286 2,24 up 1,11 down
ACACB NM_001093 2,24 up 1,10 up
PCM1 NM_006197 2,24 up 1,27 down
MRPS12 NM_021107 2,24 down 1,20 down
MEX3B NM_032246 2,24 down 1,15 up
LCE3C NM_178434 2,24 down 1,88 up
TAP1 NM_000593 2,24 up 1,19 up
COG6 NM_020751 2,24 up 1,11 down
TLR6 NM_006068 2,24 up 1,01 up
IMP3 NM_018285 2,24 down 1,08 up
GDF11 NM_005811 2,24 down 1,06 up
CD53 NM_000560 2,24 up 1,10 down
CDC5L NM_001253 2,24 up 1,58 down
NMT2 NM_004808 2,23 down 1,06 down
LSG1 NM_018385 2,23 up 1,18 down
FFAR1 NM_005303 2,23 down 1,61 up
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NR2C2AP NM_176880 2,23 down 1,31 down
NELL2 NM_006159 2,23 down 1,01 up
EPC2 NM_015630 2,23 up 1,30 down
RFWD2 NM_022457 2,23 up 1,43 down
AMN1 NR_004854 2,23 up 1,03 down
RNF152 NM_173557 2,23 up 1,06 down
NTN2L NM_006181 2,23 down 1,00 down
PIR NM_003662 2,23 up 1,05 up
ALG6 NM_013339 2,23 up 1,78 down
TMC6 NM_007267 2,23 down 1,04 up
GCA NM_012198 2,22 up 1,09 down
SSH2 NM_033389 2,22 up 1,08 up
FRMPD1 NM_014907 2,22 down 1,07 up
C4orf33 NM_001099783 2,22 up 1,02 down
DENND4C NM_017925 2,22 up 1,06 down
--- 2,22 down 1,16 down
ZNF57 NM_173480 2,22 down 1,10 down
UBA3 NM_003968 2,22 up 1,34 down
LETM1 NM_012318 2,22 down 1,02 up
SRM NM_003132 2,22 down 1,05 down
IRAK2 NM_001570 2,21 down 1,22 up
SOAT1 NM_003101 2,21 up 1,24 down
C10orf2 NM_021830 2,21 down 1,07 up
RPAP2 NM_024813 2,21 up 1,41 down
SEPSECS NM_153825 2,21 up 1,07 down
AGPS NM_003659 2,21 up 1,40 down
MANEAL NM_001113482 2,20 down 1,19 up
ELP4 NM_019040 2,20 up 1,11 down
MYSM1 NM_001085487 2,20 up 1,22 down
MTP18 NM_016498 2,20 down 1,09 up
GAB1 NM_207123 2,20 up 1,09 up
CDC25C NM_001790 2,20 up 1,29 down
NCAPG NM_022346 2,20 up 1,40 down
AKAP1 NM_003488 2,20 down 1,04 down
RPS2 NM_002952 2,20 down 1,01 down
KIAA1715 NM_030650 2,20 up 1,47 down
GDAP2 NM_017686 2,20 up 1,31 down
C16orf74 NM_206967 2,20 down 1,09 up
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RASA1 NM_002890 2,20 up 1,12 down
GOLGB1 NM_004487 2,19 up 1,14 down
SUV420H1 NM_017635 2,19 up 1,06 down
CHIC2 NM_012110 2,19 up 1,04 up
ARL6IP6 NM_152522 2,19 up 1,16 down
CSNK1A1 NM_001025105 2,19 up 1,24 down
SFXN2 NM_178858 2,19 down 1,14 down
NUF2 NM_145697 2,19 up 1,44 down
BSPRY NM_017688 2,19 down 1,01 up
FGFRL1 NM_001004356 2,19 down 1,12 up
WBP4 NM_007187 2,19 up 1,22 down
NBPF11 NM_183372 2,18 up 1,08 up
SLC33A1 NM_004733 2,18 up 1,09 down
KLHL28 NM_017658 2,18 up 1,03 down
PPARGC1B NM_133263 2,18 down 1,01 down
RAPGEF2 NM_014247 2,18 up 1,07 down
SLC30A9 NM_006345 2,18 up 1,42 down
CLIC5 NM_001114086 2,18 up 1,10 up
C18orf1 NM_181481 2,18 up 1,13 up
MRPL30 NM_145212 2,18 up 1,03 down
ANGEL2 NM_144567 2,18 up 1,21 down
SLC25A40 NM_018843 2,18 up 1,34 down
GREM1 NM_013372 2,17 down 1,18 up
CD320 NM_016579 2,17 down 1,05 down
C4orf21 BC044799 2,17 up 1,21 down
B4GALT5 NM_004776 2,17 down 1,04 down
WDR4 NM_018669 2,17 down 1,00 up
PIK3R3 NM_003629 2,17 down 1,13 down
SBDS NM_016038 2,17 up 1,48 down
OR1D4 NM_003552 2,17 down 1,50 up
RBM7 NM_016090 2,17 up 1,01 down
GAB3 NM_001081573 2,17 down 1,22 down
LRRC40 NM_017768 2,17 up 1,48 down
CCDC98 NM_139076 2,17 up 1,02 down
PHF20L1 NM_016018 2,17 up 1,33 down
CEBPA NM_004364 2,17 down 1,05 up
CERK NM_022766 2,17 up 1,00 up
HERC3 NM_014606 2,16 up 1,08 up
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ZNF385C NM_001013624 2,16 down 1,02 up
ZFAND5 NM_001102420 2,16 up 1,09 down
MOBKL1A NM_173468 2,16 up 1,08 down
C21orf122 BC004343 2,16 down 1,35 up
CCNDBP1 NM_012142 2,16 up 1,04 up
DPY19L4 NM_181787 2,16 up 1,02 down
C14orf49 NM_152592 2,16 up 1,03 up
ABI1 NM_005470 2,16 up 1,12 down
RRP12 NM_015179 2,16 down 1,09 down
FLJ33590 NM_173821 2,16 down 1,36 up
FLJ31818 NM_152556 2,16 up 1,20 down
JMJD1A NM_018433 2,15 up 1,30 down
OSR2 NM_053001 2,15 down 1,38 up
TTC33 NM_012382 2,15 up 1,14 down
FSCN1 NM_003088 2,15 down 1,17 up
KPNA4 NM_002268 2,15 up 1,46 down
ZNF652 NM_014897 2,14 up 1,19 down
DEAF1 NM_021008 2,14 down 1,12 up
C9orf31 AF220263 2,14 up 1,02 down
INSIG2 NM_016133 2,14 up 1,05 down
NIPBL NM_133433 2,14 up 1,33 down
HMGB2 NM_002129 2,14 up 1,44 down
SCLT1 NM_144643 2,14 up 1,14 down
PNPLA8 NM_015723 2,14 up 1,20 down
NAB2 NM_005967 2,14 down 1,09 down
CTSO NM_001334 2,14 up 1,01 down
AGTPBP1 NM_015239 2,14 up 1,01 down
ERAP2 NM_022350 2,14 up 1,18 down
CTNNAL1 NM_003798 2,14 up 1,20 down
WWP1 NM_007013 2,14 up 1,19 down
UBXD7 NM_015562 2,14 up 1,17 down
TCEB1 NM_005648 2,14 down 1,04 up
SEC62 NM_003262 2,14 up 1,26 down
REPS1 NM_031922 2,13 up 1,32 down
MGST2 NM_002413 2,13 up 1,11 up
MTX2 NM_001006635 2,13 up 1,46 down
OR2H2 NM_007160 2,13 down 1,28 up
ATG10 NM_031482 2,13 up 1,09 down
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USP49 NM_018561 2,13 down 1,11 up
MAP2K6 NM_002758 2,13 down 1,42 down
FKSG24 NM_032683 2,13 down 1,15 up
PYCRL NM_023078 2,13 down 1,05 up
LY6G6E NR_003673 2,13 down 1,68 up
CDKN1B NM_004064 2,13 up 1,09 up
CEP27 NM_018097 2,13 up 1,64 down
CASP6 NM_001226 2,13 up 1,29 down
NGLY1 NM_018297 2,13 up 1,34 down
MRPS10 NM_018141 2,13 up 1,38 down
CETN3 NM_004365 2,13 up 1,28 down
SEC22C NM_004206 2,13 up 1,12 down
SLC35F5 NM_025181 2,13 up 1,19 down
CBX6 NM_014292 2,12 down 1,03 up
SAMD9 NM_017654 2,12 up 1,27 down
STS NM_000351 2,12 down 1,39 down
CSDA NM_003651 2,12 up 1,17 up
FZD6 NM_003506 2,12 up 1,16 down
WDR21A NM_015604 2,12 down 1,20 down
RRP9 NM_004704 2,12 down 1,12 down
FAM27L BC031617 2,12 down 1,14 down
MYBBP1A NM_014520 2,12 down 1,05 down
TBC1D16 AL512709 2,12 up 1,38 up
RAB1A NM_004161 2,12 up 1,71 down
CHD4 NM_001273 2,12 down 1,16 down
NSMCE2 NM_173685 2,12 up 1,44 down
C18orf24 NM_001039535 2,11 up 1,09 down
NME1 NM_198175 2,11 down 1,16 down
TMCO1 NM_019026 2,11 up 1,54 down
HPDL NM_032756 2,11 down 1,23 up
CCNT2 NM_058241 2,11 up 1,34 down
ANKRD13B NM_152345 2,11 down 1,14 up
APBA1 NM_001163 2,11 down 1,17 up
TMEM30A NM_018247 2,11 up 1,20 down
ZNF721 NM_133474 2,11 up 1,45 down
CFLAR NM_003879 2,11 up 1,03 up
RSF1 NM_016578 2,11 up 1,18 up
GLT25D1 NM_024656 2,11 down 1,05 up
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PXK NM_017771 2,11 up 1,05 down
LXN NM_020169 2,11 up 1,01 down
CEP135 NM_025009 2,11 up 1,26 down
CADM2 NM_153184 2,11 down 1,36 up
EIF1B NM_005875 2,11 up 1,12 down
KIAA1333 NM_017769 2,11 up 1,07 down
PHF19 NM_015651 2,11 down 1,17 down
PIGW NM_178517 2,10 down 1,41 down
FSD1L NM_207647 2,10 up 1,22 up
CRBN NM_016302 2,10 up 1,27 down
MUM1 NM_032853 2,10 down 1,03 up
AKT3 NM_181690 2,10 up 1,08 down
ADAMTS10 NM_030957 2,10 down 1,08 up
DPH4 NM_181706 2,10 up 1,09 down
IFT74 NM_025103 2,10 up 1,05 down
ITCH NM_031483 2,10 up 1,05 down
WSB1 NM_015626 2,10 up 1,23 up
CLCN3 NM_173872 2,10 up 1,08 up
RAB28 NM_001017979 2,10 up 1,48 down
DNM1L NM_012062 2,10 up 1,90 down
FHOD1 NM_013241 2,10 down 1,04 down
MAN2A1 NM_002372 2,09 up 1,09 down
KRTAP4-4 NM_032524 2,09 down 1,43 down
TMEM135 NM_022918 2,09 up 1,33 up
ASB13 NM_024701 2,09 down 1,00 down
RDX NM_002906 2,09 up 1,04 up
C4orf41 NM_021942 2,09 up 1,20 down
SRBD1 NM_018079 2,09 up 1,12 down
C6orf62 NM_030939 2,09 up 1,36 down
SCFD1 NM_016106 2,09 up 1,26 down
SLFN5 NM_144975 2,09 up 1,16 up
C21orf66 NM_016631 2,09 up 1,13 down
NAP1L1 NM_139207 2,09 up 1,10 down
LIMS1 NM_004987 2,09 up 1,06 down
LSM8 NM_016200 2,09 up 1,16 down
SLC39A14 NM_015359 2,08 down 1,09 up
LRRCC1 NM_033402 2,08 up 1,40 down
WDR19 NM_025132 2,08 up 1,13 down
Chapter 3
106
DPH5 NM_001077394 2,08 up 1,07 down
RAB31 NM_006868 2,08 down 1,04 down
SENP2 NM_021627 2,08 up 1,19 down
ASF1A NM_014034 2,08 up 1,45 down
CARS NM_001014438 2,08 up 1,69 up
FXN NM_000144 2,08 down 1,08 down
ALKBH2 NM_001001655 2,08 down 1,09 up
C1orf55 NM_152608 2,08 up 1,25 down
RUNX2 NM_001024630 2,08 up 1,90 up
TMEM99 NM_145274 2,08 up 1,06 down
MED4 NM_014166 2,08 up 1,11 down
AKR1A1 NM_006066 2,08 down 1,02 up
WASF2 NM_006990 2,08 up 1,02 down
GNAI3 NM_006496 2,08 up 1,41 down
KRTAP5-3 NM_001012708 2,08 down 1,38 up
FASTKD1 NM_024622 2,08 up 1,29 down
POLK NM_016218 2,07 up 1,51 down
OAF NM_178507 2,07 down 1,13 up
B4GALT2 NM_003780 2,07 down 1,01 down
JARID1B NM_006618 2,07 up 1,20 down
OSGEPL1 NM_022353 2,07 up 1,05 down
SNX25 NM_031953 2,07 up 1,05 down
KLHDC2 NM_014315 2,07 up 1,04 up
KIAA1161 NM_020702 2,07 down 1,02 up
LMBR1 NM_022458 2,07 up 1,13 down
METTL10 NM_212554 2,07 up 1,19 up
HSPB1 NM_001540 2,07 down 1,24 up
CLIP2 NM_003388 2,07 down 1,25 up
NUDT8 NM_181843 2,07 down 1,04 up
ELMOD2 NM_153702 2,07 up 1,04 down
RNF138 NM_016271 2,07 up 1,12 down
POLH NM_006502 2,07 up 1,30 down
NUP54 NM_017426 2,07 up 1,50 down
NBN NM_002485 2,07 up 1,16 down
MALAT1 NR_002819 2,07 up 1,36 up
FAM134B NM_001034850 2,07 up 1,14 up
C6orf130 AK290939 2,07 up 1,17 down
ISOC2 NM_024710 2,06 down 1,02 down
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C20orf142 NM_001080472 2,06 up 1,43 up
CLYBL NM_206808 2,06 up 1,02 down
MNT NM_020310 2,06 down 1,05 up
GTPBP8 NM_014170 2,06 up 1,33 down
P15RS NM_018170 2,06 up 1,03 up
PHTF2 NM_020432 2,06 up 1,25 down
ZNF675 NM_138330 2,06 up 1,44 down
SDCBP NM_005625 2,06 up 1,12 down
RANBP2 NM_006267 2,06 up 1,45 down
YTHDC1 NM_001031732 2,06 up 1,02 down
PARP14 NM_017554 2,05 up 1,03 up
ZNF638 NM_014497 2,05 up 1,27 down
C7orf49 BC067350 2,05 up 1,32 down
KIF18A NM_031217 2,05 up 1,40 down
TRAPPC2 NM_001011658 2,05 up 1,12 down
LPPR4 NM_014839 2,05 down 1,38 up
RASSF2 NM_014737 2,05 down 1,04 down
AZI2 NM_022461 2,05 up 1,36 down
DAB2IP NM_032552 2,05 down 1,21 up
THAP6 NM_144721 2,05 up 1,37 down
DERL1 NM_024295 2,05 up 1,08 down
CXorf23 NM_198279 2,05 up 1,21 down
RPL17 NM_000985 2,05 up 1,13 down
SNX16 NM_022133 2,05 up 1,14 down
SCARF1 NM_145351 2,05 down 1,11 up
MED30 NM_080651 2,04 up 1,08 down
TROVE2 NM_004600 2,04 up 1,15 down
PYROXD1 NM_024854 2,04 up 1,12 down
BMP2K NM_198892 2,04 up 1,44 down
CBR4 NM_032783 2,04 up 1,11 up
NOLC1 NM_004741 2,04 down 1,25 down
CSRP2 NM_001321 2,04 down 1,45 up
TIMP2 NM_003255 2,04 down 1,16 up
GCC2 NM_181453 2,04 up 1,33 down
RICTOR NM_152756 2,04 up 1,30 down
ASTE1 NM_014065 2,04 up 1,42 down
C7orf38 AK024526 2,04 up 1,37 down
GARNL1 NM_014990 2,04 up 1,43 down
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LTK NM_002344 2,03 down 1,05 up
PREPL NM_006036 2,03 up 1,12 down
MTMR15 NM_014967 2,03 up 1,02 up
PDCD2L NM_032346 2,03 down 1,01 down
FASN NM_004104 2,03 down 1,72 up
CYP2A13 NM_000766 2,03 down 1,12 down
DMXL1 NM_005509 2,03 up 1,20 down
USP33 NM_015017 2,03 up 1,22 down
CCDC55 NM_032141 2,03 up 1,06 down
DIAPH3 NM_001042517 2,03 up 1,07 down
UCK2 NM_012474 2,03 down 1,11 down
GEMIN4 NM_015721 2,03 down 1,06 down
UBA5 NM_024818 2,03 up 1,14 down
SPOPL NM_001001664 2,03 up 1,11 down
STEAP3 NM_182915 2,03 down 1,07 up
FAM126A NM_032581 2,03 up 1,18 down
DUSP2 NM_004418 2,03 down 1,06 down
SLC35A5 NM_017945 2,02 up 1,52 down
ETV5 NM_004454 2,02 down 1,46 down
DMWD NM_004943 2,02 down 1,28 down
PTPN13 NM_080683 2,02 up 1,06 up
PAPOLG NM_022894 2,02 up 1,26 down
TOMM20 NM_014765 2,02 up 1,60 down
KLHL2 NM_007246 2,02 up 1,05 up
EFHA1 NM_152726 2,02 up 1,15 down
CACNB3 NM_000725 2,02 down 1,20 up
FUCA1 NM_000147 2,02 up 1,24 down
HOXA9 NM_152739 2,02 up 1,00 up
PCAF NM_003884 2,02 up 1,10 up
DNAL4 NM_005740 2,02 up 1,07 up
SEC61A2 NM_018144 2,02 up 1,01 up
ATP6V1C1 NM_001695 2,02 up 1,36 down
NOL6 NM_022917 2,02 down 1,05 down
NFE2L3 NM_004289 2,02 down 1,37 up
SASS6 NM_194292 2,02 up 1,57 down
RAP1GDS1 NM_001100426 2,02 up 1,31 down
KLF9 NM_001206 2,02 up 1,12 up
HIPK3 NM_005734 2,02 up 1,04 up
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NDUFB5 NM_002492 2,02 up 1,34 down
ARHGAP15 NM_018460 2,02 up 1,53 down
STIL NM_001048166 2,02 up 1,61 down
LRRC8B NM_015350 2,02 down 1,24 down
TRIM22 NM_006074 2,02 up 1,07 down
C14orf133 BC015054 2,01 up 1,04 up
PCGF5 NM_032373 2,01 up 1,14 up
MITD1 NM_138798 2,01 up 1,33 down
DBN1 NM_080881 2,01 down 1,01 up
C6orf167 NM_198468 2,01 up 1,46 down
NEIL3 NM_018248 2,01 up 1,03 down
FCER1A NM_002001 2,01 down 1,13 down
JTV1 NM_006303 2,01 down 1,28 down
DCTN4 NM_016221 2,01 up 1,23 down
RRAGC NM_022157 2,01 up 1,14 up
EPS8 NM_004447 2,01 up 1,02 up
ZNF417 NM_152475 2,01 up 1,02 down
EHD3 NM_014600 2,01 up 1,12 up
ARHGEF3 NM_019555 2,01 up 1,34 down
UBR3 NM_172070 2,01 up 1,22 down
ARMC6 NM_033415 2,01 down 1,12 down
EVI5 NM_005665 2,01 up 1,03 up
ABCF1 NM_001025091 2,01 down 1,21 down
CCDC88A NM_018084 2,01 up 1,31 down
DMTF1 NM_021145 2,01 up 1,21 down
SH3BP1 NM_018957 2,01 down 1,32 down
IGFBP7 NM_001553 2,01 up 1,15 up
CCDC132 NM_017667 2,01 up 1,12 down
TXNDC9 NM_005783 2,00 up 1,58 down
TRIP11 NM_004239 2,00 up 1,11 down
GPR107 NM_020960 2,00 up 1,16 down
HLA-DMB NM_002118 2,00 down 1,20 up
DNAJC13 NM_015268 2,00 up 1,33 down
CD2AP NM_012120 2,00 up 1,48 down
CECR5 NM_033070 2,00 down 1,11 down
CEP57 NM_014679 2,00 up 1,05 down
BBX NM_020235 2,00 up 1,15 down
VPS4B NM_004869 2,00 up 1,07 down
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DECR1 NM_001359 2,00 up 1,29 down
PPCS NM_024664 2,00 up 1,42 down
MAP3K2 NM_006609 2,00 up 1,25 down
PGM3 NM_015599 2,00 up 1,14 down
PDCD4 NM_145341 2,00 up 1,56 up
FLJ38973 BC036456 2,00 up 1,00 down
Table S4. Prednisolone treatment of RS4;11 shRNA1 cells affects expression of 38 genes (> 2-fold 
up- or downregulation)
Symbol Annotation
shRNA1 
 Fold change         direction
Control 
 Fold change         direction
SLC7A11 NM_014331 6,62 up 7,94 up
HSD17B7 NM_016371 4,34 up 1,08 up
TCEAL6 NM_001006938 3,23 up 1,21 up
LCE1D NM_178352 2,80 up 3,32 down
PSAT1 NM_058179 2,71 up 2,42 up
VEGFA NM_001025366 2,68 up 1,76 up
MVD NM_002461 2,64 up 1,39 down
TPMT NM_000367 2,57 down 1,94 up
SDHC NM_003001 2,51 down 6,12 up
HMGCS1 NM_001098272 2,51 up 1,04 up
ACSS2 NM_018677 2,48 up 1,44 up
SC4MOL NM_006745 2,35 up 2,53 up
VLDLR NM_003383 2,34 up 1,55 up
MVK NM_000431 2,31 up 1,21 down
CCDC23 NM_199342 2,29 down 1,34 up
POLR3G NM_006467 2,27 down 1,85 down
POM121 NM_172020 2,21 down 1,03 down
KIR2DL1 NM_014218 2,20 up 1,38 down
FTH1 NM_002032 2,19 up 1,49 up
C6orf223 NM_153246 2,17 up 1,09 down
LSS NM_002340 2,16 up 1,53 down
TRGV7 ENST00000354395 2,15 down 1,43 down
RABL2B NM_001003789 2,15 up 1,44 up
SLC16A13 NM_201566 2,13 up 1,06 up
ARPC1A NM_006409 2,13 down 1,61 up
C2orf59 BC010491 2,10 up 1,13 up
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KRTAP10-5 NM_198694 2,10 up 1,82 down
TM6SF1 NM_023003 2,10 up 3,48 up
LOC401152 NM_001001701 2,09 down 2,66 up
ALDH7A1 NM_001182 2,09 up 1,34 up
ANXA1 NM_000700 2,09 down 1,17 down
CHORDC1 NM_012124 2,09 down 1,00 down
ERV3 NM_001007253 2,07 down 3,39 up
CHAC1 NM_024111 2,05 up 1,18 up
SLC6A9 NM_201649 2,03 up 1,04 up
ANKRD36B NM_025190 2,03 down 2,42 up
KRT33A NM_004138 2,01 up 2,60 down
SLC25A33 NM_032315 2,00 down 1,70 up
Chapter 3
112
Supplemental Figures
Figure S1. BTG1 copy number loss is observed in approximately 10% of pediatric pre-B ALL cases. 
(A) Schematic representation of the position of the MLPA probes relative to the BTG1 locus. (B) Copy 
number loss of the region containing the BTG1 gene, as found in the array, was confirmed by MLPA. DNA 
copy-number of all thirty-three cases was tested and confirmed in the four previously identified cases with 
a copy-number loss.
IP: α-PRMT1
PRED - + - + - + - +
0
2
4
6
Antibody 1 Antibody 2
Fo
ld
 e
nr
ic
hm
en
t
BTG1 promoter
*
Figure S2
0
2
4
6
8
Antibody 1 Antibody 2
NR3C1 promoter
*
Figure S2. Comparison of α-PRMT1 antibodies in ChIP analysis. Quantitative ChIP analysis of PRMT1 
binding to promoter sequences of NR3C1 (the gene encoding the GR) and BTG1 in response to prednisolone 
in RS4;11 pre-B ALL cell line using two different anti-PRMT1 antibodies. Antibody 1 is obtained from Abcam, 
antibody 2 from Upstate. 
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Figure S3. BTG1 mRNA expression is induced by exposure to prednisolone in a dose- and time 
dependent manner. (A) BTG1 mRNA expression after exposure of RS4;11 BTG1 shRNA1 or RS4;11 
control shRNA cells to 1 mg/ml prednisolone for 8 and 72 hours. (B) BTG1 mRNA expression in RS4;11 
control shRNA cells after exposure to increasing concentrations of prednisolone for 8 hours.
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Figure S4. BTG1 knockdown causes resistance to GC-induced cell death. (A) Determination of relative 
apoptosis induction of RS4;11 control, BTG1 shRNA1 and BTG1 shRNA2 cell lines as determined by 
flow cytometric analysis of Annexin V and 7-AAD staining following exposure for 72 hours to increasing 
concentrations of prednisolone. (B) Individual FACS dotplots for the timepoints in the graph, shown are the 
percentage viable cells in the lower-left quadrant.
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Figure S5
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Figure S5. Expression of a GR transgene in RS4;11 BTG1 knockdown cells does not restore expression 
of GR target genes. mRNA expression of the GC-regulated genes TSC22D3/GILZ, SGK1 and VDR were 
analyzed by quantitative RT-PCR and normalized for TBP following exposure to 1 mg/ml prednisolone 
for up to 8 hours in RS4;11 control cells, BTG1 knockdown cells (shRNA1) and BTG1 knockdown cells 
complemented with GR (shRNA1+GR). Error bars represent the SEM of duplicate experiments, statistical 
significance was assessed with Student t test compared to mock treated control cells.
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Figure S6. Reduced expression of BTG1 expression correlates with reduced expression of the 
GR gene, BTG2 may compensate for low BTG1 expression levels. Quantitative RT-PCR analysis of 
BTG1 (A) and GR (B) on total mRNA of RS4;11 REH and SUP-B15 pre-B ALL cell lines. (C) Quantitative 
RT-PCR analysis showing GR mRNA expression in control REH cells and REH HA-BTG1 cells, relative to 
expression in parental RS4;11 cells. (D) Quantitative RT-PCR analysis of BTG2 mRNA levels in RS4;11, 
REH and SUP-B15 cells. In (C) and (D) cells were exposed to 1 mg/ml prednisolone for 8 hours.
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Introduction 
Transcription factors that regulate B-cell differentiation are frequently targeted by 
genetic aberrations in B-cell malignancies. The B-cell translocation gene (BTG1), which 
encodes a transcription coregulatory [1, 2], is recurrently affected by gene deletions 
in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) [3-5], and targeted by 
missense mutations in diffuse large B-cell lymphomas (DLBCL) [6, 7]. Similarly, the 
closely related BTG2 gene is subject to mutations in DLBCL, Burkitt lymphoma and 
follicular lymphoma [6-9]. To establish the role of BTG1 and BTG2 in B-lymphopoiesis, 
we studied the composition of the hematopoietic compartment in mice deficient for 
either Btg1 or Btg2, as well as in Btg1;Btg2-double knockout animals. We found that 
Btg1 and Btg2 are both required at multiple stages of early B-cell development, but also 
display specific functions in progenitor B-cells. Our data demonstrate that transcriptional 
cofactors BTG1 and BTG2 act as important regulators of B-cell differentiation, providing 
an important link to their role as tumor suppressors in B-cell malignancies.   
 
Materials and Methods 
Mice
Generation of C57BL/6J Btg1-/- mice has previously been reported by Farioli-Vecchiolo 
et al [10]. The Btg2-/- strain was generated at the University of Florida [11]. The Btg1-
/-;Btg2-/- mice have been described by Tijchon et al [12]. The animals were housed 
under specific pathogen-free conditions at the Central Animal Laboratory (Cdl) of 
the Raboud University Medical Center. All animal experiments were approved by the 
Animal Experimental Committee of the Radboud University Medical Center and were 
performed in accordance with institutional and national guidelines. In our experiments 
we used mice that were between the age of 8-12 weeks old. 
Flow cytometric analysis
Bone marrow (BM) cells were harvested by flushing femurs with RPMI medium (Gibco//
Life technologies Europe BV, Bleiswijk, The Netherlands) containing 10% FBS (Greiner 
Bio-One BV, Alphen a/d Rijn, The Netherlands) and 50µM 2-ME (Gibco). Spleen 
and thymus cells were isolated by gently flushing out the spleen and thymus on 
a 70µM filter using RPMI medium (Gibco) containing 10% FBS (Gibco) and 50µM 
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2-ME (Gibco). To isolate peritoneal cavity cells, 5ml ice-cold PBS (Lonza Benelux BV, 
Breda, The Netherlands) containing 3% FBS (Gibco) was injected into the peritoneum 
of euthanized mice followed by gently massage of the abdomen and recovery of the 
cells with a needle. All cell suspensions were treated with red cell lysis buffer (Sigma-
Aldrich Chemie BV, Zwijndrecht, The Netherlands), filtered and counted. Prepared cell 
suspensions were used for FACS analysis of different hematopoietic lineages (LSRII 
flow cytometer, BD Biosciences, Breda, The Netherlands). Single cell suspensions 
were pre-incubated with unlabeled anti–Fcγ III/II receptor (2.4G2) (BD Biosciences) 
to inhibit unspecific antibody binding. Cells were stained with the following antibodies 
purchased form BD Biosciences and eBiosciences (Vienna, Austria): anti-B220/CD45R-
PE-CY7 (RA3-6B2); BP1-PE (6C3); CD4-FITC (RM4-5); CD8-PE (53-6.7); CD11b/
Mac1-FITC (M1/70); CD19-APC-CY7 (1D3); CD24/HSA-FITC (M1/69); CD25-PE-CY7 
(PC61.5); CD43-APC (S7); CD44-PERCP-CY5.5 (IM7); CD45.1/Ly-5.1-APC (A20); 
CD45.2/Ly-5.2-V500 (104); CD117/c-Kit-PERCP-CY5.5 (2B8); CD127/IL-7Rα-FITC 
(A7R34); CD135/Flt3-PE (A2F10); GR1-PE (RB6-8C5); Lin-APC (145-2C11/M1-70/
RA3-6B2/TER119/RB6-8C5); IgM-FITC (II/41); IgD-PE (11-26c); Sca1/Ly6A-PE (D7). 
Isotype antibodies were used as control. The data were collected and analyzed by 
FlowJo software. 
Competitive repopulation assay
Bone marrow cells were harvested by flushing femurs with RPMI medium (Gibco) 
containing 10% FBS (Gibco) and 50 uM 2-ME (Gibco), and the cell suspension was 
treated with red cell lysis buffer (Sigma), filtered and counted. For the competitive in 
vivo repopulation, two experimental groups were created (each 6 mice). In the first 
group bone marrow cells from wild-type donor mice (C57BL/6; Ly5.2/CD45.2) were 
mixed 1:1 with bone marrow cells from wild-type mice (n=3) of the same strain as the 
recipient mouse (C57BL/6, Ly5.1/CD45.1). In the second group the knockout donor 
mice (C57BL/6 Btg1-/-; Btg2-/-; Ly5.2/CD45.2) were mixed 1:1 with bone marrow (BM) 
cells from wild-type mice (n=3) of the same strain as the recipient mouse (C57BL/6; 
Ly5.1/CD45.1). The BM cells from the CD45.1 were obtained from 3 donor mice 
and pooled for all the transplantation experiments. The BM cells from the wild-type 
and Btg1-/-;Btg2-/- CD45.2 mice were each derived from 3 independent animals and 
also transplanted separately in two independent recipients. The mixture of cells was 
intravenously injected into lethally irradiated (9 Gy, Cs137) 8–12 week old Ly5.1/CD45.1 
recipient mice, with each recipient receiving 1×106 donor (Ly5.2-CD45.2) and 1×106 
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competitor (Ly5.1-CD45.1) bone marrow cells. The contribution within the CD45.1 and 
CD45.2 donor fractions for T cells (CD3+), B-cells (B220+), and myeloid cells (Mac-
1+) was assessed 5 and 10 weeks post transplantation by flow cytometry from blood 
samples and at 11 weeks from spleen. Two animals receiving CD45.2 from wild-type 
mice died at the age of 3-4 weeks, due to failure of transplantation procedure.
Methylcellulose colony assays
Total bone marrow cells (1x105 cells/plate) and MACS sorted CD19+ cells (0.2x105 cells/
plate) derived of WT, Btg1-/-, Btg2-/- and Btg1-/-;Btg2-/- mice, were cultured in 1.1ml  B-cell 
specific methylcellulose cultures in 35mm plates (M3630, STEMCELL Technologies, 
SARL, Grenoble, France), in duplicate, to study the outgrowth of B-cell progenitors. 
Microarray gene expression analysis
Hardy fractions ABC and DEF [13] (early and late B-cell stage) isolated from BM 
of WT and Btg1-/-;Btg2-/- animals were obtained by sorting with FACS AriaII (BD), 
as follows: B220+ CD43hi (Hardy ABC), B220+CD43- (Hardy DEF). Total RNA was 
extracted of 1-3x106 cells according to manufacturer protocol (Qiagen RNAeasy kit) 
(QIAGEN Benelux BV, Venlo, The Netherlands). Biotinylated RNA was prepared using 
the Illumina TotalPrep RNA Amplification kit (Ambion, Inc., Austin, TX, U.S.A.) according 
to manufacturer’s specifications with an input of 200ng total RNA. Samples were 
hybridized onto the Illumina MouseRef-8 v2 (Illumina, Inc., San Diego, CA, U.S.A.). 
Image analysis and extraction of raw expression data was performed with Illumina 
GenomeStudio v2011.1 Gene. The Quality control, RNA labeling, hybridization and 
data extraction were performed at ServiceXS B.V (Leiden, The Netherlands). Samples 
were normalized to Robust Multi-array Average (RMA) and analyzed with ArrayStar 
software. KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis was 
performed using the online Gene set enrichment analysis (GSEA) Molecular Signature 
Database (MSigDB) tool [14], only including  genes with an expression cutoff of ≥ 5 
and ≥ 1.6 fold difference. Illumina bead array expression data is submitted to the NCBI 
Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/), accession 
code: GSE55997.
Apoptosis and proliferation assays 
MACS sorted CD19+ BM cells (1x106 cells/ml) derived from WT and Btg1-/- mice, were 
cultured in IMEM medium (Gibco) containing 20% FBS for Mouse Pre-B Lymphoid 
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Colony-Forming Cells (STEMCELL Technologies), 1% Penicillin-Streptomycin 
(Invitrogen/ Life technologies Europe BV, Bleiswijk, The Netherlands), 0,3% w/v 
Primatone (Sigma) and 55µM 2-ME (Gibco) in the presence of 20ng/ml IL-7 (R&D 
Systems Europe, Abingdon, United Kingdom) in a 6-well tissue-culture (TC) plate. 
The cells were cultured for 4 days. Apoptosis was measured using the AnnexinV-PE 
Apoptosis Detection Kit I (BD Biosciences) and analyzed on a LSRII flow cytometer (BD 
Biosciences). For measuring cell proliferation, the cell cycle distribution was determined 
using Ki-67 staining according to the manufacturer’s instructions (BD Biosciences).
RNA isolation and quantitative RT-PCR
RNA was isolated from B220+ BM cells derived from WT, Btg1-/-, Btg2-/- and  Btg1-/-
;Btg2-/- mice according to manufacturer protocol (Qiagen RNeasy kit). For quantitative 
reverse transcription polymerase chain reaction (qRT-PCR), cDNA was generated with 
the iScript cDNA synthesis kit (Bio-Rad Laboratories BV, Veenendaal, The Netherlands) 
and analyzed by qRT-PCR using SYBR Green method (Bio-Rad). Expression levels 
were normalized to the housekeeping gene TATA box-binding protein (TBP). Primers 
sequences used in qRT-PCR experiments are listed in Supplementary Table S2. 
Statistical Analysis
Statistical data are expressed as mean ± SEM, as indicated in the text. Statistical 
differences were determined with 2-sided, unpaired Student’s t test when comparing 
two biological datasets or one-sided ANOVA combined with Dunetts’s post-hoc test in 
case of comparing multiple biological datasets to wild-type controls. P values < 0.05 
(*), <0.01 (**) or <0.001 (***) were considered statistically significant.    
Results  
To determine the function of Btg1 and Btg2 during normal hematopoiesis we performed 
flow cytometric analysis of the bone marrow (BM) compartment and spleen. The fraction 
of B220+ progenitor B-cells was significantly reduced in Btg1- and Btg2-deficient mice, 
ranging from a 10% decrease in the Btg2-/- mice, 20% in Btg1-/- mice, to 40% in the 
Btg1-/-;Btg2-/- double knockout animals relative to control mice (Figure 1A). Similarly, 
B-cell counts in the spleen were most significantly reduced in Btg1-/-;Btg2-/- mice, 
with about ~30% fewer B220+IgM+ B-cells (Figure 1B). In contrast, the fraction of 
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myeloid progenitor cells in BM was not altered in the Btg1- and Btg2-deficient animals 
(Supplementary Figure S1). In addition, we did not observe any specific defects in T-cell 
development in mice lacking Btg1 and Btg2 expression (Supplementary Figure S2).
To assess whether the defect in B-lymphopoiesis was not related to defective support 
from the BM microenvironment in the Btg1 and Btg2 knockout animals, competitive 
repopulation assays were performed. BM cells derived from either wild-type (CD45.2) 
or Btg1-/-;Btg2-/- mice (CD45.2) were mixed with competitor wild-type cells (CD45.1) 
and transplanted into lethally irradiated C57BL6/J mice (CD45.1). FACS analysis on 
peripheral blood and spleen demonstrated that contribution to the B-cell lineage was 
significantly reduced using Btg1-/-;Btg2-/- donor cells when compared to wild-type donor 
cells (Figure 1C), arguing that the observed defect in B-development is cell-autonomous.
To establish at what stage of early B-cell development Btg1- and Btg2-deficiency 
affect B-cell differentiation, we investigated the relative frequencies of the different 
B-cell subsets within the BM compartment. Analysis of the common lymphoid progenitor 
(CLP) fraction, defined as lineage negative (Lin-) Sca-1+c-Kit+Flt3+Il-7Rα+ cells, revealed 
no significant differences in Btg1-/-, Btg2-/- and Btg1-/-;Btg2-/- mice compared to wild-type 
controls (Supplementary Figure S3). Next, we employed the cell surface markers 
B220, CD43, CD24, IgD and IgM, to distinguish different B-cell precursor populations, 
generally known as Hardy fractions (Figure 1D). When we examined the single knockout 
animals, the Btg2-/- mice displayed decreased B-cell fractions at both the early and 
later stages of B-cell differentiation, while Btg1-deficiency resulted only in reduced 
B-cell fractions beyond the pre-B cell stage, including the immature B-cells (Hardy 
fractions E and F) (Figure 1E).  
In the Btg1-/-;Btg2-/- mice, we observed a similar phenotype as the Btg2-/- mice at 
the early stages of B-lineage differentiation, with a moderate decrease in the pool of 
pro-B cells (Hardy BC) compared to control mice. However, from the pre-B cell stage 
onwards, the Btg1-/-;Btg2-/- mice displayed a more pronounced phenotype in comparison 
to the Btg1-/- and Btg2-/- single knockout animals, showing a 2-fold reduction in the 
B220+CD43- cell fraction relative to control mice (Hardy D, E and F) (Supplementary 
Figure S4). We conclude from these results that Btg1 and Btg2 are both required for 
mouse B-cell development, while deficiency for each of the genes shows a different 
outcome on the relative abundance of the specific Hardy fractions.  
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To more specifically assess the function of Btg1 and Btg2 in early B-lymphopoiesis, 
we investigated whether interleukin-7 (IL-7) dependent outgrowth of B-lymphoid 
progenitor cells was affected in the absence of Btg1 and Btg2 expression. BM cells 
derived from Btg1-/-, Btg2-/- single knockout and Btg1-/-;Btg2-/- double knockout mice 
were plated in methylcellulose and cultured for one week in the presence of cytokine 
IL-7. The number of colonies in methylcellulose was about 4-fold lower in cultures 
derived from Btg1-/- and Btg1-/-;Btg2-/- BM cells relative to those derived from control 
BM cells (Figure 2A). Moreover, also colony size was reduced in these two knockout 
genotypes (data not shown). In contrast, Btg2-deficiency had no significant impact 
on the outgrowth of lymphoid progenitor cells in the IL-7-dependent methylcellulose 
colony formation assay. Given the fact that the number of B220+ B-cell progenitors 
was decreased in BM of the different Btg1 and Btg2 knockout lines, we also analyzed 
the colony outgrowth of similar amounts of purified CD19+ progenitor B-cells under the 
same conditions. Again, colony formation was significantly impaired using CD19+ cells 
derived from Btg1-/- and Btg1-/-;Btg2-/- mice, but not with Btg2-/- progenitor B-cells, which 
indicates that loss of Btg1 function is largely responsible for the defective outgrowth 
of B-lymphoid progenitors (Figure 2B). 
To assess whether differences in colony formation could be attributed to reduced 
expression levels of the IL-7 receptor alpha (IL-7Rα/CD127), CD127 expression was 
measured on B220+ BM cells by flow cytometry. We observed that IL-7Rα expression 
was not decreased in Btg1-/- progenitor B-cells, but even upregulated in Btg1-/-;Btg2-/- 
cells (Figure 2C), arguing that the low number of colonies due to Btg1-deficiency 
was not related to reduced IL-7Rα expression levels. Next, we examined whether 
Btg1-deficient CD19+ cells displayed intrinsic differences in the level of apoptosis 
and proliferation. We observed a moderate but significant increase in the fraction of 
Figure 1. Decreased B-cell numbers in mice deficient for Btg1 and Btg2. (A-B) Flow cytometric analysis 
was performed on mononuclear cells isolated from bone marrow (BM) and spleen of wild-type (WT) control 
(n=16), Btg1-/- (n=7), Btg2-/- (n=8) and Btg1-/-;Btg2-/- mice (n=11). The fractions of B220+ BM cells (A) and 
B220+IgM+ splenocytes (B) are indicated. Each dot represents an individual sample and the horizontal line 
indicates the mean. (C) Competitive repopulation assay of wild-type and Btg1-/-;Btg2-/- donor cells (CD45.2) 
derived of BM mixed 1:1 with CD45.1 wild-type cells which were transplanted into 9Gy (Gray) irradiated 
C57BL6/J mice (CD45.1). Flow cytometric analysis was performed on blood and spleen. The fraction of 
B220, CD3 and Mac-1 of WT:WT (CD45.1:CD45.1) (n= 4) and WT:Btg1-/-;Btg2-/- (CD45.1:CD45.2) (n=6) 
cells are indicated. (D) Schematic representation of the different B-cell developmental stages according to 
Hardy nomenclature. Cell surface markers that distinguish specific Hardy fractions are indicated. (E) The 
percentage for the different Hardy B-cell fractions within BM is indicated as determined in WT control (n=16 
), Btg1-/- (n=7), Btg2-/- (n=8), and Btg1-/-;Btg2-/- (n=11) mice. Each bar represents the mean of each group 
of mice ± the standard error of the mean (SEM). *, P< 0.05, **, P< 0.01, ***, P< 0.001.
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AnnexinV-positive cells derived from Btg1-/- mice (Figure 2D; Supplementary Figure 
S5), while the cell cycle distribution, as determined by Ki-67 staining, was not affected 
(Figure 2E). Thus, Btg1 appears to be required for optimal IL-7 dependent B-lymphoid 
colony formation, in part by promoting cell survival in early progenitor B-cells.
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Figure 2. Btg1 stimulates B-cell progenitor 
outgrowth in response to IL-7. (A) Bone 
marrow (BM) mononuclear cells (1 x 105 
cells) were isolated from wild-type (WT) 
control (n=18), Btg1-/- (n=7), Btg2-/- (n=8) 
and Btg1-/-;Btg2-/- mice (n=11) and added 
in methylcellulose containing 10 ng/mL IL-
7. (B) BM mononuclear cells were isolated 
from WT control (n=10), Btg1-/- (n=7), Btg2-/- 
(n=4) and Btg1-/-;Btg2-/- mice (n=4) and added 
after CD19 isolation (2 x 104 CD19+ cells) 
in methylcellulose containing 10ng/ml IL-7. 
(A, B) Mean colony counts (and SEM) were 
determined (>30 cells/colony) after seven 
days of culture. Data are representative of 
at least two independent experiments. **, P< 
0.01, ***, P< 0.001. (C) BM cells from WT, 
Btg1-/-, Btg2-/-, and Btg1-/-;Btg2-/- mice (all n=2) 
were stained with B220 and IL-7Rα/CD127 
antibodies and the percentage of IL-7Rα-
positive cells within the B220+ fraction was 
determined. The black line indicates IL-7Rα 
expression in the WT cells, while the blue 
peak shows the IL-7Rα expression in the Btg1-
/-, Btg2-/- and Btg1-/-;Btg2-/- double knockout 
cells. (D) Apoptosis assay of CD19+ BM cells 
isolated from WT (n= 4) and Btg1-/- (n=7) 
cultured for 4 days in B-cell specific medium, 
by measuring AnnexinV using flow cytometry. 
The percentage of AnnexinV-positive cells in 
CD19+ BM cells is indicated. (E) Proliferation 
assay of CD19+ BM cells isolated from WT 
(n= 3) and Btg1-/- (n=3) cultured for 4 days in 
B-cell specific medium, measuring Ki-67 by flow cytometry. The cell cycle distribution according to Ki-67 
staining in CD19+ BM cells is indicated. Each bar represents the mean of each group of mice ± the standard 
error of the mean (SEM). **, P< 0.01. 
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To elucidate how Btg1 and Btg2 regulate B-cell development in vivo, we examined the 
expression of key transcription factors involved in early B-cell differentiation, including 
E2a (Tcf3), Foxo1, Ebf1, and Pax5 [15, 16]. Quantitative reverse transcription polymerase 
reaction (qRT-PCR) on RNA isolated from B220+ sorted BM cells of Btg1-/-, Btg2-/- and 
Btg1-/-;Btg2-/- mice demonstrated that the expression of these master regulators of 
B-cell differentiation was not decreased (Figure 3A). To the contrary, mRNA expression 
levels of these transcription factors were even somewhat elevated in the absence 
of Btg1 and Btg2. Hence, the partial block in B-cell differentiation observed in the 
Btg1-/-;Btg2-/- animals cannot be explained by diminished expression levels of these 
B-lineage transcription factors. 
Next, we performed microarray based gene expression profiling using early 
(B220+CD43+) and late progenitor B-cells (B220+CD43-) isolated from control and 
Btg1-/-;Btg2-/- mice and performed Gene Set Enrichment Analyses (GSEA) using the 
Molecular Signature Database (MSigDB) to define KEGG pathways that were specifically 
affected (Figure 3B). Interestingly, several signaling pathways were identified, including 
the presence of a T-cell receptor signaling signature in early B-cells of Btg1-/-;Btg2-/- mice 
showing upregulation of Cd3d (Cd3delta) and Cd3g (Cd3gamma) (Supplementary 
Table S1). Therefore, we aimed to assess whether Btg1;Btg2-deficient progenitor 
B-cells displayed aberrant expression of other T-lineage specific genes, including Cd4, 
Ikzf2, Tcf7, Gata3 and Notch1. Indeed, qRT-PCR revealed that Btg1-/-;Btg2-/- B220+ 
BM cells showed significantly increased expression levels of these T-lineage marker 
genes (Figure 3C), while we also observed higher expression of the CD3, CD4 and 
CD8 cell surface markers on Btg1-/-;Btg2-/- committed B-cells (Supplementary Figure 
S6). These findings suggest that Btg1 and Btg2 are implicated in regulating B-lineage 
commitment by suppressing the expression of lineage-inappropriate genes. 
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Figure 3. Aberrant T-lineage gene expression in progenitor 
B-cells deficient for Btg1 and Btg2. (A) Relative expression levels 
of B-cell transcription factors E2A (Tcf3), Foxo1, Ebf1 and Pax5 was 
determined using cDNA generated from B220+ bone marrow (BM) 
cells of wild type control (WT), Btg1-/-, Btg2-/- and Btg1-/-;Btg2-/- mice 
by qRT-PCR and normalized to the expression of the housekeeping 
gene TBP. (B) RNA was isolated from B220+CD43+ and B220+CD43- 
cells derived from wild type control and Btg1-/-;Btg2-/- mice (n=4) and 
analyzed by microarray using the Illumina BeadArray platform. The 
data obtained were RMA normalized and relative gene expression 
differences of >1.6-fold was determined. KEGG pathway analysis was performed using the online Gene 
Set Enrichment Analysis (GSEA) tool and relevant pathways with highest p-value that are differentially 
expressed between WT and Btg1-/-;Btg2-/- cells are indicated. (C) Relative expression levels of Cd4, Ikzf2, 
Tcf7, Gata3 and Notch1 were determined on cDNA generated from B220+ BM cells of the different genotypes 
by real-time PCR and normalized to TBP expression. (A and C) Data represent the mean and SEM  of 
three independent experiments containing cDNA derived from 2 different biological samples. *, P< 0.05, 
**, P< 0.01, ***, P< 0.001.
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Discussion 
In summary, using genetic mouse models, we demonstrate that both Btg1 and Btg2 
promote mouse B-cell differentiation at multiple stages of development, and mostly 
display overlapping functions during B-lymphopoiesis, which corresponds with an 
additive phenotype in the Btg1-/-;Btg2-/- mice. On the other hand, Btg1 fulfills a more 
prominent role in promoting the proliferative expansion of lymphoid progenitors by 
inhibiting apoptosis. This is in agreement with the finding that Btg1 ablation in the 
mouse brain decreases the pool of proliferating stem and progenitor cells, which is 
accompanied by increased apoptosis [10]. Importantly, Btg1 and Btg2 are both required 
to repress T-lineage gene expression in progenitor B-cells. These findings are partially 
overlapping with the phenotype observed in Ebf1 and Pax5 knockout mice, where it 
has been shown that EBF1 and PAX5 are critical regulators of B-lineage specification 
and commitment by repressing alternative non-B-cell fates [17-19]. As the expression 
of Ebf1 and Pax5 itself is not inhibited in Btg1-/-;Btg2-/- progenitor B-cells, the BTG1 
and BTG2 transcriptional coregulators may affect B-lineage commitment by modifying 
the function of these B-cell specific transcription factors or by epigenetic regulation of 
their target genes. Notably, PAX5 and EBF1, similar to BTG1, are also subject to gene 
deletions in BCP-ALL, and combinations of these deletions often co-occur in the same 
leukemia [4]. Together our findings suggest that the block in differentiation observed 
in BCP-ALL may result from gene alterations affecting multiple master regulators of 
B-cell differentiation.        
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Name Forward (5’  3’) Reverse (5’  3’)
mBtg1 CCACCATGATAGGCGAGATCG CTGGGAACCAGTGATGTTTG
mBtg2 GGGTTTCCTCTCCAGTCTCC GATACGGATACAGCGATAGC
mCd4 TCCCACTCACCCTCAAGATA CCATCACCTCACAGGTCAAA
mIkzf2 GCCTTTTGAGAGACCTGCTG TGATGGCTTGGTCCATCATA
mTcf7 CCAGAAGCAAGGAGTTCACA GCAGGGAAGTGCTGTCTATATC
mPax5 CGCGTGTTTGAGAGACAGCACTACT GTCTCGGCCTGTGACAATAGGGTAG
mEbf1 CCATCCGAGTTCAGACACCTCCT ACCTCTGGAAGCCGTAGTCGATG
mTcf3 GGGAGGAGAAAGAGGATGA GCTCCGCCTTCTGCTCTG
mFoxo1 CATCGAGAGCTCAGCCGAGAA ATGGACGCAGCTCTTCTCCG
Tbp GCACAGGAGCCAAGAGTGAA ACATCACAGCTCCCCACCAT
Table S2. Primers for quatitative RT-PCR
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M Figure S1. Myeloid development in bone marrow compartment 
of mice deficient for Btg1 and Btg2. Flow cytometric analysis 
was performed on mononuclear cells isolated from bone marrow 
(BM) of wild-type (WT) control (n=6), Btg1-/- (n=3), Btg2-/- (n=4) and 
Btg1-/-;Btg2-/- (n=4) mice. The percentage of Mac-1+Gr-1+ myeloid 
progenitor cells in BM is indicated.
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Figure S2. T-lymphopoiesis in thymus and spleen of Btg1 and Btg2 knockout animals. (A-E) Flow 
cytometric analysis was performed on mononuclear cells isolated from spleen and thymus of wild-type 
control (WT) (n=10-16), Btg1-/- (n=6-7) Btg2-/- (n=5-8) and Btg1-/-;Btg2-/- mice (n=9-10). (A-B) The percentage 
of CD4+ and CD8+ T cells in spleen (C-D) and thymus are indicated. (E) Early T-cell development can be 
defined as lineage negative (Lin-) CD4-CD8-, double negative T-cells. To distinguish the double negative 
(DN) T-cell fractions, DN1-DN4, cells were gated for CD25 and CD44. Each bar represents the mean of 
each group of mice ± the standard error of the mean (SEM). *, P< 0.05, **, P< 0.01, ***, P< 0.001. 
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Figure S3. Analysis of common lymphoid progenitor population 
of Btg1 and Btg2 knockout mice. Flow cytometric analysis was 
performed on mononuclear cells isolated from bone marrow (BM) of 
wild-type control (WT) (n=15), Btg1-/- (n=7) Btg2-/- (n=8) and Btg1-/-
;Btg2-/- mice (n=11). BM cells were stained with lineage cocktail, SCA-1/
Ly6A/E, c-KIT/CD117, FLT-3L/CD135 and IL-7Rα/CD127 antibodies to 
determine the percentage of common lymphoid progenitor (CLP) cells. 
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Figure S4. Flow cytometric analysis of the early B-cell developmental stages of mice deficient for 
Btg1 and Btg2. Bone marrow (BM) cells from wild-type (WT) control (n=16), Btg1-/- (n=7), Btg2-/- (n=8), 
and Btg1-/-;Btg2-/- (n=11) mice were stained with a cocktail of antibodies directed against B220, CD43, 
BP-1, CD24, IgD and IgM. Cells were first gated according to the expression levels of B220 and CD43, 
followed by quantitative analyses of BP-1 and CD24 on the B220+CD43+ cells to identify Hardy fractions 
A (B220+CD43+CD24-) and BC (B220+CD43+CD24+), or IgD and IgM expression on B220+CD43- cells to 
distinguish Hardy fractions D (B220+CD43-IgM-IgD-), E (B220+CD43-IgM+IgDlo) and F (B220+CD43-IgM+IgD+). 
The mean percentage for each population of cells is indicated for the different genotypes.
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Figure S5. Analysis of apoptosis in CD19+ cells of Btg1-
deficient mice by AnnexinV staining. Apoptosis assay 
was performed on CD19+ cells isolated from bone marrow 
of wild-type (WT) (n= 4) and Btg1-/- (n=7) mice that were 
cultured for 4 days in B-cell specific culture medium by 
measuring AnnexinV and 7-AAD with flow cytometry.  
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Figure S6. Btg1 and Btg2 suppress expression of inappropriate T-lineage markers on committed 
B-cells. Bone marrow (BM) cells derived from wild-type (WT) (n=6), Btg1(n=9), Btg2 (n=6) and Btg1;Btg2 
(n=6) knockout mice were stained for CD19 in combination with T-cell surface markers (CD3, CD4, CD8) 
and analyzed by flow cytometry. Cells were first gated for CD19+ B-cells and within that gate we analyzed the 
fraction of CD3, CD4 and CD8 T-cell marker expression. Data shown are representative of three separate 
experiments and indicate the mean value (and SEM) of at least two independent biological samples, and 
compared relative to WT levels. *, P< 0.05, **, P< 0.01, ***, P< 0.001.
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Abstract 
Translocation t(12;21)(p13;q22) giving rise to the ETV6-RUNX1 fusion gene, is the most 
common genetic abnormality in childhood B-cell precursor acute lymphoblastic leukemia 
(BCP-ALL). The ETV6-RUNX1 translocation frequently arises in utero, but its expression 
is insufficient to induce leukemia and requires other cooperating genetic lesions for 
BCP-ALL to develop. Deletions affecting the BTG1 are frequently observed in ETV6-
RUNX1-positive leukemia, which appear to arise due to off-target RAG recombinase 
activity. BTG1 acts as a transcriptional regulator through recruitment of the protein 
arginine methyltransferase PRMT1. Here, we show that ETV6-RUNX1 interacts with 
PRMT1 in a Btg1-dependent manner. Moreover, Btg1 deficiency enhances the self-
renewal capacity of ETV6-RUNX1-positive mouse fetal liver-derived hematopoietic 
progenitors (FL-HPCs), which involves upregulation of the proto-oncogene Bcl6 and 
downregulation of BCL6 target genes, such as p19Arf and Tp53. Similarly, ectopic 
expression of BCL6 promotes the self-renewal and clonogenic replating capacity of 
FL-HPCs by suppressing the expression of p19Arf and Tp53. Moreover, we find that 
silencing of BTG1 expression by short hairpin RNA (shRNA), combined with expression 
of an ETV6-RUNX1 transgene, results in derepression of BCL6 expression in human 
NALM6 cells. Together these results identify BCL6 as a potential driver of ETV6-RUNX1 
induced self-renewal, which is subject to regulation by BTG1.
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Introduction 
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common childhood 
malignancy and characterized by a variety of distinct genetic abnormalities with different 
clinical outcome, including chromosomal translocations, submicroscopic gene deletions 
and point mutations. The t(12;21)(p13;q22) chromosomal translocation, giving rise 
to ETV6-RUNX1 fusion protein, is the most common genetic subtype in childhood 
BCP-ALL representing 25% of the cases [1-5]. It has been established that the ETV6-
RUNX1 fusion frequently arises in utero, generating a preleukemic clone that can 
persist for many years and requires additional cooperating events before overt leukemia 
develops [6-8]. Genomic profiling of ETV6-RUNX1 positive BCP-ALL has revealed 
recurrent copy number aberrations (CNAs), including gene deletions affecting the 
wild-type copy of ETV6, genes implicated in lymphoid signalling (BTLA, TOX) and 
nuclear receptor transcription regulation (TBL1XR1, BTG1, NR3C1, NR3C2) [9-11]. 
We and others have shown that BTG1 deletions and other critical secondary events 
in ETV6-RUNX1 positive BCP-ALL are frequently driven by genomic rearrangements 
mediated by aberrant RAG recombinase activity [12, 13]. 
The ETV6-RUNX1 fusion protein comprises two-thirds of the ETS-transcription 
factor ETV6, which is fused to almost the complete open reading frame of RUNX1 
(AML1) [1]. Both RUNX1 and ETV6 are frequently targeted by genetic aberrations in 
human myeloid and lymphoid leukemias [12, 14, 15]. The ETV6-RUNX1 fusion protein 
functions as a constitutive repressor of transcription by recruitment of co-repressor 
molecules, e.g. Sin3A and NCoR [5, 16-18]. Previous studies have demonstrated that 
ETV6-RUNX1 expression leads to activation of the JAK-STAT pathway and deregulation 
of the TGF-β and PI3K pathways as well as p53 function, but the exact contribution 
of these pathways to ETV6-RUNX1-induced leukemic transformation has not been 
firmly established [19-23]. 
In the past 15 years, the effects of ETV6-RUNX1 on leukemic transformation have 
been studied in different mouse models, including an ETV6-RUNX1 knock-in model 
and transgenic mouse lines expressing ETV6-RUNX1 [19, 24-27]. While expression 
of the ETV6-RUNX1 transgene on its own was found to be insufficient for leukemia 
formation, insertional- and ENU-induced mutagenesis predisposed to precursor B-cell 
and myeloid leukemia in these ETV6-RUNX1 transgenic mice [25, 26]. Alternative 
approaches to model ETV6-RUNX1 leukemia have been achieved through retroviral 
transduction of ETV6-RUNX1 in either adult bone marrow (BM) cells or fetal liver (FL)-
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derived hematopoietic progenitor cells (HPCs). Also, transplantation of these cells into 
irradiated recipient mice was insufficient to induce overt leukemia [28-31]. Together, these 
experiments confirm that while expression of the ETV6-RUNX1 transgene predisposes 
to leukemia formation, additional genetic events are required for leukemia to develop.
Focal deletions affecting the B-cell translocation gene 1 (BTG1), which is a member 
of the BTG/Tob family of anti-proliferation genes, are present in 9% of all BCP-ALL 
cases [9, 10, 32]. Notably, BTG1 deletions are enriched in ETV6-RUNX1-positive 
leukemia (20%), and are found to occur more frequently in relapsed patients [13, 33, 
34]. BTG1 functions as a transcriptional cofactor that acts by recruitment of effector 
molecules, such as the protein arginine methyltransferase I (PRMT1), to specific 
transcription factors [35-38]. BTG1 regulates various cellular processes including cell 
cycle regulation, proliferation and differentiation. In a recent study, Btg1 was identified 
as a regulator of normal B-cell development in mice [39]. 
To examine the combined effect of ETV6-RUNX1 with deletion of Btg1 on self-
renewal in vitro, we analyzed the phenotype of wild-type and Btg1-deficient fetal 
liver-derived hematopoietic progenitor cells (FL-HPCs) transduced with either control 
or ETV6-RUNX1 retrovirus. 
 
Materials and Methods 
Mice
Generation of C57BL/6J Btg1 knockout (KO) mice has been previously described by 
Farioli-Vecchiolo et al [40]. The animals were maintained under specific pathogen-
free conditions at our animal facility. All animal experiments were approved by the 
Animal Experimental Committee of the Radboud university medical center and were 
performed in accordance with institutional and national guidelines. For the retroviral 
transduction experiments, fetal liver cells derived from day 13.5 of wild-type and Btg1-
/- embryos were used.
Transduction of fetal liver-derived progenitor cells and bone marrow
The pMSCV-IRES-EGFP (pMIG) and pMSCV-HA-ETV6-RUNX1-IRES-EGFP (pMIG-
ER) retroviral constructs were obtained from O. Williams (UCL, Londen, UK) [29]. The 
pLZRS-IRES-GFP (pLZRS) and pLZRS-IRES-GFP-BCL6 (pLZRS-BCL6) retroviral 
constructs were described by Shvarts et al [41]. Phoenix ecotropic cells were transfected 
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with the following retroviral constructs: pMIG, pMIG-ER, pLZRS and pLZRS-BCL6 
using lipofectamine 2000 (Invitrogen/ Life technologies Europe BV, Bleiswijk, The 
Netherlands). The viral supernatant was harvested 48 hours after transfection, cleared 
from cell debris, and concentrated 10-fold by centrifugation for 1 hour at 16000xg. The 
viral titer was determined by transduction of NIH3T3 cells. 
Primitive fetal liver hematopoietic progenitor cells (FL-HPCs) were purified as 
c-Kit+Ter119- cells from fetal livers of embryonic day 13.5 (E13.5) of C57Bl6/J wild-type 
and Btg1-/- mice by MACS sort using Ter119 and cKit (CD117) beads (Miltenyi Biotec 
BV, Leiden, The Netherlands). FL-HPCs were expanded in Iscoves modified Dulbecco 
medium (IMDM) (Gibco/Life technologies Europe BV, Bleiswijk, The Netherlands) 
supplemented with 10% fetal-bovine serum (FBS) (Greiner Bio-One BV, Alphen a/d 
Rijn, The Netherlands), 1% Penicillin-Streptomycin (Invitrogen) and 55µM 2-ME (Gibco) 
in the presence of 10ng/ml fms-like tyrosine kinase-3 ligand (Flt-3L) (R&D Systems 
Europe, Abingdon, United Kingdom), 20ng/ml Interleukin 7 (IL-7) (R&D) and 100ng/
ml stem cell factor (SCF) (R&D) for 24 hours. Cells were transduced with retrovirus by 
spinoculation for 45 min at 700xg (25°C) in the presence of 5µg/ml polybrene (Sigma-
Aldrich Chemie BV, Zwijndrecht, The Netherlands) and cultured with the same growth 
factors for 48 hours, as has been described by Morrow et al [29]. 
CD19+ bone marrow cells were purified from 10 weeks old wild-type and Btg1-/- mice 
by MACS sorting using CD19 beads (Miltenyi). CD19+ cells were cultured in improved 
minimal essential medium (IMEM) (Gibco) supplemented with 2% FBS (Greiner Bio-
One), 1% Penicillin-Streptomycin (Invitrogen), 0.03% primatone (Sigma-Aldrich) and 
55µM 2-ME (Gibco) in the presence of 20ng/ml IL-7 (R&D) on OP9 stroma for 48 hours. 
Cells were transduced with 10-fold concentrated pMIG and pMIG-ER retrovirus by 
spinoculation (45 min at 700xg, 25°C) in the presence of 10µg/ml protamine sulphate 
(Bio-Connect BV, Huissen, The Netherlands) and cultured in the same pro-B cell 
medium for 24 hours. Transduction efficiency was determined by analyzing EGFP 
expression using flow cytometry.     
B-cell colony-forming assays 
Transduced FL-HPCs (1x104 cells/plate) and CD19+ bone marrow cells (1x105 cells/plate) 
derived of wild-type and Btg1-/- day 13.5 embryos or mice, were cultured in duplicate 
methylcellulose cultures using 35mm plates (M3630, STEMCELL Technologies SARL, 
Grenoble, France), 48 hours after viral transduction. The FL-HPC methylcellulose 
cultures were supplemented with 10ng/ml FLT3L (R&D), 20ng/ml IL-7 (R&D) and 
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100ng/ml SCF (R&D). After 6-10 days, colonies containing more than 30 cells were 
scored, pooled and counted. Replating of 1x104 cells/plate was performed under 
identical conditions.  
Liquid culture assays
Transduced wild-type and Btg1-/- FL-HPCs (1x105 cells/well) were cultured in IMDM 
medium (Gibco) supplemented with 10% FBS (Greiner Bio-One), 1% Penicillin-
Streptomycin (Invitrogen) and 55µM 2-ME (Gibco) in the presence of FLT3L, IL-7 and 
SCF (R&D) in a 24 well TC plate. The cells were split every 3-4 days to a concentration 
of 1x105 cells/well. 
Microarray gene expression analysis
FL-derived HPCs derived from wild-type or Btg1-deficient embryos, which were 
transduced with pMIG or pMIG-ER, were expanded for 12 days in liquid culture. Total 
RNA was extracted from 4x106 cells according to manufacturer’s protocol (Qiagen 
RNAeasy kit) (QIAGEN Benelux BV, Venlo, The Netherlands). Biotinylated cRNA was 
prepared using the Illumina TotalPrep RNA Amplification kit (Ambion, Inc., Austin, TX, 
U.S.A.) according to manufacturer’s specifications with an input of 200ng total RNA. 
Samples were hybridized onto the Illumina MouseRef-8 v2 (Illumina, Inc., San Diego, 
CA, U.S.A.). Image analysis and extraction of raw expression data was performed with 
Illumina GenomeStudio v2011.1 Gene. The Quality control, RNA labeling, hybridization 
and data extraction were performed at ServiceXS B.V (Leiden, The Netherlands). 
Samples were normalized to Robust Multi-array Average (RMA) and analyzed with 
ArrayStar software. KEGG pathway analysis was performed using the online Gene 
set enrichment analysis (GSEA) Molecular Signature Database (MSigDB) tool [42], 
only including genes with an expression cutoff of ≥ 5 and ≥1.6 fold difference. 
Plasmids and transient transfections
The open reading frames (ORFs) BTG1 and PRMT1 were amplified by PCR from first 
strand cDNA using the primers depicted in supplemental table 1. The FLAG-tagged 
BTG1 and PRMT1 ORFs were cloned into pCDNA3.1 using XhoI-EcoRI restriction 
sites for BTG1, and EcoRI restriction site for PRMT1. The HA-tagged EVT6-RUNX1 
was obtained from the pMSCV-HA-ETV6-RUNX1-IRES-EGFP retroviral construct 
[29] using the EcoRI restriction site and cloned into pCDNA3.1. All plasmids were 
verified by sequencing. HEK293 cells were seeded in a 10cm dish at a concentration 
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of 5x106 cells. The cells were transfected with the following expression constructs: 
pCDNA3.1-FLAG-BTG1, pCDNA3.1-PRMT1 and pCDNA3.1-HA-ETV6-RUNX1 using 
polyethylenimine (PEI) (Brunschwig Chemie BV, Amsterdam, The Netherlands). MG132 
proteasome inhibitor (Bio-Connect) was added 24 hours after transfection for another 
16 hours at a final concentration of 5µm.
 
Immunoprecipitation 
Cell extracts from wild-type and Btg1-/- derived FL-HPCs (28x106 cells) were prepared 
after 12 days of liquid culture using RIPA buffer (1x PBS (Lonza/Westburg, Leusden, 
The Netherlands), 1% Igepal CA-630 (Sigma-Aldrich), 0.5% Na-deoxycholaat (VWR 
International BV, Amsterdam, The Netherlands), 0.1% SDS (Sigma-Aldrich)). Cell lysates 
were cleared by centrifugation for 15 minutes at 25000xg (4°C) to remove the insoluble 
membrane fraction and the supernatant was stored at -80°C. For immunoprecipitation 
cell lysates were incubated with either anti-PRMT1 (A33) (Cell Signaling Technology 
Europe BV, Leiden, The Netherlands), anti-FLAG (M2) (Sigma-Aldrich) or anti-HA 
(16B2) (Covance/Sanbio BV, Uden, The Netherlands) antibody overnight, followed 
by addition of protein G (VWR) beads and rotation at 4°C for 2 hours. 
Western blotting
Proteins were separated on 8-12% SDS-PAGE gels and transferred to a polyvinylidene 
difluoride (PVDF) membrane (Millipore BV, Amsterdam, The Netherlands). Blots were 
probed with the following antibodies: anti-FLAG M2 (Sigma-Aldrich), anti-HA (16B2) 
(Covance), anti-β-actin (AC-15) (Santa Cruz Biotechnology, Heidelberg, Germany), 
anti-PRMT1 (A33) (Cell Signaling) and anti-p53 (1C12) (Cell Signaling). 
Transduction of NALM6
The NALM6 cell line was purchased from DSMZ (Braunschweig, Germany). The cells 
were maintained in RPMI 1640 with L-Glutamine (Invitrogen) supplemented with 10% 
fetal bovine serum (FBS) (Greiner Bio-One) and 1% penicillin/streptomycin (Invitrogen).
Non-targeting (NT) and BTG1 shRNAs (supplemental table 2) were cloned into the pEntry 
vector according to manufacturer protocol (Invitrogen). The lentiviral short hairpin vector 
was generated by recombination between the pEntry and pLenti-Block-it-blasticidine 
destination vector. HEK293 cells were seeded in a 10cm dish at a concentration of 
5x106 cells. The cells were transfected with the following lentiviral constructs: pLenti-
Block-it-blasticidine-BTG1-shRNA or pLenti-Block-it-blasticidine-NT-shRNA using 
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Lipofectamine2000 (Invitrogen). The viral supernatant was harvested 48 hours after 
transfection. The cells were transduced with lentivirus using retronectin (Lonza) and 
stable cell lines were generated after 48 hours by adding10 µg/ml blasticidine. 
The pMSCV-puro-HA-ETV6-RUNX1 (pMP-ER) was generated by cloning the HA-ETV6-
RUNX1 from the pMIG-ER construct into the pMP vector using the  EcoRI restriction 
site. HEK293 cells were seeded in a 10cm dish at a concentration of 5x106 cells. The 
cells were transfected with the following lentiviral constructs: pMP or pMP-ER using 
Lipofectamine2000 (Invitrogen). The viral supernatant was harvested 48 hours after 
transfection. The cells were transduced with lentivirus using retronectin (Lonza) and 
stable cell lines were generated after 48 hours by adding 1 µg/ml puromycin.
Quantitative RT- PCR analysis   
For RT-PCR, cDNA was generated with the iScript cDNA synthesis kit (Bio-Rad 
Laboratories BV, Veenendaal, The Netherlands) and analyzed by quantitative real-time 
PCR using SYBR Green method (Bio-Rad). Expression levels were normalized to the 
housekeeping gene TATA box-binding protein (TBP) or Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH). Primers sequences used in RT-PCR experiments are 
depicted in supplemental table 3.  
Statistical Analysis
Statistical data are expressed as mean ± SEM, as indicated in the text. Statistical 
differences were determined with 2-sided, unpaired Student’s t test. P values < 0.05 
(*), <0.01 (**) or <0.001 (***) were considered statistically significant. 
Accession numbers
Illumina bead array expression data is submitted to the NCBI Gene Expression Omnibus 
database (http://www.ncbi.nlm.nih.gov/geo/), accession code: GSE60589 
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Results  
Btg1-deficiency promotes ETV6-RUNX1-mediated self-renewal of fetal progenitor B-cells 
Based on the observation that BTG1 deletions occur more frequently in ETV6-RUNX1-
positive leukemia, we explored whether loss of Btg1 enhances the self-renewal capacity 
of ETV6-RUNX1 in vitro, using fetal liver-derived hematopoietic progenitor cells (FL-
HPCs) isolated from C57Bl/6J wild-type and Btg1-/- embryos at 13.5 days post coitum 
(dpc). After retroviral transduction of cKit+Ter119- FL-HPCs with control pMSCV-IRES-
GFP (pMIG) and pMIG-ETV6-RUNX1 (pMIG-ER) retrovirus, the efficiency of transduction 
was determined by analyzing GFP expression using flow cytometry. The percentage 
GFP positive cells varied between 40-70% (Figure 1A). In addition, expression of 
HA-ETV6-RUNX1 protein in wild-type and Btg1-/- FL-HPCs was confirmed by western 
blot analysis (Figure 1B).  
Wild-type and Btg1-/- FL-HPCs transduced with either control or ETV6-RUNX1 virus 
were cultured in methylcellulose, containing FLT3-ligand, stem cell factor (SCF), and 
IL-7, cytokines that facilitate expansion of B-cell progenitors. Subsequently, these 
cells were analyzed for their ability to maintain self-renewal capacity of progenitor 
cells by serial replating assays and in liquid culture. As previously described, retroviral 
transduction with ETV6-RUNX1 promoted an increase in colony counts from the second 
plating onwards, which were clearly enlarged in size compared to control transduced 
cells [29]. In the absence of Btg1, ETV6-RUNX1 expression resulted in even higher 
colony counts (Figure 1C), however without affecting colony size (data not shown). 
These data demonstrate that loss of Btg1 expression potentiates self-renewal induced 
by ETV6-RUNX1 in fetal colony-forming B cell progenitors.
To determine whether this phenotype was specific for FL-derived progenitors, we also 
examined the effect of ETV6-RUNX1 expression in CD19+ bone marrow cells, derived 
from wild-type and Btg1-/- mice. These CD19+ cells were expanded on OP9 stroma 
and cultured in B-cell specific methylcellulose. Consistent with previous reports [28], 
we observed reduced colony formation in the presence of ETV6-RUNX1, which was 
even stronger in the absence of Btg1 (Figure 1D). This shows that, in sharp contrast 
to FL-derived early progenitors, expression of ETV6-RUNX1 inhibits proliferation of 
both wild-type and Btg1-/- CD19+ bone marrow cells, consistent with the notion that 
ETV6-RUNX1 mediated leukemic transformation occurs mainly in the developing 
embryo rather than in adult bone marrow. 
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Figure 1. Btg1-deficiency enhances the clonogenic replating capacity of early FL-HPCs expressing 
ETV6-RUNX1. (A-C) FL-derived hematopoietic progenitor cells (FL-HPCs) (cKit+Ter119-) were isolated from 
wild-type or Btg1-/- embryos at day 13.5dpc and transduced with control and ETV6-RUNX1 virus. (A) Flow 
cytometric analysis was performed to determine expression of the Green Fluorescent Protein (GFP) after 
retroviral transduction. The percentage of GFP+ FL progenitor cells is indicated. (B) Protein expression of 
HA-tagged ETV6-RUNX1 was determined in transduced wild-type and Btg1-/- FL-HPCs by Western blot 
analysis. Immunoblot demonstrates expression of ETV6-RUNX1 in whole cell extract (WCE) as detected 
with HA Ab. (C) Control and ETV6-RUNX1 transduced FL-HPCs (1x104 cells) were seeded 48 hours after 
transduction in duplicate in B-cell specific methylcellulose in the presence of FLT3L, IL-7 and SCF. Serial 
replating was performed under identical conditions. Mean colony counts (and SEM) were determined (>30 
cells/colony) after 6-10 days of culture. Data set is representative of 2 independent experiments. *, P< 0.05, 
**, P< 0.01. (D) BM mononuclear cells were isolated from wild-type control and Btg1-/- mice and transduced 
after CD19 isolation with control and ETV6-RUNX1 virus. The transduced BM cells (1x105 cells) were added, 
24 hours after expansion on OP9 stroma, in methylcellulose containing 10 ng/ml IL-7. Mean colony counts 
(and SEM) were determined (>30 cells/colony) after 7 days of culture. *, P< 0.05      
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Btg1 loss synergizes with ETV6-RUNX1 by inducing Bcl6 expression
To elucidate the molecular mechanism by which Btg1 deficiency enhances the self-
renewal induced by ETV6-RUNX1 in FL-derived progenitors, we performed gene 
expression analysis on FL-HPCs, cultured for 12 days in our standard cytokine-
containing culture medium. After obtaining the dataset, we first performed Gene Set 
Enrichment Analysis (GSEA) using the Molecular Signature Database (MSigDB) to 
define KEGG pathways that are specifically affected by ETV6-RUNX1 expression in the 
two different genetic backgrounds (Figure 2A and Supplemental table 4). Interestingly, 
we identified a p53 signaling signature in both wild-type and Btg1-/- FL-HPCs expressing 
ETV6-RUNX1, including downregulation of p53 target genes Cdkn2a, Gadd45g and 
CcnD2 expression (Supplemental table 4). This correlated with lower levels of Tp53 in 
Btg1-/- HPCs expressing ETV6-RUNX1, suggesting that an upstream regulator of the 
p53 pathway was affected in these cells. Notably, we observed a 4-fold induction of 
Bcl6 mRNA levels in ETV6-RUNX1-positive Btg1-deficient HPCs compared to control 
cells. Indeed, by qRT-PCR we could validate that Bcl6 mRNA expression was induced, 
and its known target genes p19Arf, Tp53, CcnD2, Bcl2 and c-Myc were repressed 
in Btg1-/- FL-HPCs expressing ETV6-RUNX1 (Figure 2B). As p53 is tightly controlled 
by MDM2 [43] and ETV6-RUNX1 was found to promote MDM2 expression [21], we 
examined Mdm2 mRNA expression in these FL-HPCs, which revealed no significant 
increase (Figure 2B). By western blot analysis we confirmed that p53 protein levels 
were lower in wild-type FL cells expressing ETV6-RUNX1, and these levels were even 
further decreased in ETV6-RUNX1 positive FL cells lacking Btg1 function (Figure 2C). 
These data show that Btg1 loss synergizes with ETV6-RUNX1 by inhibiting the p53 
pathway, resulting in enhanced self-renewal of early lymphoid progenitors.
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Figure 2. Btg1 loss synergizes with ETV6-RUNX1 in regulating differential gene expression. (A-B) 
FL-derived hematopoietic progenitor cells (HPCs) (cKit+Ter119-) were isolated from wild-type and Btg1-/- 
embryos at day 13.5dpc and transduced with control or ETV6-RUNX1 virus. Total RNA was extracted from 
FL-HPCs, which were expanded for 12 days in liquid cultures in the presence of cytokines FLT-3L, IL-7 and 
SCF. (A) mRNA expression was analyzed by microarray using the Illumina BeadArray platform. The data 
were RMA normalized and relative gene expression differences of >1.6-fold were included. KEGG pathway 
analysis was performed using the online Gene Set Enrichment Analysis (GSEA) tool and relevant pathways 
that are differentially expressed between wild-type and ETV6-RUNX1 as well Btg1-/-+ETV6-RUNX1 FL cells 
are indicated. (B) Relative expression levels of Bcl6, Tp53, p19Arf, Mdm2, CcnD1, CcnD2, Bcl2 and c-Myc 
were determined on cDNA generated from transduced wild-type and Btg1-deficient FL progenitor cells 
by real-time PCR and normalized to the expression of the housekeeping gene TATA box binding protein 
(TBP). Data represent the mean and SEM of three independent experiments. *, P< 0.05, **, P< 0.01, ***, P< 
0.001. (C) FL-derived hematopoietic progenitor cells (HPCs) (cKit+Ter119-) were isolated from wild-type and 
Btg1-/- embryos at day 13.5dpc and transduced with control and ETV6-RUNX1 virus. Protein lysates were 
generated from FL-HPCs that were expanded for 12 days in liquid cultures in the presence of cytokines 
FLT-3L, IL-7 and SCF. The immunoblot demonstrates expression of p53 and β-actin as a loading control. 
Quantitation of relative expression levels is indicated. 
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BCL6 promotes self-renewal of early lymphoid progenitors by repressing p19Arf and 
Tp53 expression
Recently, BCL6 was found to be essential for the survival and self-renewal of pre-B 
cells, as well as that of leukemic stem cells, both in chronic myeloid leukemia and 
BCR-ABL1-positive ALL, a mechanism involving repression of Arf and Tp53 [44, 45]. 
In contrast, exogenous BCL6 expression in adult precursor B-cells leads to cell cycle 
exit and no additional survival [44, 45]. To further investigate whether BCL6 expression 
alone was sufficient to produce the phenotype observed in ETV6-RUNX1-positive Btg1-
/- FL-HPCs, we transduced wild-type FL-derived progenitor cells with either control or a 
BCL6-expressing retrovirus (Figure 3A). The transduction efficiency of these cells was 
determined by FACS using the GFP marker, which showed 53% GFP+ cells in control, 
while transduction with BCL6 virus resulted in 30% GFP+ cells. Transduced FL-HPCs 
were cultured in B-cell specific methylcellulose in the presence of our standard cocktail 
of cytokines. Indeed, expression of BCL6 similarly promoted the clonogenic replating 
capacity of FL-derived progenitor cells (Figure 3B). These results strongly suggest 
that the combination of ETV6-RUNX1 and deletion of Btg1 promotes self-renewal of 
FL progenitor cells by enhancing expression of BCL6. 
To examine how BCL6 promotes proliferation of FL-lymphoid progenitors, we analyzed 
expression of known target genes involved in cell cycle regulation and apoptosis. 
To this end, wild-type expanded FL-progenitor cells in the absence or presence of 
BCL6 retrovirus were grown for 10 days in the standard liquid culture medium and 
subjected to expression analyses using qPCR. This targeted expression analysis 
showed a significant reduction in p19Arf, Tp53 and Bcl-2 expression, which mirrors 
the phenotype observed in FL cells expressing ETV6-RUNX1 in the absence of Btg1 
(Figure 3C). By western blot analysis we further confirmed that p53 protein levels were 
decreased in wild-type FL cells expressing the BCL6 retrovirus (Figure 3D). These 
data show that BCL6 promotes proliferation of primitive B-lymphoid progenitors by 
suppressing the p53 pathway. 
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Figure 3
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Figure 3. BCL6 stimulates self-renewal of early B-cell progenitors. (A-D) FL-derived hematopoietic 
progenitor cells (HPCs) (cKit+Ter119-) were isolated from wild-type embryos at day 13.5dpc and transduced 
with control or BCL6 virus. (A) Flow cytometric analysis was performed to determine expression of the 
GFP after retroviral transduction. The percentage GFP+ FL progenitor cells is indicated. (B) Control and 
ETV6-RUNX1 transduced FL-HPCs (1x104 cells) were added 48 hours after transduction in B cell specific 
methylcellulose in the presence of FLT-3L, IL-7 and SCF. Serial replating was performed under identical 
conditions. Mean colony counts (and SEM) were determined (>30 cells/colony) after 6-10 days of culture. 
Data set is representative of 2 independent experiments. **, P< 0.01. (C) RNA was isolated from FL-HPCs 
that were expanded for 10 days in liquid cultures in the presence of cytokines FLT-3L, IL-7 and SCF. Relative 
expression levels of Tp53, p19Arf, Mdm2, CcnD1, CcnD2, Bcl2 and c-Myc were determined on cDNA 
generated from transduced wild-type FL progenitor cells by real-time PCR and normalized to TBP. Data 
represent the mean and SEM of three independent experiments. *, P< 0.05, **, P< 0.01, ***, P< 0.001. (D) 
FL-derived hematopoietic progenitor cells (HPCs) (cKit+Ter119-) were isolated from wild-type embryos at 
day 13.5dpc and transduced with control and BCL6 virus. Protein lysates were generated from FL-HPCs 
that were expanded for 13 days in liquid cultures in the presence of cytokines FLT-3L, IL-7 and SCF. The 
immunoblot shows expression of p53 and the loading control β-actin. Quantitation of relative expression 
levels is indicated. 
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Figure 4. Loss of BTG1 promotes BCL6 expression in ETV6-RUNX1-positive NALM6 cells. NALM6 
non-targeting (NT-shRNA) and BTG1 knockdown cells were transduced with pMP and pMP-ER retrovirus 
and total RNA was extracted (A) or protein lysates were generated (B). (A) Relative expression levels of 
BTG1 and BCL6 were determined on cDNA generated from NALM6 non-targeting, NALM6 BTG1 kd, NALM6 
ETV6-RUNX1 and NALM6 BTG1 kd+ETV6-RUNX1 by real-time PCR and normalized to GAPDH. Data 
represent the mean and SEM of three independent experiments. *, P< 0.05, **, P< 0.01, ***, P< 0.001. (B) 
The immunoblot demonstrates expression of HA-ETV6-RUNX1 in WCE using an anti HA-Ab. 
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Silencing of BTG1 promotes ETV6-RUNX1-dependent induction of BCL6 expression 
in human BCP-ALL
As we found that BCL6 mRNA upregulated in ETV6-RUNX1-positive Btg1-/- FL-HPCs, 
we further explored whether this phenotype can also be observed in human BCP-ALL 
cells. Therefore, we transduced NALM6 cells with a non-targeting shRNA or BTG1-
shRNA and in a second round we subsequently transduced these cells with either an 
ETV6-RUNX1 containing retrovirus or a vector control. We determined the extent BTG1 
knockdown by qRT-PCR, which revealed a 50% reduction in BTG1 expression in both 
the BTG1-shRNA and ETV6-RUNX1-postive BTG1-shRNA NALM6 cells (Figure 4A). 
In addition, expression of the ETV6-RUNX1 protein was confirmed by western blot 
analysis (Figure 4B). Expression analysis showed a significant upregulation of BCL6 
in ETV6-RUNX1-positive NALM6 cells which further increased upon loss of BTG1, 
similar to our observations in Btg1-deficient FL cells expressing ETV6-RUNX1 (Figure 
4A). Overall, these data demonstrate that BTG1 loss synergizes with ETV6-RUNX1 
in upregulating the expression of the proto-oncogene BCL6. 
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Btg1 is required for interaction between PRMT1 and ETV6-RUNX1 in FL-derived cells
As our data revealed a synergy between ETV6-RUNX1 and loss of Btg1 in the regulation 
of gene expression, we explored whether ETV6-RUNX1 may physically interact with the 
transcriptional coregulator Btg1, and the protein arginine N-methyltransferase PRMT1. 
Previous studies have demonstrated that RUNX1 activity is subject to regulation by 
arginine methylation, catalyzed by arginine methyltransferases PRMT1, PRMT4 and 
PRMT6 [37, 46, 47]. Moreover there is accumulating evidence that Btg1 acts by recruiting 
and stimulating the enzymatic activity of PRMT1 [36, 37, 48]. More recently, PRMT1 
was shown to interact both physically and functionally with the oncogenic AML1-ETO 
fusion protein [49]. Therefore, we combined transient expression of recombinant FLAG-
BTG1 and HA-ETV6-RUNX1 in HEK293 cells. Co-immunoprecipitation from lysates 
of transiently transfected HEK293 cells, revealed an interaction between FLAG-BTG1 
and HA-ETV6-RUNX1 (Figure 5A).  Figure 5
+
+-
-
-
+
+
WCE
IP: HA
IB: HA
IB: HA
IB: PRMT1
IB: PRMT1
HEK293 cells
-
PRMT1
HA-ETV6-RUNX1
+- +
WCE
IP: PRMT1
IB: PRMT1
IB: HA
IB: PRMT1
IB: HA
FL-HPCs
-HA-ETV6-RUNX1
+
+-
-
-
-+
+FLAG-BTG1
HA-ETV6-RUNX1
WCE
IP: FLAG
IB: HA
IB: HA
IB: FLAG
IB: FLAG
HEK293 cellsA B
C
WT Btg1-/-
Figure 5. ETV6-RUNX1 interacts with PRMT1 and 
its cofactor Btg1. (A) HEK293 cells were transfected 
with expression plasmids encoding HA-ETV6-RUNX1 
and FLAG-Btg1 and treated for 16 hours with 5µM of 
the proteasome inhibitor MG132. Protein lysates were 
generated and subjected to immunoprecipitation (IP) 
by incubation with FLAG antibody (Ab). Immunoblot 
demonstrates the expression of Btg1 using a FLAG-
Ab and ETV6-RUNX1 with a HA-Ab in whole cell 
extracts (WCE) and IP samples. (B) HEK293 cells 
were transfected with expression plasmids encoding 
HA-ETV6-RUNX1 and PRMT1 and treated for 16 
hours with 5µM of the proteasome inhibitor MG132. 
Protein lysates were subjected to IP using HA-Ab. 
The immunblot shows expression of PRMT1 using a PRMT1-Ab and ETV6-RUNX1 with a HA-Ab in WCE 
and IP. (C) FL-HPCs (cKit+Ter119-) were isolated from wild-type and Btg1-/- embryos at day 13.5dpc and 
transduced with control and ETV6-RUNX1 virus. Protein lysates were generated from FL-HPCs that were 
expanded for 12 days in liquid cultures in the presence of cytokines FLT-3L, IL-7 and SCF and subjected 
to IP using PRMT1 Ab. The immunoblot shows expression of PRMT1 using a PRMT1-Ab and HA-ETV6-
RUNX1 using an HA-Ab in WCE and IP from wild-type FL cells. 
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Furthermore, we observed that, similar to BTG1, PRMT1 associated with ETV6-RUNX1 
(Figure 5B), strongly suggesting that the ETV6-RUNX1 fusion protein may be subject 
to regulation by PRMT1. To examine whether the interaction between ETV6-RUNX1 
and PRMT1 requires the presence of endogenous Btg1, we compared wild-type and 
Btg1-deficient FL-HPCs that were transduced with either control or ETV6-RUNX1 virus. 
Indeed, by co-immunoprecipitation of endogenous PRMT1 from wild-type FL cells, we 
were able to confirm that PRMT1 is associated with the ETV6-RUNX1 fusion protein. 
At the same time however, this association was lost in Btg1-deficient FL-HPCs. We 
conclude from these results that ETV6-RUNX1 fusion protein associates with PRMT1, 
which requires the presence of Btg1 (Figure 5C). 
Discussion 
ETV6-RUNX1-positive leukemia represents the largest cytogenetic subgroup in 
pediatric BCP-ALL, comprising 25% of all cases [1, 3, 4]. While associated with a 
favorable prognosis, 10-15% of these patients still relapse. Previous reports have 
shown that the ETV6-RUNX1 fusion protein is insufficient to induce a full leukemia 
phenotype and that additional cooperating events are required for overt ALL to develop 
[10, 11, 13]. Deletions affecting the transcriptional coregulator BTG1 are a frequent 
event in this ALL subgroup [13], however, a role for BTG1 as a tumor suppressor in 
ETV6-RUNX1-mediated leukemic transformation has not yet been investigated. In 
this study, we demonstrate an association between ETV6-RUNX1, BTG1 and PRMT1, 
both physically and functionally, suggesting an important role for these proteins as 
transcriptional cofactors of ETV6-RUNX1. First, we find that loss of Btg1 enhances 
the clonogenic replating capacity of ETV6-RUNX1 in FL-derived progenitors, arguing 
that it may contribute to ETV6-RUNX1-mediated self-renewal. By gene expression 
analysis of FL-derived HPCs, we further demonstrate that loss of Btg1, combined 
with expression of ETV6-RUNX1, affects mRNA expression of the proto-oncogene 
BCL6 and its known target genes, such as p19Arf, Tp53, CcnD1, CcnD2, c-Myc and 
Bcl2. Similarly, expression of BCL6 promotes self-renewal of FL-derived HPCs and 
negatively affects the expression of p19Arf and Tp53 (Figure 6). We conclude from 
these experiments that BCL6 plays an important role in the maintenance of these 
primitive hematopoietic cells and may be an important and targetable determinant 
of leukemic stem cell survival. Similar to what we observed in mouse FL cells, loss 
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of BTG1 combined with ETV6-RUNX1 expression in the human pre-B ALL cell line 
NALM6  leads to an increase in BCL6 expression. 
RUNX1 activity is regulated by arginine methylation, catalyzed by arginine methyl 
transferases PRMT1, PRMT4 and PRMT6 [37, 46, 47]. PRMT1 is subject to regulation 
by cofactors, such as the tumor suppressor BTG1, which positively modulates the 
activity of PRMT1 [35, 36]. More recently, PRMT1 was shown to interact both physically 
and functionally with the oncogenic AML1-ETO fusion protein [49]. Our data show that 
PRMT1 is also recruited to an ETV6-RUNX1 transcriptional complex, and that this 
interaction is lost in Btg1-deficient FL cells. However, the exact functional consequence 
of this interaction and whether this involves changes in PRMT1-mediated arginine 
methylation of ETV6-RUNX1 remains to be established.
Consistent with earlier studies, our data show that ETV6-RUNX1 expression 
stimulates self-renewal of FL-derived HPCs [29]. In addition, we find that loss of 
Btg1 promotes ETV6-RUNX1-induced self-renewal in FL-HPCs, while expression of 
ETV6-RUNX1 inhibits proliferation of both wild-type and Btg1-/- CD19+ bone marrow 
cells. The increased proliferative capacity of ETV6-RUNX1 leukemia cells most likely 
involves enhanced survival signaling due to deregulation of transcriptional networks 
and signaling pathways. Previous studies have demonstrated that ETV6-RUNX1 
expression deregulates various pathways, including JAK-STAT signaling, TGF-β and 
BCL6 P19Arf
MDM2
P53
Enhanced self-renewal
Figure 6
PRMT1
ETV6-RUNX1
BTG1
B cell progenitor expansion
BTG1
PRMT1
ETV6-RUNX1
BCL6 P19Arf
MDM2
P53
Figure 6. Hypothetical model of enhanced self-renewal by ETV6-RUNX1 in absence of Btg1.  Expression 
of ETV6-RUNX1 in wild-type FL-derived HPCs results in repression of p19Arf and consequently Tp53, 
resulting in expansion of progenitor B-cells. In absence of BTG1 the binding between PRMT1 and ETV6-
RUNX1 is disrupted, which results in de-repression of the proto-oncogene BCL6. Both BCL6 and ETV6-
RUNX1 repress the expression of p19Arf and Tp53, giving rise to enhanced self-renewal.
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PI3K pathways as well as p53 function, but the exact contribution of these pathways 
to leukemic transformation has not been established [19-23]. 
Our most intriguing observation relates to the finding that Btg1 loss combined with 
ETV6-RUNX1 induces expression of the proto-oncogene BCL6. By Gene Set Enrichment 
Analysis we identified a p53 signature in FL-HPCs expressing the ETV6-RUNX1 
protein as wells as in the Btg1-deficient FL progenitor cells. Our targeted expression 
analysis confirms that several genes involved in the p53 pathway, including p19Arf, 
Tp53 and CcnD2, are downregulated in FL-HPCs expressing ETV6-RUNX1, an effect 
that is further enhanced when ETV6-RUNX1 expression is combined with deletion of 
Btg1. Specifically, these genes are normally repressed by BCL6 during germinal B-cell 
maturation and downstream of pre-B cell receptor (pre-BCR) signaling. BCL6 is one 
of the most frequently affected oncogenes in diffuse large B-cell lymphomas, whereas 
BCL6 is also identified as a critical determinant of leukemic stem cell survival in chronic 
myeloid leukemia (CML) and BCR-ABL1-positive ALL, via a mechanism involving 
repression of ARF and TP53 [44, 45]. Deletion of the CDKN2A locus is frequently 
observed in BCP-ALL subtypes, including ETV6-RUNX1-positive ALL [9, 10, 13, 41].
This locus encodes two closely linked tumor suppressors p16INK4A and p14ARF, 
the human homolog of mouse p19Arf. Previous reports have shown that RUNX1 in 
mouse cells promotes p19Arf expression, whereas AML1-ETO, an important driver 
of acute myeloid leukemia, represses transcription of p14ARF [50]. Our own data 
indicate that the fusion protein ETV6-RUNX1 represses p19Arf expression, an effect 
that is further enhanced by deletion of Btg1. As both BCL6 and p19Arf are involved 
in cell cycle regulation and apoptosis, deregulation of these genes may result in 
proliferation stimulatory effects. Consistent with this notion, we show that expression of 
BCL6 enhances the clonogenic replating efficiency of FL cells, which involves reduced 
expression of the tumor suppressors Tp53 and p19Arf. In contrast, in adult precursor 
B-cells, expression of BCL6 was shown to induce cell cycle exit [44], suggesting that 
BCL6, like ETV6-RUNX1, has a unique role in primitive B-cell progenitors that differs 
from the effects on progenitors B-cells within the bone marrow compartment. Whether 
these differences relate to the B-1 cell population that is more dominant at the fetal 
liver stage, remains to be assessed. The implications of our findings could be that, 
besides Ph+ ALL, inhibition of BCL6 could be effective in the eradication of leukemia-
initiating cells in other BCP-ALL subtypes.     
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Supplementary data 
 
Supplemental Tables 
Name Forward (5’ 3’) Reverse (5’ 3’)
BTG1
CGCCTCGAGACCATGGACTACAAAGAC 
GATGACGATAAACATCCCTTCTACACCC 
GGG
CGCGAATTCTAACCTGATACAGTCATCA 
TATTG
PRMT1 CGCCTCGAGACCATGGCGGCAGCCGA GGCCGC
CGCGAATTCTCAGCGCATCCGGTAGTC 
GGTGG
Table S1. cDNA primers
Name Top (5’ 3’) Bottom (5’ 3’)
BTG1 shRNA CACCGCTGCTGGCAGAACATTATAA CGAATTATAATGTTCTGCCAGCAGC
AAAAGCTGCTGGCAGAACATTATAAT 
TCGTTATAATGTTCTGCCAGCAGC
Non-targetting 
shRNA
CACCGCTACAAGAGAAACCAAATCT 
CGAAAGATTTGGTTTCTCTTGTAGC
AAAAGCTACAAGAGAAACCAAATCT 
TTCGAGATTTGGTTTCTCTTGTAGC
Table S2. shRNA primers 
Name Forward (5’ 3’) Reverse (5’ 3’)
Bcl6 TGAGCAGTTTAGAGCCCATAAG GTACATGAAGTCCAGGAGGATG 
p19Arf CGTGAACATGTTGTTGAGGCTAGA CGCAGTTCAAATCTGCACCGTAGT
Tp53 ACCTGGGCTTCCTGCAGTCTGGGA GTGGCGCTGACCCACAACTGCACA
Mdm2 TTGACGATGGCGTAAGTGAG TGATAGACTGTGACCCGATAGA
CcnD1 CAGAGGCGGATGAGAACAAG GAGGGTGGGTTGGAAATGAA 
Ccnd2 CTCCCGCAGTGTTCCTATTT TCACAGACCTCTAGCATCCA 
Bcl2 ATCTTCTCCTTCCAGCCTGA TCAGTCATCCACAGGGCGAT
c-Myc ACAGTGTTCTCTGCCTCTGCCCGC GTAGTCGAGGTCATAGTTCCTGTT
TBP GCACAGGAGCCAAGAGTGAA ACATCACAGCTCCCCACCAT
GAPDH CTCCTCCACCTTTGACGCTG TCCACCACCCTGTTGCTGTA
BCL6 ACAGTGACAAACCCTACAAGTGTG CTTCTCTCCAGAGTGAATTCGAGT
BTG1 AGCGGATTGGACTGAGCAG GGTGCTGTTTTGAGTGCTACC
 
Table S3. Primers for quantitative real-time PCR
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Abstract  
Deletions and mutations affecting lymphoid transcription factor IKZF1 (IKAROS) are 
associated with an increased relapse risk and poor outcome in B-cell precursor acute 
lymphoblastic leukemia (BCP-ALL). However, additional genetic events may either 
enhance or negate the effects of IKZF1 deletions on prognosis. In a large cohort of 
childhood BCP-ALL patients (N=533), we observed that single copy losses of BTG1 
were significantly enriched in IKZF1-deleted BCP-ALL. While BTG1 deletions alone 
had no impact on prognosis, the combined presence of BTG1 and IKZF1 deletions 
was associated with a significantly lower 5-year event-free survival (EFS; Cox P-value: 
0.0003) and higher 5-year cumulative incidence of relapse (CIR: Gray P-value: 0.005) 
as compared with IKZF1-deleted cases without BTG1 aberrations. In contrast, other 
copy number losses commonly observed in BCP-ALL, such as CDKN2A/B, PAX5, 
EBF1 or RB1, did not affect outcome of IKZF1-deleted ALL. To establish whether the 
combined loss of IKZF1 and BTG1 function contributes to leukemogenesis, we used 
Btg1-deficient mice crossed onto an Ikzf1 heterozygous background. We observed 
that loss of Btg1 increased the tumor incidence of Ikzf1+/- mice in a dose-dependent 
manner. Together, our results identify BTG1 as a haploinsufficient tumor suppressor 
in leukemia that, when deleted, enhances relapse risk in IKZF1-deleted BCP-ALL. 
More importantly, this study identifies IKZF1;BTG1-double deleted patients as a new 
high-risk group in pediatric BCP-ALL. 
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Introduction  
Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children 
and is characterized by recurrent genetic aberrations and chromosomal abnormalities, 
which represent distinct genetic subtypes that are used for risk stratification [1]. In the 
past, we and others have demonstrated that genomic alterations affecting the lymphoid 
transcription factor gene IKZF1 represent a strong prognostic factor associated with 
relapse in childhood B-cell precursor ALL (BCP-ALL) [2-5]. Deletion of IKZF1 is a 
hallmark of BCR-ABL1-positive BCP-ALL [6], and within this high-risk cytogenetic 
subtype, IKZF1 loss is associated with an even worse outcome [7]. IKZF1 gene lesions 
are also frequently present in high-risk leukemias of patients with a Philadelphia- or BCR-
ABL1-like expression signature [2, 5, 8], which often carry activated tyrosine kinases 
(i.e. ABL1, PDGFRB, JAK2, FLT3) or mutations targeting the RAS pathway [9-11]. 
Mouse studies have confirmed that two of these genomic alterations, namely BCR-
ABL1 and mutant RAS, cooperate with loss of IKZF1 during leukemic transformation 
[12, 13]. On the other hand, ERG gene deletions constitute a specific subtype of BCP-
ALL with favorable outcome, despite the frequent co-occurrence of IKZF1 deletions 
[14, 15]. Thus, specific genetic interactions may modulate the tumor suppressive 
functions of IKZF1 during leukemia development at initial diagnosis and at relapse 
after chemotherapy treatment. 
Besides IKZF1, many other recurrent genetic aberrations have been observed in 
BCP-ALL, which include deletions affecting BTG1, CDKN2A/B, EBF1, ETV6, PAX5, 
RAG1, RB1 and TCF3 [16-18]. For some of these co-occurring genetic lesions synergistic 
effects have been reported on leukemia development. For example, loss of Rag1 was 
shown to accelerate the onset of B-cell lymphoblastic leukemia in Cdkn2a/p19Arf-
deficient mice [19], while increasing the incidence of T-cell lymphomas in Tcf3-/- mice 
[20]. Furthermore, combined heterozygosity for Ebf1 and Pax5 results in a strong 
increase in the frequency of pro-B cell leukemia in mice [21].  
Here we describe the impact of deletions affecting the transcriptional coregulator 
B-cell translocation gene 1 (BTG1), in co-occurence with IKZF1 loss. We demonstrate 
that BTG1 deletions are enriched in IKZF1-deleted pediatric ALL, and correlate with 
increased relapse risk in this patient group. Using mouse knockout models, we further 
demonstrate that loss of Btg1 cooperates with Ikzf1+/- in the onset of ALL. 
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Materials and Methods  
Clinical samples
This study comprised 533 patients with newly diagnosed BCP-ALL from three consecutive 
Dutch Childhood Oncology Group trials (DCOG ALL-8, ALL-9 and ALL-10) and two 
German Cooperative ALL trials (COALL 06-97 and 07-03). In accordance with the 
Declaration of Helsinki, written informed consent was obtained from parents or guardians, 
and institutional review boards approved the use of excess diagnostic material for 
research purposes. Details on this patient cohort, treatment regimens and outcomes, 
were described previously [5]. Cases were screened for high hyperdiploidy (51-65 
chromosomes), ETV6-RUNX1 and BCR-ABL1 fusion products and rearrangements of 
TCF3 and MLL by routine diagnostic procedures. Cases were identified as BCR-ABL1-
like, based on a previously described expression signature of 110 probe sets [5, 8]. 
Molecular analysis of patient samples
The multiplex ligation-dependent probe amplification assay SALSA MLPA P335 ALL-
IKZF1 (MRC-Holland, Amsterdam, the Netherlands) was performed according to 
the manufacturer’s protocol and analyzed as previously described [5]. A ratio lower 
than 0.75 for the exon intensity in patients versus the healthy control reference was 
considered to represent a deletion. For scoring CDKN2A/B deletion, it was sufficient 
to have either CDKN2A or CDKN2B deleted. 
Statistics patient data 
Cumulative incidence of relapse (CIR) probabilities were estimated using a competing 
risks model, equality of CIRs was tested with Gray’s test. Relapse and non-response 
to induction chemotherapy were considered as events, with death as competing 
event. Event-free survival (EFS) was calculated with non-response, relapse and death 
considered as events. EFS probabilities were estimated using the actuarial Kaplan-
Meier method and survival data between groups were compared using univariate and 
multivariate Cox regression. The proportions of patients with IKZF1 and other B-cell 
development gene deletions as well as other categorical variables were compared using 
the Fisher exact test. All P-values are two-sided, and a significance level of 0.05 was 
used. Analyses were performed in R 3.0.1 (2013-05-16), using the packages cmprsk 
[22] version 2.2-7, mstate [22] version 0.2.7 [23], and survival [24] version 2.37-4.
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Mice
Btg1 and Ikzf1Neo constitutive knockout lines have been described previously [25, 26], 
and were intercrossed to obtain Btg1+/-;Ikzf1+/- and Btg1-/-;Ikzf1+/- mice on a C57Bl/6J 
background. Mice were maintained under specific pathogen-free conditions at our 
Central Animal Laboratory facility. Genotyping of the mice was performed by PCR 
on genomic DNA obtained from ear clips (primers are listed in supplemental Table 
1). Animal experiments were approved by the Animal Experimental Committee of the 
Radboud university medical center and were performed in accordance with institutional 
and national guidelines. 
Immunohistochemistry
Tissues isolated from diseased mice were fixed in 4% formalin for 24 hours. Specimens 
were embedded in paraffin, 4 µM serial sections were prepared and stained with 
hematoxylin and eosin (HE). For immunohistochemistry, slides were dewaxed and 
rehydrated prior to heat-induced antigen retrieval using sodium citrate buffer. After 
blocking with 2% goat serum and 2% BSA in 0.05% Tween-PBS, the slides were 
incubated overnight with B220/CD45R (RM2600) (Invitrogen, Amsterdam, The 
Netherlands) and CD3 (A0452) (DAKO Netherlands BV, Heverlee, Belgium) antibodies. 
Biotinylated  anti-rat IgG (BA9401) (Vector Laboratories, Peterborough, United Kingdom) 
and anti-rabbit IgG (BA1000) (Vector Laboratories) were used as secondary antibody 
and subsequently the slides were incubated with metal-enhanced diaminobenzidine 
in stable peroxide substrate buffer (Thermo Fisher Scientific Inc., Amsterdam, The 
Netherlands), counterstained with hematoxylin, and after dehydration coverslipped 
with Entellan.
VDJ rearrangement analysis
DNA was extracted from spleen or lymph nodes infiltrated with leukemic cells as 
well as control ear clips, which served as control for germline T-cell receptor (TR)/
immunoglobulin (Ig) gene using the Gentra Puregene Mouse Tail kit (Qiagen, Venlo, 
The Netherlands). PCR analysis was performed with primers specific for the DB1-JB 
region of Trb1, Dβ2.1-Jβ2.7 region of Trb2, and 5’VH2-3’Cµ and 5’VH2-3’Ck primers 
for the Igh and Igk genes, respectively (see supplemental Table 1).
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Flow cytometric analysis
Enlarged lymph nodes were dissected from the diseased mice and frozen as viable 
cell suspension. Cells were thawed and leukemic blasts of diseased wild-type, Ikzf1+/-, 
Btg1-/-, Btg1+/-;Ikzf1+/-and Btg1-/-;Ikzf1+/- mice were analyzed by FACS  to determine the 
cell lineage and differentiation stage using the LSRII flow cytometer (BD Biosciences, 
Breda, The Netherlands). Single cell suspensions were pre-incubated with unlabeled 
anti–Fcγ III/II receptor (2.4G2) (BD Biosciences) to inhibit unspecific antibody binding. 
Cells were stained with the following antibodies purchased from BD Biosciences and 
eBiosciences (Vienna, Austria): anti-B220/CD45R (RA3-6B2); CD4 (RM4-5); CD8 
(53-6.7); CD11b/Mac1 (M1/70); CD25 (PC61.5); CD44 (IM7). The data were collected 
and analyzed by FlowJo software. 
Kaplan Meier survival curves leukemic mice
The pathology cohort included wild-type (n=49), Ikzf1+/- (n=36), Btg1+/- (n=34), Btg1-/- 
(n=33), Btg1+/-;Ikzf1+/- (n=35) and Btg1-/-;Ikzf1+/- (n=30) mice, which were monitored for 
18 months or euthanized upon disease symptoms. Mice were scored for macroscopic 
visible abnormalities, including enlarged lymph nodes and spleen. Mice with a spleen 
weight of ≥1.0 percent of their body weight were suspected of leukemia/lymphoma 
and analyzed by immunohistochemistry and microscopy. Kaplan Meier (KM) survival 
curves were generated by SPSS software and the survival between groups were 
compared using the Log rank (Mantal-Cox) test. All mice that showed overt T-cell 
leukemia/lymphoma before and at the age of 18 months were defined as an event 
and included in Table 4, while mice in the KM survival curves were included in case 
the animals developed lymphoid malignancies before the age of 17 months .  
 
Results  
BTG1 deletions are enriched in IKZF1-deleted pediatric BCP-ALL
Heterozygous deletion of the tumor suppressor IKZF1 is an important predictor of 
poor outcome in BCP-ALL [2, 3, 5], but to what extent other additional common single 
gene deletions, such as CDKN2A/B, PAX5, BTG1, ETV6, EBF1 or RB1 impact the 
prognostic value of IKZF1 has not been clearly established. To address this question, 
we studied a previously described childhood BCP-ALL cohort of 533 cases enrolled in 
consecutive DCOG and COALL trials [5]. The representation of the different BCP-ALL 
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subtypes was similar between the DCOG and COALL cohorts, and comparable to 
that described in literature (supplemental Table 2). We identified 105 BCP-ALL patient 
samples containing an IKZF1 deletion. Within the IKZF1-deleted group, we observed 
a significant enrichment for BTG1 deletions (Fisher P-value: 0.007), where 17 of the 
105 IKZF1-deleted cases (16%) harbored BTG1 deletions as compared to 31 of the 
397 IKZF1-wild type cases (7%) (Table 1). 
IKZF1 no deletion IKZF1 deletion Fisher Test
n % n % P-value Odds ratio
BTG1 no deletion 397 0.93 88 0.84
0.0071 2.5
BTG1 deletion 31 0.07 17 0.16
PAX5 no deletion 330 0.77 55 0.52
1.40E-06 3.1
PAX5 deletion 98 0.23 50 0.48
CDKN2A/B no deletion 298 0.70 53 0.50
3.40E-04 2.2
CDKN2A/B deletion 130 0.30 52 0.50
EBF1 no deletion 405 0.95 96 0.91
0.25 1.6
EBF1 deletion 23 0.05 9 0.09
RB1 no deletion 400 0.93 91 0.87
0.026 2.2
RB1 deletion 28 0.07 14 0.13
Table 1. Co-occurrence of IKZF1 deletion with other common gene deletions in BCP-ALL
Similarly, deletions affecting PAX5 (Fisher P-value <0.0001), CDKN2A/B (Fisher P-value: 
0.0003) and RB1 (Fisher P-value: 0.026) were present at higher frequencies in IKZF1-
deleted cases, while this was not observed for EBF1 or ETV6 deletions (Table 1). 
Previously, it was shown that both IKZF1 and BTG1 deletions are strongly enriched in 
the cytogenetic BCR-ABL1 subtype [6, 27]. Consistent with this notion, we observed 
that of 24 BCR-ABL1-positive cases 7 (29%) harbored deletions in both IKZF1 and 
BTG1 (Table 2), which represents 47% of IKZF1-deleted and 100% of the BTG1-
deleted cases found in the BCR-ABL1-positive group (Table 2). 
Chapter 6
172
Combined loss of BTG1 and IKZF1 predicts inferior outcome in BCP-ALL
We next compared clinical characteristics of IKZF1;BTG1 double-deleted cases, IKZF1 
and BTG1 only-deleted cases, and cases without IKZF1 or BTG1 deletion in our 
complete childhood BCP-ALL cohort. The characteristics of these four groups were 
similar to the total cohort with respect to gender and treatment protocol (Table 2). The 
double-deleted and IKZF1 only-deleted groups contained more patients older than 
10 years of age and increased white blood cell counts, and hence more NCI-Rome 
Patients’ 
characteristics
IKZF1 del; 
BTG1 del
IKZF1 del; 
BTG1 no del
BTG1 del; 
IKZF1 no del
IKZF1 no del; 
BTG1 no del Total
Fisher 
P-value
n=17 (3%) n=88 (20%) n=31 (6%) n=397 (74%) n=533 (100%)
n % n % n % n % n %
Gender
0.3
 
 
Female
Male
5
11
29%
71%
44
44
50%
50%
11
20
35%
65%
183
214
46%
54%
243
290
46%
54%
Age (years)
0.0054
 
 
< 10
≥ 10
11
6
65%
35%
60
28
68%
32%
26
5
84%
16%
330
67
83%
17%
427
106
80%
20%
WBC (cells/nl)
0.066
 
 
< 50
≥ 50
11
6
65%
35%
55
33
62.5%
37.5%
23
8
74%
26%
299
96
76%
24%
388
143
73%
27%
NCI-Rome
0.016
 
 
SR
HR
8
9
47%
53%
39
49
44%
56%
19
12
61%
39%
245
151
62%
38%
311
221
58%
42%
Protocol
0.54
 
 
DCOG
COALL
14
3
82%
18%
63
25
72%
28%
25
6
81%
19%
311
86
78%
22%
413
120
77%
23%
Subtype
 
 
 
 
 
 
 
ETV6-RUNX1
HeH
B-other
BCR-ABL1-like 
TCF3r
BCR-ABL1
MLLr
2
1
4
3
0
7
0
12%
6%
24%
18%
0%
41%
0%
2
16
23
38
0
8
1
2%
18%
26%
43%
0%
9%
1%
24
2
5
0
0
0
0
77%
7%
16%
0%
0%
0%
0%
126
107
75
51
19
9
10
32%
27%
19%
13%
5%
2%
3%
154
126
107
92
19
24
11
29%
24%
20%
17%
4%
5%
2%
<0.0001
0.0055
0.41
<0.0001
0.093
<0.0001
0.89
 
Table 2. Pediatric BCP-ALL patient characteristics in the IKZF1- and BTG1-single and –double 
deleted groups. del, deletion; WBC, white blood cell count; NCI-Rome HR, high risk defined by age at 
diagnosis ≥ 10 years and/or WBC ≥ 50 cells/nl; HeH, high hyperdiploid (51-65 chromosomes); P-value, 
Fisher exact test across the four deletions groups; WBC for 2 cases missing, NCI Risk for 1 case missing, 
both in IKZF1 no del; BTG1 no del group.
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high-risk cases (Table 2). We compared the event-free survival (EFS) and cumulative 
incidence of relapse (CIR) between cases with both IKZF1 and BTG1 deletions (n=17) 
with IKZF1-only deleted cases (n=89) (Figure 1A-B). The 5-year CIR in IKZF1 plus 
BTG1-deleted cases was 53% ± 13% compared with 28% ± 5% in IKZF1 only-deleted 
cases (Gray P-value: 0.005; Table 3A). Similarly, the 5-year EFS was lower in double-
deleted cases compared with IKZF1 only-deleted cases (HR 3.5, Cox P-value: 0.0003; 
Table 3A). In contrast, the BTG1 only-deleted cases (n=31) showed a similar outcome 
(5-year CIR: 10% ± 6%) as the reference cases without IKZF1 or BTG1 deletions 
(n=397; 5-year CIR:13% ± 2%). The synergistic effect of BTG1 and IKZF1 on outcome 
remained after correction for subtype in the Cox model (Table 3A) and after leaving out 
the BCR-ABL1-positive cases (Figure 1C-D; Table 3B). For the BCR-ABL1-positive 
cases, BTG1 deletions did not further impact the poor treatment outcome as observed 
for the IKZF1 only-deleted cases (Figure 1E-F; Table 3C). 
A
BCP-ALL (n=533) Univariate Multivariate
Deletion Total Relapse Death 5-yr CIR(SE)
Gray
P
EFS HR
(95% CI)
Cox
P
EFS HR
(95% CI) Cox P
IKFZ1;BTG1
IKZF1
BTG1
none
17
88
31
397
10
25
3
52
2
5
0
12
53% (13%)
28% (5%)
10% (6%)
13% (2%)
0.005
3.5
(1.8-6.8)
0.0003
2.5
(1.0-5.9)
0.043
 
B
BCP-ALL without BCR-ABL1 (n=509) Univariate Multivariate
Deletion Total Relapse Death 5-yr CIR(SE)
Gray
P
EFS HR
(95% CI)
Cox
P
EFS HR
(95% CI) Cox P
IKFZ1;BTG1
IKZF1
BTG1
none
10
88
31
388
6
21
3
52
1
2
0
10
50% (17%)
26% (5%)
10% (6%)
13% (2%)
0.011
4.4
(1.9-10.3)
0.0007
6.7
(2.7-16)
0.00003
 
C
BCP-ALL BCR-ABL1 only (n=24) Univariate Multivariate
Deletion Total Relapse Death 5-yr CIR(SE)
Gray
P
EFS HR
(95% CI)
Cox
P
EFS HR
(95% CI) Cox P
IKFZ1;BTG1
IKZF1
BTG1
none
7
8
0
9
4
4
0
0
1
3
0
2
57% (22%)
50% (21%)
 
0% (0%)
0.7
0.8
(0.3-2.5)
0.7 ND ND
 
Table 3. CIR and EFS analysis of IKZF1- and BTG1-double deleted pediatric BCP-ALL cases 
compared with IKZF1-only deleted cases. CIR, cumulative incidence of relapse; SE, standard error; 
EFS, event-free survival; HR, hazard ratio; CI, confidence interval; multivariate, corrected for BCP-ALL 
subtype and stratified for study cohort (DCOG, COALL)
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Figure 1. Cumulative incidence of relapse (CIR) and event-free survival (EFS) curves for pediatric 
BCP-ALL cases with or without IKZF1 and BTG1 deletions. (A) CIR and (B) EFS curves for total BCP-
ALL cohort (n=533), IKZF1 plus BTG1 deletion, (C) CIR and (D) EFS curves for BCP-ALL without BCR-
ABL1-positive cases (n=509), IKZF1 plus BTG1 deletion, (E) CIR (F) EFS curves for BCR-ABL1-positive 
cases (n=24), IKZF1 plus BTG1 deletion. Colors: black, IKZF1 and BTG1-wildtype; green, IKZF1-wildtype, 
BTG1-deleted; red, IKZF1-deleted, BTG1-wildtype; blue, both IKZF1 and BTG1-deleted. Abbreviations: wt, 
wildtype; del, deletion; n, total number. For CIR curves, both relapsed and non-responders are included; 
for EFS curves an event is defined as relapse, non-response, or death.
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As deletions of PAX5, CDKN2A/B and RB1 were similarly enriched in IKZF1-deleted 
BCP-ALL, we examined the impact of these deletions on the outcome of IKZF1-deleted 
cases. In contrast to IKZF1;BTG1 double-deleted patients, the outcome of patients 
with co-occurring PAX5, CDKN2A/B or RB1 deletions did not differ from IKZF1 only-
deleted cases (Figure 2; supplemental Table 3). Similarly, co-occurrences of IKZF1 
deletions with either EBF1 or ETV6 deletions did not affect outcome compared with 
IKZF1 only-deleted. Together, these data show that BTG1 deletion by itself is not of 
poor prognostic value but BTG1 deletions specifically exacerbate the effects of IKZF1 
deletion on inferior outcome in BCP-ALL.  
 
Leukemia predisposition in Btg1 knockout mice
Although deletions affecting the BTG1 gene are a frequent event in BCP-ALL, a 
role for BTG1 in leukemia development has not been reported. Therefore, we first 
examined the tumor suppressive function of BTG1 using a constitutive Btg1 knockout 
line harboring a Neo-cassette into the first coding exon [25]. Animals carrying either 
one or two copies of the Btg1-knockout allele were followed over a period of 18 months 
and compared to control litter mates. About 6% (n=3/49) of wild-type C57BL6/J mice 
developed B-cell lymphomas between the age of 14 and 18 months (Table 4), which 
is consistent with previous observations [28]. Within the same time period 6% of the 
Btg1+/- (n=2/34) and 18% of the Btg1-/- (n=6/33) mice developed exclusively T-cell 
leukemia (Table 4), characterized by enlarged primary lymphoid organs, such as spleen 
and lymph nodes, and focal infiltration of leukemic T-cells into peripheral organs, such 
as lung and liver. These Btg1-deficient T-cell leukemias expressed the T-cell surface 
marker CD3, and displayed clonal T-cell receptor (TCR) rearrangements (Figure 3). In 
addition, these T-cell leukemias showed increased expression of the T-cell activation 
marker CD44, but also large numbers of B220+ cells within the infiltrated areas and 
affected lymph nodes (supplemental Figure 1). There was no evidence for clonal 
immunoglobulin gene rearrangements in these Btg1-/- T-cell leukemias (supplemental 
Figure 1), suggesting the presence of non-malignant B-lymphocytes in the proximity 
of these activated leukemic T-cells. These data show that, although somatic BTG1 
deletions predominantly occur in BCP-ALL, Btg1 deficiency in the mouse germline 
predisposes to T-cell malignancies. This predilection for T-lineage leukemias in mice 
is also observed for Ikzf1 mutant mice [29, 30]. 
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Figure 2. Cumulative incidence of relapse (CIR) curves for pediatric BCP-ALL cases with or without 
IKZF1 deletions in combination with other single common gene deletions. (A) IKZF1 plus PAX5, (B) 
IKZF1 plus CDKN2A/B, (C) IKZF1 plus RB1, (D) IKZF1 plus EBF1, (E) IKZF1 plus ETV6 (n=533). Colors: 
black, none of the indicated deletions; green, IKZF1-wildtype, indicated gene deleted; red, IKZF1-deleted, 
indicated gene wildtype; blue, both IKZF1 and indicated gene deleted. Abbreviations: wt, wildtype; del, 
deletion; n, total number. For CIR curves both relapsed and non-responders are included.
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Loss of Btg1 increases leukemia incidence in Ikzf1+/- mice
To investigate cooperation between BTG1 and IKZF1 during leukemogenesis, we 
intercrossed Btg1-deficient mice with haplodeficient Ikzf1 mice. We followed Ikzf1+/-, 
Btg1+/-;Ikzf1+/- and Btg1-/-;Ikzf1+/- mice for a period of 18 months. In our cohort, 14% 
(n=5/36) of the Ikzf1+/- mice developed T-cell leukemia between 3 and 18 months of 
age, with a median age of 12 months (Table 4). 
Genotype
Tumor 
incidence   
(% mice)
Mean age      
(months)
Tumor 
phenotype   Ikzf1
+/-     P-value
a 
Btg1+/-      Btg1
-/-
Wild-type
Ikzf1+/-
Btg1+/-
Btg1+/-;Ikzf1+/-
Btg1-/-
Btg1-/-;Ikzf1+/-
3/49    (6%)
5/36    (14%)
2/34    (6%)
10/35  (29%)
6/33    (18%)
12/30  (40%)
16.4
12.4
15.8
13.6
17.4
9.4
B-cell lymphoma
T-cell leukemia
T-cell leukemia
T-cell leukemia
T-cell leukemia
T-cell leukemia
  -
  -
0.271
0.134
0.703
0.012
   -
0.271
  -
0.013
0.143
0.001
  -
0.703
0.143
0.231
  -
0.026
 
Table 4. Characteristics lymphoid tumors of single and intercrossed Btg1 and Ikzf1 knockout 
lines. a Chi-square analysis comparing incidence of T-cell leukemia to indicated genotype at 18 months
Similar to Btg1-deficient leukemia, the Ikzf1+/- T-cell leukemias showed infiltration of 
CD3+ leukemic blasts into distant organs and clonal TCR rearrangements (Figure 3). 
Interestingly, we observed an increased leukemia incidence upon combined loss of 
Btg1 and Ikzf1, which is consistent with our finding that BTG1 deletions are enriched 
in human BCP-ALL cases with IKZF1 aberrations. We found that 26% of the Btg1+/-
;Ikzf1+/- mice (n=10/35) and 40% of the Btg1-/-;Ikzf1+/- (n=12/30) animals developed T-cell 
leukemia while leukemias in Btg1-/-;Ikzf1+/- appeared with a slightly shorter latency (9.4 
months) relative to Ikzf1+/- mice (12.4 months) (Table 4). Tumors in these compound 
mice where characterized by higher leukocyte counts in peripheral blood compared with 
the single knockout animals, and infiltration of leukemic cells into liver and lungs, as 
well as clonal TCR rearrangements (Figure 3). Flow cytometric analysis of the different 
T-cell leukemias revealed that most of the Btg1-/-;Ikzf1+/- leukemias were CD4+CD8+ 
double positive T-cells with ongoing differentiation towards CD4 or CD8 single positive 
stage (Figure 3, supplemental Table 4). Moreover, isolated leukemic T-cells, derived 
from all the different genetic backgrounds included in our studies (Ikzf1+/-, Btg1-/- and 
Btg1-/-;Ikzf1+/-), could be serially transplanted into syngeneic C57BL6/J mice giving rise 
to similar (oligo)clonal T-cell leukemias (supplemental Figure 2). Taken together, our 
data demonstrate that loss of Btg1 cooperates with haplodeficiency for Ikzf1 during 
mouse leukemia development in a dose-dependent manner.
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Discussion 
BCP-ALL is a heterogeneous disease characterized by recurrent deletions enriched 
in specific genetic subtypes [1]. For instance, it is known that deletions affecting the 
transcriptional co-regulator BTG1 are unevenly distributed among cytogenetic subgroups 
as we and others have shown that BTG1 deletions are strongly enriched in ETV6-
RUNX1-positive leukemia as well as BCR-ABL1-positive ALL [31, 32]. The presence of 
these lesions in such distinct BCP-ALL subgroups may relate to the fact that deletions 
of IKZF1 and BTG1 appears to be the result of illegitimate RAG recombination [32]. In 
addition to these earlier observations, we find a specific co-occurrence of BTG1 and 
Figure 3. Leukemia incidence and phenotype of Btg1 knockout mice intercrossed with haplodeficient 
Ikzf1 animals. (A) Kaplan-Meier survival curve indicates the leukemia event free survival in wild-type, Ikzf1+/-, 
Btg1+/-, Btg1+/-;Ikzf1+/-, Btg1-/-, and Btg1-/-;Ikzf1+/- mice over a time period of 17 months. Leukemia incidence 
is significantly increased in Btg1-/-;Ikzf1+/- mice as compared to Ikzf1+/- mice (P=0.011). (B) Peripheral blood 
smear stained with Giemsa and immunohistochemistry for CD3 on lung and liver tissues of diseased Ikzf1+/-, 
Btg1-/-,  Btg1+/-;Ikzf1+/-, and Btg1-/-;Ikzf1+/- mice. (C) T-cell receptor beta 2 (Trb2) gene rearrangement analysis 
by PCR on control tissue, B-cell lymphoma derived from wild-type mice (#3863), and T-cell leukemias derived 
from Ikzf1+/- (#13135, #350), Btg1-/- (#160), Btg1+/-;Ikzf1+/- (#5103 and #5102) and Btg1-/-;Ikzf1+/- mice (#9073, 
#7169, #7173). (D) Flow cytometry analyzing CD4 and CD8 expression on T-cell leukemia samples of two 
Ikzf1+/-, Btg1-/-,  Btg1+/-;Ikzf1+/- and Btg1-/-;Ikzf1+/- mice.
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IKZF1 gene deletions across cytogenetic subtypes, suggesting that the combined loss 
of BTG1 and IKZF1 may actively contribute to leukemogenesis. Previous studies, mostly 
carried out in mouse models, revealed that Ikzf1 and Arf alterations in BCR-ABL1-positive 
ALL synergize to promote the development of leukemia by conferring stem cell like 
properties [33]. This leads us to hypothesize that the preponderance of IKZF1;BTG1 
double-deletions in this particular subgroup may have similar consequences, although 
this remains to be assessed in well-established BCR-ABL1-positive mouse models. 
As BTG1 and IKZF1 deletions also (co)occur in lymphoid blast crises of CML [6], it 
will be interesting to study if and how combined loss of BTG1 and IKZF1 drive the 
progression of this disease. Of all common copy number losses analyzed in our study, 
including CDKN2A/B, PAX5, EBF1, and RB1, only loss of BTG1 appears to worsen 
outcome of IKZF1-deleted ALL. Our data are consistent with the findings of Moorman 
et al. showing that specific combinations of different deletions impact outcome in 
BCP-ALL [34].  
A number of different knockout mouse models have provided insight into the 
spontaneous tumor incidence and latency caused by single gene deletions. However, 
in the mouse, loss of early B-cell transcription factors affected in BCP-ALL, such as 
E2A [35] and IKZF1 [36] gives rise to T-cell malignancies. E2a-deficient tumors are 
characterized by a strong increase in c-Myc mRNA expression [35], an oncogene known 
to promote the development of T-cell lymphomas [37]. Similarly, while IKZF1 deletions 
predominantly occur in human BCP-ALL [16, 17], heterozygous Ikzf1 knockout and 
dominant-negative Ikzf1 mice exclusively develop T-cell malignancies [29, 30], which 
has been attributed to activation of the Notch pathway [30, 38-40]. In our studies we 
observed a rather lower incidence of T-cell leukemia in Ikzf1+/- mice as compared to what 
has been reported for some other genetically engineered Ikzf1 mouse models, where 
expression of dominant-negative isoforms of Ikzf1 alleles yielded a higher susceptibility 
to T-cell malignancies [29, 30, 38]. Similar to Ikzf1 mutant mice, Btg1 heterozygous 
and homozygous knockout mice develop T-cell leukemia, while BTG1 deletions are 
almost exclusively found in human BCP-ALL [32]. However, consistent with our finding 
that BTG1 deletions are enriched in human BCP-ALL cases with IKZF1 aberrations, 
Btg1+/-;Ikzf1+/- mice are more prone to develop leukemia relative to Btg1-/- or Ikzf1+/- 
single-knockout mice. In addition, we observed an acceleration in the onset of disease 
in Btg1-/-;Ikzf1+/- mice compared with Btg1-/- or Ikzf1+/- mice, indicating that loss of these 
tumor suppressor genes cooperates during leukemogenesis. Genomic DNA analyses 
further indicate that the wild-type Btg1 allele is maintained in the Btg1+/-;Ikzf1+/- leukemias 
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(data not shown), arguing that Btg1 dosage contributes to leukemia development. 
In conclusion, we have identified BTG1 as haploinsufficient tumor suppressor gene 
that synergizes with IKZF1 loss during leukemia development. As the combined loss 
of IKZF1 and BTG1 in our patient cohort appears to be correlated with a very poor 
outcome, it will be important to replicate these findings in other patient cohorts.
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Supplementary Appendix  
Supplemental Tables
Gene locus Forward primer (5’  3’) Reverse primer (5’  3’)
Wild-type Btg1 CCATGCATCCCTTCTACACCC TGCAGGCTCTGGCTGAAAGT
Knockout Btg1 CCATGCATCCCTTCTACACCC CGGAGAACCTGCGTGCAATC
Wild-type Ikzf1 ATGGATGTCGATGAGGGTCAAGAC AGTTCTCTGAACACAGACACACGT
Knockout Ikzf1 GCGGAGCTCCTCAGGTGCAGGCT 
GCCTATC
GACGCGTCGACGCTAACATCCTGA 
GGGACTGT
Trb1 (DJ) CAGCCCCTTCAGCAAAGAT CCTAAGTTCCTTTCCAAGACCAT
Trb2 (DJ) GTAGGCACCTGTGGGGAAGAAACT TGAGAGCTGTCTCCTACTATCCATT
Igh CCCGAATTCCAGGTCCAGTTGCAG 
CAGWCWGG
CCCGAATTCGCTCTCGCAGGAGAC
Igk CCCGAATTCCAGGTCCAGTTGCAG 
CAGWCWGG
CCCGAATTCTAACTGCTCACTGGA
Table S1. Oligonucleotide primers used for genotyping and clonality analysis.
 
ALL subtypes DCOG (N=470) COALL (N=128) Total (N=598) Literature*
N Perc N Perc N Perc Perc
ETV6-RUNX1 120 26% 34 27% 154 26% 25%
High hyperdiploid (51-65 
chr) 95 20% 31 24% 126 21% 25%
Non-BCR-ABL1-like 
B-other 80 17% 27 21% 107 18% 10-15%
BCR-ABL1-like B-other 69 15% 23 18% 92 15% 10-15%
TCF3-rearranged 17 4% 2 2% 19 3% 5%
BCR-ABL1 22 5% 2 2% 24 4% 3%
MLL-rearranged 10 2% 1 1% 11 2% 2%
T-ALL 57 12% 8 6% 65 11% 15%
Table S2. Representation of pediatric ALL subtypes in DCOG and COALL cohorts. * Pui et al, 
Journal of Clinical Oncology 2011 [41]
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 PAX5 Univariate multivariate
Deletion Total Relapse Death
5-yr CIR
(SE)
Gray
P
EFS HR 
(95% CI)
Cox
P
EFS HR 
(95% CI)
Cox 
P
IKFZ1; PAX5 50 17 3 32% (7%)
0.8 1.0 (0.6-1.9) 0.9
0.7
(0.3-1.3) 0.2IKZF1 55 18 4 33% (7%)
PAX5 98 19 1 19% (4%)
none 330 36 11 11% (2%)
CDKN2A/B Univariate multivariate
Deletion Total Relapse Death 5-yr CIR(SE)
Gray
P
EFS HR 
(95% CI)
Cox
P
EFS HR 
(95% CI)
Cox 
P
IKFZ1; 
CDKN2A/B 52 20 3 39% (7%) 0.2 1.4(0.8-2.5) 0.3
0.9
(0.4-1.8) 0.7
IKZF1 53 15 4 26% (6%)
CDKN2A/B 130 23 5 18% (4%)  
 none 298 32 7 10% (2%)
EBF1 Univariate multivariate
Deletion Total Relapse Death 5-yr CIR(SE)
Gray
P
EFS HR 
(95% CI)
Cox
P
EFS HR 
(95% CI)
Cox 
P
IKFZ1; EBF1 9 3 1 22% (15%)
0.9 1.2(0.4-3.3) 0.7
2.1
(0.7-6.9) 0.2IKZF1 96 32 6 33% (5%)
EBF1 23 3 0 15% (8%)  
 none 405 52 12 13% (2%)
RB1 Univariate multivariate
Deletion Total Relapse Death 5-yr CIR(SE)
Gray
P
EFS HR 
(95% CI)
Cox
P
EFS HR 
(95% CI)
Cox 
P
IKFZ1; RB1 14 5 1 37% (14%)
0.7 1.2(0.5-2.9) 0.6
0.6
(0.2-1.6) 0.3IKZF1 91 30 6 31% (5%)
RB1 28 5 1 18% (8%)  
 none 400 50 11 12% (2%)
ETV6 Univariate multivariate
Deletion Total Relapse Death 5-yr CIR(SE)
Gray
P
EFS HR 
(95% CI)
Cox
P
EFS HR 
(95% CI)
Cox 
P
IKFZ1; ETV6 25 10 0 40% (10%)
0.4 1.0(0.5-2.0) 0.9
1.5  
(0.7-3.4) 0.3IKZF1 80 25 7 30% (5%)
ETV6 132 11 1 8% (3%)  
 none 296 44 11 15% (2%)
 
Table S3. Outcome analysis in BCP-ALL cases double-deleted for common gene deletions and 
IKZF1 versus IKZF1-only deleted cases. CIR, cumulative incidence of relapse; SE, standard error; 
EFS, event-free survival; HR, hazard ratio; CI, confidence interval; multivariate, corrected for BCP-ALL 
subtype and stratified for study cohort (DCOG, COALL)
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Supplemental Figures 
 
 
Figure S1. Characteristics of Btg1-deficient T-cell leukemias. (A-B) T-cell leukemias in Btg1-deficient 
mice are characterized by a significant proportion of B220+ B-lymphocytes within the tumor area, which can 
be demonstrated by B220-positive staining as determined by immunohistochemistry of infiltrated liver (A) and 
flow cytometry of the primary leukemia (B). The recruitment of normal B-lymphocytes by the T-lymphoblasts 
correlates with high CD44 expression of the T-leukemic cells. (C) Immunoglobulin gene rearrangements 
for heavy chain (Igh) and kappa light chain (Igk) show clonal rearrangement in B-cell malignancies derived 
from wild-type C57Bl/6J mice, but not in leukemias derived from  Btg1-/- mice.
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Figure S2. Leukemias arising in Btg1 and Ikzf1 knockout animals are (oligo)clonal and transplantable 
into syngeneic mice. (A) Schematic overview of the transplantation experiments. Leukemias (L) derived 
from either Ikzf1+/-, Btg1-/-, and  Ikzf1+/-;Btg1-/- mice were transplanted intravenously into syngeneic mice at 
a concentration of 2 x 105 cells (transplant-1; T1) or 5 x 105 cells (transplant-2; T2). T-cell leukemias were 
observed 4 weeks after transplantation. (B) T-cell receptor beta 2 (Trb2) gene rearrangements were determined 
by PCR on DNA isolated from non-lymphoid tissue (earclip) as control for germline configuration, and DNA 
derived from L, T1 and T2 tumor tissues of  Ikzf1+/-, Btg1-/-, and  Ikzf1+/-;Btg1-/- mice. (C) Flow cytometry was 
performed on the original leukemia (L) and two independent serial transplantations (T1 and T2). The upper 
panel shows the side scatter (SSC) and CD3 profile. The CD3-postive fraction was subsequent analyzed 
for CD4 and CD8 staining (middle panel) and CD44 and CD25 staining (lower panel).
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Supplementary  information: 
Leukemia incidence in Btg1- and Btg2-deficient mice and in Btg1/Btg2 double 
knockout mice
Introduction 
Deregulation of the BTG1 and BTG2 genes is frequently observed in solid tumors where 
decreased expression levels have been correlated with the formation and progression of 
various cancers [42-44]. The B-cell translocation gene 2 (BTG2) and its closely relative 
BTG1 are targeted by missense mutations in diffuse large B cell lymphoma (DLBCL) 
[45, 46], and mutations in BTG2 have also been identified in Burkitt and follicular 
lymphoma [47, 48]. Monoallelic deletions affecting the  BTG1 locus are present in 9% 
of the BCP-ALL cases as a result of illegitimate RAG-mediated recombination, while 
this has not been observed for BTG2 [16, 17, 32]. We recently demonstrated that both 
Btg1 and Btg2 display unique and overlapping functions during B-cell development 
in mice [49]. To further explore a role for these genes during leukemogenesis, we 
analyzed the leukemia incidence in mice deficient for either Btg1 or Btg2 and in Btg1/
Btg2 double knockout mice.
 
Methods 
Experimental animals
Btg1 and Btg2 single- as well as double-knockout mice have been described previously 
[25, 50, 51]. Mice were maintained under specific pathogen-free conditions at our 
Central Animal Laboratory facility. Animal experiments were approved by the Animal 
Experimental Committee of the Radboud university medical center and were performed 
in accordance with institutional and national guidelines. 
Immunohistochemistry
Tissues isolated from diseased mice were fixed in 4% formalin for 24 hours. Specimens 
were embedded in paraffin, 4 µM serial sections were prepared and stained with 
hematoxylin and eosin (HE). For immunohistochemistry, slides were dewaxed and 
rehydrated prior to heat-induced antigen retrieval using sodium citrate buffer. After 
Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase 
relapse risk in B-cell precursor ALL patients
191
6
blocking with 2% goat serum and 2% BSA in 0.05% Tween-PBS, the slides were 
incubated overnight with B220/CD45R (RM2600) (Invitrogen) and CD3 (A0452) (DAKO) 
antibodies.  Biotinylated  anti-rat IgG (BA9401) (Vector Laboratories) and anti-rabbit IgG 
(BA1000) (Vector Laboratories) were used as secondary antibody and subsequently 
the slides were incubated with metal-enhanced diaminobenzidine in stable peroxide 
substrate buffer (Thermo Fisher Scientific), counterstained with hematoxylin, and after 
dehydration coverslipped with Entellan.
Flow cytometry
Enlarged lymph nodes were dissected from the diseased mice and frozen as viable 
single cells. The leukemic blasts derived from lymph nodes of diseased wild-type, 
Btg1-/-, Btg2-/- and Btg1-/-;Btg2-/- mice were analyzed by FACS  to determine the cell 
lineage of origin using the LSRII flow cytometer (BD). Single cell suspensions were 
pre-incubated with unlabeled anti–Fcγ III/II receptor (2.4G2) (BD Biosciences) to inhibit 
unspecific antibody binding. Cells were stained with the following antibodies purchased 
from BD Biosciences and eBiosciences: anti-B220/CD45R (RA3-6B2); CD4 (RM4-
5); CD8 (53-6.7); CD11b/Mac1 (M1/70); CD25 (PC61.5); CD44 (IM7). The data were 
collected and analyzed by FlowJo software. 
Analysis of leukemia incidence
The pathology cohort included wild-type (n=49), Btg1+/- (n=34), Btg2+/- (n=25), Btg1-/- 
(n=33), Btg2-/- (n=33), Btg1-/-;Btg2-/- (n=30) mice, which were monitored for 18 months 
or euthanized upon disease symptoms. Mice were scored for macroscopic visible 
defects, including enlarged lymph nodes and spleen. Mice with a spleen weight of ≥1.0 
percent of their body weight were suspected of leukemia/lymphoma and analyzed by 
immunohistochemistry and microscopy. Leukemia incidence data were analyzed by 
SPSS software and the survival between groups was compared using the Log rank 
(Mantal-Cox) test. All mice that developed overt T-cell leukemia/lymphoma before the 
age of 18 months were included in the analyses. 
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Results 
To investigate whether loss of either Btg1 or Btg2 is sufficient to drive leukemia formation 
in the mouse, we examined cohorts of Btg1 and Btg2 single knockout, as well as the 
Btg1-/-;Btg2-/- double knockout animals, until the age of 18 months. Some of the mice 
showed signs of illness between the age of 14 and 18 months, but most of the animals 
were sacrificed at the end of the observation period.
Similar to the phenotype that has been observed in Btg1 knockout mice, Btg2-deficiency 
gave rise to T-cell leukemia in 6% of the animals, which was only evident at the age 
of 18 months. In contrast to Btg1+/- mice, haploinsuffiency for Btg2 was not associated 
with a predisposition to T-cell leukemia. Notably, mice that lacked both Btg1 and Btg2 
expression developed T-cell malignancies with a similar incidence and latency as 
Btg2-/- mice, displaying no evidence of cooperative interactions between these tumor 
suppressor genes (Table1). 
Genotype Tumor incidence Mean age tumor development (months) Tumor phenotype P-Value
Wild-type 3/49 (6%) 16.4 B-cell lymphoma 1.000a
Btg1+/- 2/34 (3%) 15.8 T-cell leukemia 0.968a
Btg1-/- 6/33 (18%) 17.4 T-cell leukemia 0.100a
Btg2+/- 0/25 (0%) - - 0.211a
Btg2-/- 2/33 (6%) 18.0 T-cell leukemia 0.965a
Btg1-/-;Btg2-/- 2/30 (7%) 18.0 T-cell leukemia 0.914a
 
Table 1. Tumor incidence and phenotype in Btg1 and Btg2 knockout animals. aChi-square analysis 
comparing tumor phenotype with wild-type mice 
 
All mice that developed hematological malignancies displayed an enlarged spleen with 
a relative weight of ≥1.0 percent compared to their body weight (Figure 1A). While the 
strongly enlarged lymph node tissues of the diseased wild-type animals predominantly 
showed  cells positive for the B cell marker B220, without infiltrations into other organs, 
loss of Btg1 and Btg2 resulted in infiltration of CD3+ lymphoblasts into spleen, lung and 
liver (Figure 1B-C). Next, flow cytometric analysis of the mononuclear cells isolated 
from enlarged lymph nodes was performed to further investigate the lineage origin 
and differentiation stage of these leukemic blasts in more detail, using Mac-1, B220, 
CD3, CD4, CD8, CD44 and CD25 antibodies. Analysis of the leukemic cells isolated 
from the Btg1- and Btg2-deficient animals confirmed that all tumors were CD3 positive. 
In addition, we observed CD4+ and CD8+ single-positive T-lymphoblasts, indicating a 
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more mature phenotype in these leukemic cells (Figure 1D). We conclude from these 
experiments that leukemias in the Btg1 and Btg2 knockout animals are exclusively 
of T-cell origin.
WT Btg1-/-;Btg2-/-
A B Wild-type (control) Btg2-/- #4097C
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8
0
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104
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C
D
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Figure S1. Analysis of the tumor phenotype of Btg1- and Btg2 deficient mice. (A) Spleen derived 
from wild-type and leukemic Btg1-/-;Btg2-/- mouse (#4345). (B-D) Immunohistochemical analysis of liver 
tissue from a wild-type control (non-diseased) (B) and Btg2-/- (C) mouse using antibodies directed against 
CD3. (D) Flow cytometric analysis was performed on lymph node-derived cells isolated from Btg1-/-;Btg2-/- 
mice. Cells were stained with B220, CD3 and a cocktail of antibodies directed against CD4 and CD8. The 
percentage for each population of cells in lymph node is indicated. 
Discussion 
 
The tumor suppressor genes BTG1 and BTG2 are involved in regulating critical cellular 
processes, such as cell proliferation, differentiation and apoptosis and are subject to 
deletion or mutation in B cell malignancies such as BCP-ALL and DLBCL [16, 45, 46] 
as well as in solid tumors [42-44, 52]. 
B-cell malignancies are characterized by the presence of genetic alterations affecting 
genes involved in various cellular processes such as lymphoid differentiation and 
cell cycle regulation. These include EBF1, IKZF1, TCF3, CDKN2A deletions [16, 
17]. Previous studies involving knockout mouse models have provided insight in the 
spontaneous tumor incidence and latency of single gene deletions. However, in the 
mouse, loss of transcription factors affected in BCP-ALL, such as E2A [35] and IKZF1 
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[36], appear to give rise to T-cell malignancies. Similarly, we observed that Btg1- 
and Btg2-deficient mice develop T-cell leukemia, while BTG1 and BTG2 mutations 
or deletions are exclusively found in B-cell malignancies. The tumor incidence was 
not increased in the Btg1-/-;Btg2-/- mice compared to the Btg2 single knockout mice, 
indicating that there is no cooperation in leukemia development between Btg1 and 
Btg2. Haplodeficiency for Btg1, but not Btg2, is associated with a predisposition to 
T-cell leukemia. Furthermore, leukemia incidence is lower in Btg2-/- mice compared 
to Btg1-/- mice, which could indicate that Btg1 is a more dominant tumor suppressor 
in the T-cell lineage than Btg2. 
Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase 
relapse risk in B-cell precursor ALL patients
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Abstract 
Btg1 and Btg2 encode highly homologous proteins that are broadly expressed in 
different cell lineages, and have been implicated in different types of cancer. Btg1 and 
Btg2 have been shown to modulate the function of different transcriptional regulators, 
including Hox and Smad transcription factors. In this study, we examined the in vivo 
role of the mouse Btg1 and Btg2 genes in specifying the regional identity of the axial 
skeleton. Therefore, we examined the phenotype of Btg1 and Btg2 single knockout 
mice, as well as novel generated Btg1-/-;Btg2-/- double knockout mice, which were viable, 
but displayed a non-mendelian inheritance and smaller litter size. We observed both 
unique and overlapping phenotypes reminiscent of homeotic transformation along the 
anterior-posterior axis in the single and combined Btg1 and Btg2 knockout animals. 
Both Btg1-/- and Btg2-/- mice displayed partial posterior transformation of the seventh 
cervical vertebra, which was more pronounced in Btg1-/-;Btg2-/- mice, demonstrating 
that Btg1 and Btg2 act in synergy. Loss of Btg2, but not Btg1, was sufficient for 
complete posterior transformation of the thirteenth thoracic vertebra to the first lumbar 
vertebra. Moreover, Btg2-/- animals displayed complete posterior transformation of the 
sixth lumbar vertebra to the first sacral vertebra, which was only partially present at 
a low frequency in Btg1-/- mice. The Btg1-/-;Btg2-/- animals showed an even stronger 
phenotype, with L5 to S1 transformation. Together, these data show that both Btg1 
and Btg2 are required for normal vertebral patterning of the axial skeleton, but each 
gene contributes differently in specifying the identity along the anterior-posterior axis 
of the skeleton. 
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Introduction  
The vertebrate axial skeleton is comprised of similar structures that extend from anterior 
to posterior along the body axis: the occipital skull bones, cervical, thoracic, lumbar, 
sacral and caudal vertebrae. In mice, there are 30 precaudal vertebrae distributed into 
seven cervical, thirteen thoracic, six lumbar and four sacral vertebrae [1]. Vertebral 
development involves two phases, an early stage of somite segmentation from the 
presomitic mesoderm (PSM) and a later stage of somatic patterning and specification 
[2]. Segmental identity of the axial skeleton is regulated by a variety of signaling 
mechanisms and requires the local activation of specific transcriptional regulators, 
known as Hox genes. This gene family comprises 39 highly conserved transcription 
factors that are organized into four clusters, including HoxA, HoxB, HoxC and HoxD 
[3, 4]. Hox genes are expressed in gradients along the anterior-posterior axis of the 
body [5-7], and as such control the identity of the axial skeleton.. Deregulation of Hox 
gene function leads to homeotic transformations, in which one structure acquires the 
morphological characteristics of an adjacent homologous structure, a phenotype dictated 
by the cluster of Hox genes that is affected [8, 9]. Other transcriptional regulators 
important for proper control of vertebral identities include the mammalian Trithorax 
group (TrxG) and Polycomb group (PcG) proteins, which control the expression of 
Hox genes [10, 11]. Moreover, Hox gene expression is regulated by different signaling 
pathways, including bone morphogenetic protein (BMP), which is required for normal 
axial skeletal development [12, 13]. 
The B cell translocation gene 1 (Btg1) and Btg2 belong to the BTG/TOB family 
of anti-proliferation genes, and their gene products share 74% protein sequence 
similarity [14, 15]. Btg1 and Btg2 proteins regulate various cellular processes including 
proliferation, differentiation and apoptosis, while deregulated expression has been 
observed in various cancers, including B cell malignancies [16-19]. In addition, the 
BTG1 gene is frequently affected by monoallelic deletions in pediatric B-cell precursor 
acute lymphoblastic leukemia (BCP-ALL), while this has not been observed for BTG2 
[18, 20]. On the other hand, both genes are targeted by point mutations in diffuse large 
B cell lymphomas [21, 22]. Furthermore, both proteins enhance the transcriptional 
activity of the homeodomain protein HoxB9, whereas Btg2 was shown to associate 
with receptor regulated SMAD proteins SMAD1 and SMAD8, thereby activating BMP-
dependent transcription [23, 24]. Previous studies using Btg2-/- mice revealed posterior 
homeotic transformations of axial skeleton vertebrae, which has been attributed to 
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impaired BMP/Smad signaling [23]. However, it remains to be established whether 
Btg1 regulates patterning of axial vertebrae and displays similar functions as Btg2.
Several classes of leukemia-associated genes, including Hox transcription factors 
and their upstream regulator Bmi1, play a critical role in regional patterning of the 
vertebrate body plan [8, 25-27]. Here, we examined the in vivo role of Btg1 and Btg2 
in specifying the regional identity of vertebrae along the anterior-posterior axis of the 
skeleton using both single and double knockout mice for Btg1 and Btg2. This analysis 
revealed that both Btg1 and Btg2 regulate vertebra specification at the cervical-thoracic 
and lumbar-sacral junction. On the other hand, Btg2 fulfills a unique role in patterning 
of the thoracic-lumbar junction, which is not affected in the Btg1-/- mice. 
Methods 
Experimental Animals
C57BL/6J Btg1-/- and Btg2-/- mice have been described earlier [28]D and were a kind 
gift of J.P. Rouault and F. Tirone respectively. [23]. Btg1-/-;Btg2-/- mice were obtained 
by multiple intercrossing of Btg1-/- with Btg2-/- mice. Animals were maintained under 
specific pathogen-free conditions at our animal facility. All animal experiments were 
approved by the Animal Experimental Committee of the Radboud university medical 
center and were performed in accordance with institutional and national guidelines.
Genotyping of mice was routinely performed by PCR, using DNA derived from ear clips. 
To identify mice carrying either null or wild-type alleles, two primers complementary 
to the targeted exon 1 (mBtg1_F 5’-CCATGCATCCCTTCTACACCC-3’; mBtg1_R 
5’- TGCAGGCTCTGGCTGAAAGT-3’) and one primer complementary to the 
neomycin cassette (mBtg1 Neo_R 5’-CGGAGAACCTGCGTGCAATC-3’) were 
combined. The wild-type (WT) non-targeted Btg1 allele was identified as a 136bp 
PCR fragment with the exon 1 primers, and the Btg1-/- allele as a 360bp PCR fragment 
with neomycin specific primer. Btg2 null wild-type alleles were identified by PCR 
using four primers, two complementary to the targeted exon 2 for detection of the 
endogenous Btg2 allele (mBtg2_F 5’-  CATCCAAAGGTTCTGGCTATC-3’; mBtg2_R 
5’- GCCATCACATAGTTCTTCGAG-3’), one complementary to the neomycin cassette 
and one specific for exon 1 (mBtg2 Neo_F 5’-CTTCTATCGCCTTCTTGACGAG-3’; 
mBtg2 ExI_R 5’-CCACGGGAAGAGAACCGACAT-3’), which were combined in the 
PCR reaction. The wild-type (WT) non-targeted Btg2 allele was identified as a 289bp 
Targeted deletion of Btg1 and Btg2 results in homeotic transformation of the axial skeleton
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PCR fragment with the exon 2 primers, and the Btg2-/- allele as a 1372bp PCR fragment 
with the exon 1 and neomycin specific primers. 
Skeletal Staining and Analysis
Embryos of day 18.5dpc were eviscerated and fixed in 95% EtOH at 4°C. The skeleton 
was stained for cartilage in 70% ethanol/5% acetic acid and 5% Alcian Blue (8GX, 
Sigma Aldrich) (0.4% Alcian Blue in 70% EtOH) and bone by addition of 0.005% Alizarin 
Red S (Sigma Aldrich) for 24-48 hours at room temperature. Embryos were destained 
in series of gradual lower concentrations of KOH and increasing concentrations of 
glycerol, and finally stored in 100% glycerol.
The skeletons were scored for axial transformations by counting the number of 
sternebrae, vertebrae (cervival, thoracic, lumbar and sarcral) and ribs by microscopic 
analysis. 
Results 
Generation of Btg1 and Btg2 knockout mice
To investigate the function of Btg1 and Btg2 during normal development we obtained 
Btg1-/- and Btg2-/- single knockout [23, 28], and generated Btg1-/-;Btg2-/- double knockout 
mice on a C57Bl/6J background and examined their appearance for gross abnormalities 
(Figure 1A-1B). Genotyping the offspring showed a non-mendelian inheritance pattern 
for the Btg1 knockout allele in the single knockout crosses (Table 1), while the Btg2 
knockout allele was strongly underrepresented in the compound crosses (Table 2). The 
different homozygous knockout animals showed no obvious developmental defects, 
although the litter size upon interbreeding of the Btg1, Btg2 or Btg1;Btg2 homozygous 
knockout lines appeared to be smaller compared to WT animals (Figure 1C).
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Figure 1. Characterization of Btg1-/-, Btg2-/- and Btg1-/-;Btg2-/- mice. (A) The mouse Btg1 gene is disrupted 
by insertion of a neomycin resistance cassette via SacII restriction sites in the first exon. The second exon 
of the Btg2 gene is replaced by a neomycin cassette in the antisense direction. The arrows indicate the 
position of primers used for genotyping. (B) Genotyping of mice was performed by PCR on genomic DNA 
using primers specific for the Btg1 and Btg2 wild-type (WT) and knockout (KO) allele. (C) Number of pups 
obtained from wild-type, heterozygous and homozygous Btg1, Btg2 and Btg1xBtg2 breedings. Data are 
from at least 4 independent crossings. *, P< 0.05, **, P< 0.01, ***, P< 0.001 
Breeding pairs % WT % +/- % -/- P-value
 exp./obs. exp./obs. exp./obs.
WT x WT 100 / 100 0 / 0 0 / 0 n.s (n=176)
Btg1+/+ x Btg1+/-  50 / 71 50 / 29 0 / 0 <0.0001 (n=24)
Btg1+/- x Btg1+/- 25 / 32 50 / 59  25 / 9 0.001 (n=104)
Btg1+/- x Btg1-/- 0 / 0 50 / 56 50 / 44 n.s (n=126)
Btg1-/- x Btg1-/- 0 / 0 0 / 0 100 / 100 n.s (n=234)
Btg2+/+ x Btg2+/-  50 / 49 50 / 51 0 / 0 n.s (n=61)
Btg2+/- x Btg2+/- 25 / 30 50 / 54  25 / 16 n.s (n=32)
Btg2+/- x Btg2-/- 0 / 0 50 / 49 50 / 51 n.s (n=41)
Btg2-/- x Btg2-/- 0 / 0 0 / 0 100 / 100    n.s. (n=177)
Table 1. Mendelian inheritance in the offspring of Btg1-, and Btg2 single knockout mice. Expected 
(exp.) mendelian inheritance and observed (obs.) inheritance after WT, Btg1 and Btg2 breedings. P-values 
of the mendelian ratios are calculated with the Chi-square test and are either significant if p <0.05 or not 
significant (n.s)
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Homeotic transformation of the axial skeleton in the cervical and thoracic region of 
Btg1- and Btg2-deficient mice
To establish whether Btg1 may display distinct or overlapping functions compared 
to Btg2 in specifying the regional identity of the axial skeleton [23], we analyzed 
the skeletal defects of Btg1 and Btg2 single knockout, as well as Btg1;Btg2 double 
knockout embryos at the age of 18.5 days post-coitus (dpc). In total, we examined 
the skeletons of 18 wild-type, 21 Btg1-/-, 20 Btg2-/- and 22 Btg1-/-;Btg2-/- animals, which 
were obtained from three independent breeding pairs.
Inspection of the upper cervical region in the Btg1-/-, Btg2-/- and Btg1-/-;Btg2-/- animals 
did not uncover any abnormalities in the structure and shape of the atlas (C1) or axis 
(C2). However, skeletal analysis of the cervical-thoracic junction revealed a common 
defect among the Btg1- and Btg2-deficient animals. As expected, most wild-type 
C57Bl6/J mice (72%), showed a small rib anlagen visible as a rudimentary rib attached 
to the seventh cervical vertebra (C7) (Figure 2A).  
In contrast, Btg1- and Btg2-knockout mice displayed a partial or full extensive rib 
at C7, ranging from 62% in Btg1-/-, 35% in Btg2-/- and 95% in Btg1-/-;Btg2-/- mice. As 
a consequence the presence of the rib anlagen on C7 occurred far less frequently in 
Btg1-/- mice (38%) and was almost absent in Btg1-/-;Btg2-/- animals (4.5%) (Table 3). This 
indicates that in these mice the C7 vertebra acquired the morphological characteristics 
Figure 2. Skeletal abnormalities within the cervical-thoracic region in mice deficient for Btg1 and 
Btg2 . (A-D) Lateral view of the skeletons from 18.5 dpc wild-type, Btg1-/-, Btg2-/- and Btg1-/-;Btg2-/- embryos, 
which were stained with alizarin red and alcian blue . (A-C) Wild-type C57Bl6/J mice show a rib anlage at 
C7 (indicated by asterisk), whereas Btg1-/- and Btg2-/- mice display a partial rib at C7 (indicated by asterisk). 
The extra formed T1 rib in Btg1 knockout animal is fused to T2 rib. (D) Btg1-/-;Btg2-/- double knockout mice 
display a full rib at C7 that is directly attached to the sternum (indicated by asterisk). (B and D) Btg1-/- and 
Btg1-/-;Btg2-/- embryos show often a reduction in the amount of ossified sternebrae (indicated by arrow) 
compared to wild-type. (C) Btg2-deficient mice display occasionally an extra sternebra (indicated by arrow).
Wild-type Btg1-/- Btg2-/- Btg1-/-;Btg2-/-A B C D
Figure 2
* C7 * C7 C7* C7*
Targeted deletion of Btg1 and Btg2 results in homeotic transformation of the axial skeleton
205
7
of the adjacent posterior T1 vertebra, which is therefore termed posterior homeotic 
transformation. While Btg1-deficient mice with a C7 to T1 transformation displayed a 
fusion of the T1 to the T2 rib without direct attachment to the sternum (Figure 2B), loss 
of Btg2 resulted in both fusion of the T1 to T2 rib as well as direct attachment of the 
T1 rib to the sternum (Figure 2C). The Btg1-/-;Btg2-/- double knockout mice displayed 
a more complete and stronger phenotype, where all mice displayed an extra rib at 
C7, and in 82% of mice the T1 rib was directly attached to the sternum (Figure 2D).
Normally, the first seven pairs of ribs (T1-T7) form sternocostal junctions with the 
sternum, where five ossified sternebrae can be distinguished as well as the posterior 
xiphoid process. In the Btg1-/- and Btg2-/-  mice we observed that in about 5% of the 
animals the T7 rib at one side was not attached to the sternum. However, a more 
severe phenotype was observed in the Btg1-/-;Btg2-/- mice, where 36% of the animals 
displayed attachment of T7 on only one side and 27% lost the sternocostal junctions of 
T7 on both sides and had only six ribs attached to the sternum (Table 3). Interestingly, 
we observed ectopic ossification centers in the sternum of Btg2-deficient animals, 
which resulted in supernumerary sternebrae in 20% of the mice (Figure 2C), probably 
due to the posterior homeotic transformation. On the other hand, the Btg1-deficient 
mice showed a reduced number of ossified sternebra(e), where the fourth and fifth 
sternebra lacked mineralization in 62% of mice, which was observed with much lower 
penetrance in Btg2-/- (10%) and Btg1-/-;Btg2-/- mice (27%) (Figure 2B-2D). During sternal 
development, ossification of the cartilage is inhibited at the site where the ribs contact 
the sternal rudiments. Therefore, this process may become disturbed in the Btg1-/- 
mice due to formation of inappropriate connections between the ribs and sternum. 
In addition, one Btg1 knockout embryo showed an asymmetric pattern of ossification 
of the sternebrae, which was even more severe in another mouse lacking both Btg1 
and Btg2 expression (Figure 3). Presumably, this type of sternal malformation, called 
crankshaft sternum, results from incorrect positioning of the attachment points of the 
costal cartilages on either sides of the sternal bar. In conclusion, these data show that 
both Btg1 and Btg2 regulate specification of cervical and thoracic vertebrae, whereas 
Btg1 has a dominant function in regulating sternal ossification. 
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Btg2 has a unique role in mediating homeotic transformation at the thoracic-lumbar 
region of the axial skeleton
The rib pairs derived from T8 to T13 are termed “false ribs”, since they do not connect to 
the sternum. Instead, the T8 to T11 ribs form cartilaginous connections with the adjacent 
ribs, while T12 and T13 are considered floating ribs, since they form no connections 
to adjacent rib pairs (Figure 4A). Deletion of Btg1 resulted in fourteen thoracic ribs in 
62% of mice, as a consequence of the extra rib at C7, without any evidence of posterior 
transformation at the thoracic-lumbar junction (Figure 4B/Table 3). In contrast, mice 
deficient for Btg2 displayed thirteen thoracic ribs as they acquired an extra rib at C7, 
while the thirteenth rib (T13) was often rudimentary or completely absent and acquired 
the identity of the first lumbar vertebra (L1) (Table 3). As a consequence, most Btg2-/- 
mice showed only twelve thoracic ribs compared to thirteen in wild-type animals, and 
all Btg2-/- mice displayed posterior homeotic transformation at the thoracic-lumbar 
junction (Figure 4C). Mice deficient for both Btg1 and Btg2 expression showed again 
normal numbers of thoracic ribs in 95% of the animals, since these mice displayed 
both C7 to T1 and T13 to L1 posterior transformations (Figure 4D/Table 3). These data 
demonstrate a unique function for Btg2 in regulating the regional identity of vertebra 
at the thoracic to lumbar transition. 
 
 
Figure 3. Targeted deletion of Btg1 and Btg2 results 
in malformation of the sternum. (A-B) Ventral view 
of the sternum with attached ribs of 18.5 dpc wild-type 
and Btg1-/-;Btg2-/- embryos stained with alizarin red and 
alcian blue. Wild-type C57BL6/J mice display normal 
ossification of the five sternbrae, whereas an asymmetric 
pattern of ossification of the sternebrae is observed in 
mice lacking both Btg1 and Btg2 expression. The xiphoid 
process (Xip) of the sternum is not affected in Btg1- and 
Btg2-deficient mice.
Wild-type Btg1-/-;Btg2-/-A B
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Vertebral transformation WT Btg1-/- Btg2-/- Btg1-/-;Btg2-/-
(n=18) (n=21) (n=20) (n=22)
Cervical region
C7  rudimentary rib 13 8 13 0
C7  T1 Fused (T1 to T2) 1 13 4 3
               Full 0 0 3 18
Thoracic region
Ossified Sternebrae
#1 18 21 20 22
#2 18 21 20 22
#3 18 21 20 22
#4 18 20 18 22
#5 18 9 14 16
#6 0 0 4 0
Asymmetric sternum 0 1 0 1
Number of Ribs
12 0 0 14 0
13 18 8 6 22
14 0 13 0 0
Ribs attached to sternum
6 0 0 0 6
6/7 0 1 1 8
7 18 20 19 8
Lumbar region
T13  L1 partial 0 0 4 0
                 complete 0 0 16 21
Sacral region
L5  S1 partial 0 0 0 5
complete 0 0 0 10
L6  S1 partial 0 5 0 1
               complete 0 1 20 6
 
Table 3. Skeletal malformations in Btg1- and Btg2-deficient mice
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Btg1 and Btg2 function are both required for specifying the vertebral identity at the 
lumbosacral region
Next, we examined the regional identity around the lumbosacral region of the axial 
skeleton in the Btg1- and Btg2-deleted mice. While Btg1 single knockout mice showed a 
partial or complete transformation of the sixth lumbar (L6) vertebra towards the identity 
of the first sacral vertebra (S1) with a penetrance of 29%, all Btg2-/- mice displayed a 
complete transformation of L6 to S1 resulting in 6 lumbar vertebra due to the T13 to 
L1 transformation (Table 3). Interestingly, we observed a more severe phenotype in 
mice lacking both Btg1 and Btg2 expression, which showed complete transformation 
of L6 to S1 in 27% of mice, a partial transformation of L5 to S1 with a penetrance of 
23% and a complete L5 to S1 transformation in 45% of the Btg1-/-;Btg2-/- mice (Figure 
5A-5C). As a consequence, mice with the L5 to S1 homeotic transformation had a 
reduction in the total amount of lumbar vertebrae. As a consequence of the L6 to S1 
and L5 to S1 transformations, an anterior shift was observed in the position of the 
hindlimb, which is normally always connected to the position of the first sacral vertebra. 
Together these results demonstrate that there is a synergistic requirement for both 
Btg1 and Btg2 expression in specifying the correct identity of the lumbar vertebrae.
 
Figure 4. Posterior homeotic transformation of the thirteenth thoracic vertebra in mice deficient for 
Btg2. (A-D) Dorsal view of the cervicothoracic region of the skeleton in 18.5 dpc wild-type, Btg1-/-, Btg2-/- 
and Btg1-/-;Btg2-/- embryos stained with alizarin red and alcian blue. (A-B) Wild-type C57BL6/J mice have 
thirteen thoracic ribs, while Btg1-deficient mice display fourteen ribs due to the extra extensive rib at C7. 
(D) Although the T13 rib is absent in Btg1-/-;Btg2-/- mice they still have thirteen thoracic ribs due to the C7 
to T1 posterior transformation.
Wild-type Btg1-/- Btg2-/- Btg1-/-;Btg2-/-A B C D
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Discussion 
The transcriptional cofactors Btg1 and Btg2 represent homologous proteins that regulate 
cellular proliferation and differentiation in different cell lineages. It was  shown previously 
that  Btg2 is expressed in the presomitic mesoderm (PSM)-tail bud region of the mouse 
as well as in developing somites and that Btg2 is involved in normal patterning of axial 
vertebrae [23]. However, a role for Btg1 in regulating the development and regional 
specification of the mouse skeleton has not been reported so far. In this study, we used 
both Btg1- and Btg2-single and double deficient mice, to show that both genes play 
an essential role in conferring positional information along the anterior-posterior axis 
of the skeleton. Interbreeding of Btg1 and Btg2 homozygous knockout lines resulted 
in a smaller litter size and a non-mendelian inheritance pattern for the Btg1 single 
knockout crosses and the Btg2 knockout allele in the compound crosses. Btg1 and 
Btg2 are separately implicated in regulating patterning of the lower cervical region, but 
the combined action of both genes is required for specifying the correct identity of the 
seventh cervical  and the sixth lumbar vertebra. On the other hand, Btg2 expression 
appears to be more uniquely involved in the specification of the vertebra at the thoracic-
lumbar junction (Figure 6). 
Figure 5. Btg1;Btg2 double knockout mice display posterior homeotic transformation at the lumbo-
sacral transition. Skeletal defects in 18.5 dpc wild-type, Btg1-/- and Btg1-/-;Btg2-/- embryos. (A-C) Dorsal view 
showing the lumbar-sacral regions. (B) Btg1-/-;Btg2-/-  mice frequently show five lumbar vertebrae compared 
to six in wild-type mice. (C) Btg1-/- mice may show asymmetric L6 in which the right side (indicated by arrow) 
indicates a lumbar vertebra and the left side a sacral vertebra.
A BWild-type Btg1-/-;Btg2-/- Btg1-/-C
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Our studies demonstrate that deletion of both Btg1 and Btg2 results in an aggravated 
phenotype, revealing a synergistic effect upon a combined loss of these genes. An 
extra rib at the seventh cervical vertebra was observed with a low incidence in the 
Btg2 knockout mice, and posterior homeotic transformation at this position was more 
pronounced in the absence of Btg1 expression. In 95% of the Btg1-/-;Btg2-/- double 
knockout mice a complete C7 to T1 transformation was observed, arguing that the 
action of both genes is required for instructing the proper identity of the seventh cervical 
vertebra. In agreement with previous studies, we found that Btg2-/- mice displayed 
homeotic transformation of the thirteenth thoracic vertebra. In contrast, Btg1-deficiency 
had no significant impact on regulating the identity of this last thoracic vertebra, which 
was also evident from the fact that the double knockout showed a phenotype similar 
to the Btg2-/- mice at the thoracic-lumbar junction. Both Btg1- and Btg2-deficient mice 
displayed partial or complete homeotic transformation of the sixth lumbar vertebra 
towards the first sacral vertebra (L6 to S1), and this phenotype was even more severe 
in the Btg1-/-;Btg2-/- double knockout mice. Thus, Btg1 and Btg2 display both unique 
and overlapping functions along the anterior-posterior axis in regulating specification 
of vertebral identity.
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Figure 6. Overview of the skeletal phenotypes in Btg1- and Btg2-deficient mice. Axial vertebrae are 
indicated by different colors: green (cervical), yellow (thoracic), blue (lumbar) and red (sacral). The thoracic 
ribs are indicated by the grey horizontal lines, of which T1-T7 form sternocostal junctions with the sternum. 
Btg1- and Btg2-deficient mice display C7 to T1 posterior transformation, while Btg1-/- mice show also partial 
or complete L6 to S1.  Btg2-/- mice display in most cases T13 to L1 and complete L6 to S1 transformations. 
Btg1-/-,Btg2-/- double knockout animals display a more pronounced phenotype with C7 to T1, T13 to L1 and 
L6 to S1 homeotic transformations.   
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Deficiency of Btg1 resulted in reduced ossification of the distal sternebra(e) as 
a consequence of delayed ossification within the sternal bands. We also observed 
abnormal ossification of the sternum where the corresponding costal cartilages invariably 
inserted into the sternum at different levels at the two sides leading to an asymmetric 
sternum, known as “crankshaft sternum” [29]. Endochondral bone ossification is 
regulated by several different signaling pathways, including the action of Runx1 and 
Runx2 transcription factors [30, 31]. However, it remains to be established whether 
these defects are primarily the consequence of endochondral ossification defects, or 
occur secondary to inappropriate connections made between the rib ends and the 
sternum.
Previously, Btg2 has been considered to regulate skeletal development by modulating 
BMP/Smad signaling, but the skeletal abnormalities observed in the Btg1- and Btg2-
deleted mice are more reminiscent of the phenotype of several knockout mouse models 
deficient in Polycomb group genes (PcG), including Bmi1, Mel18 and M33 [32-35]. 
In addition, similar abnormalities have been described for mice deficient in E2f6 and 
the spliceosomal protein Sf3b1, which are known to associate with a number of PcG 
proteins. The interaction of PcG proteins with Sf3b1 and E2f6 is essential for the 
PcG-mediated repression of Hox genes [36-40]. Compared to single PcG mutants, 
the Bmi1-/-;M33-/- and E2f6-/-;Bmi1-/- double knockout mice reveal extended skeletal 
transformations [35, 41], due to enhanced deregulation and loss of direct transcriptional 
control of the Hox genes.
Taken together, our data show that Btg1 and Btg2 play an important role in anterior-
posterior patterning along the vertebral column and both genes fulfill largely overlapping 
functions in specifying the correct positional identity.
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Summary 
B-cell translocation gene 1 (BTG1) and BTG2 belong to the family of anti-proliferation 
genes and share 74% identity in protein sequence, suggesting that they fulfill 
overlapping functions [1, 2]. BTG1 and BTG2 act as transcriptional cofactors that 
modulate transcription through recruitment of specific effector molecules, such as protein 
arginine methyltransferase 1 (PRMT1) [3, 4]. BTG1, in association with the arginine 
methyltransferase PRMT1, positively modulates glucocorticoid receptor mediated gene 
expression in leukemia cell lines (Chapter 3) [5]. Moreover, loss of BTG1 protects 
cells from cellular stress mediated apoptosis, and BTG1 regulates PRMT1-mediated 
arginine methylation of ATF4 [6]. Both BTG1 and BTG2 are involved in critical cellular 
processes such as proliferation, differentiation and apoptosis, whereas deregulation 
of these tumor suppressor genes has been associated with various types of cancer 
[7-10] (Chapter 1). Deletions affecting the BTG1 gene are observed in 9% of B-cell 
precursor acute lymphoblastic leukemia (BCP-ALL) cases, while both BTG1 and BTG2 
are subjected to missense mutations in diffuse large B-cell lymphomas (DLBCL) [7, 
11, 12].
Hematopoietic stem cells differentiate into B-cell progenitors via the coordinated 
action of key transcription factors, such as RUNX1, IKZF1, E2A, EBF1 and PAX5 
[13, 14]. Deregulation of these key determinants of B-cell development is frequently 
observed in B-cell neoplasms, including BCP-ALL [15, 16] (Chapter 1 and 2). BCP-ALL 
is a heterogeneous disease, characterized by various genetic aberrations, including 
chromosomal translocations, gene deletions and point mutations. In the last decade, 
we have begun to understand the essential contributions of driver mutations and 
cooperating genetic events in BCP-ALL. Many of the chromosomal translocations, 
including ETV6-RUNX1 and BCR-ABL1, constitute oncogenic drivers, however it is 
evident from previous studies that additional copy number alterations (CNAs) and 
mutations are required to induce overt lymphoblastic leukemia [17]. These lesions 
disrupt normal B-lymphoid development and target transcription factors as well as 
different proteins involved in cell cycle regulation, cytokine signaling and epigenetic 
regulation [7, 18]. Moreover, therapy-induced selection of minor sub-clones may lead to 
therapy resistance and promote relapse. The mechanisms that contribute to leukemic 
transformation are complex and require more precise understanding before novel 
targeted therapies can be developed (Chapter 1 and 2). 
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Synthetic glucocorticoids (GCs) are cornerstone drugs in the treatment of children 
with BCP-ALL. A poor response to GC therapy at the start of induction treatment predicts 
an adverse outcome. As BTG1 deletions frequently occur in BCP-ALL and members 
of the BTG1/TOB family have been implicated in nuclear receptor signaling [19], we 
investigated a potential role for BTG1 in GC therapy resistance. The experiments 
described in Chapter 3 demonstrate that loss of BTG1 expression contributes to 
glucocorticoid resistance in pre-B ALL cell lines. Knockdown of BTG1 in the pre-B ALL 
cell line RS4;11 leads to strongly reduced expression of the Glucocorticoid receptor 
(GR) and consequently a failure to induce GC target genes in response to GC exposure. 
In line with these findings, a BTG1 transgene rescues GR expression and GC therapy 
responses in REH pre-B ALL cells. Finally, chromatin immunoprecipitations (ChIP) 
revealed an association between PRMT1 and the promoter regions of BTG1 and 
NR3C1 (GR) in response to GC exposure, whereas this interaction was no longer 
present in the BTG1 knockdown cells. Overall, these data demonstrate that BTG1 is 
a novel determinant of GC-induced apoptosis that acts by regulating GR-mediated 
gene expression. 
As there is accumulating evidence that genetic alterations affecting BTG1 and BTG2 
contribute to the development of B-cell malignancies, we studied their role in normal 
B-cell development using Btg1 and Btg2 knockout mouse models. In Chapter 4, we 
showed that the combined loss of Btg1 and Btg2 impaired B-cell differentiation at the 
early stages of development. Deficiency for either Btg1 or Btg2 showed moderate 
effects on the frequencies of pro- and pre-B cells, which was more pronounced in 
the absence of both Btg1 and Btg2. Deficiency of Btg1, but not Btg2, impaired the 
outgrowth of IL-7 dependent lymphoid progenitors in methylcellulose cultures. These 
data show that Btg1 and Btg2 display both unique and overlapping functions during 
B-cell development. Moreover, microarray and targeted expression analysis of Btg1-
/-;Btg2-/- progenitor B-cells revealed induction of T-cell lineage genes, which partially 
resembled the phenotype of Ebf1 and Pax5 knockout mice. Together, these data 
suggest that the block in B-cell development observed in BCP-ALL may arise from gene 
alterations in master regulators of B-cell differentiation, like BTG1, EBF1 and PAX5. 
BTG1 deletions occur frequently in BCP-ALL and were found to be enriched in specific 
cytogenetic subtypes, including ETV6-RUNX1 and BCR-ABL1-positive leukemias [20]. 
The experiments in Chapter 5 demonstrated that Btg1-deficiency enhanced ETV6-
RUNX1-mediated self-renewal of primitive lymphoid progenitor cells derived from the 
fetal liver, which involved upregulation of proto-oncogene Bcl6 and downregulation 
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of tumor suppressor genes p19Arf and Tp53 that are known transcriptional targets of 
oncoprotein BCL6. In line with these findings, ectopic expression of BCL6 in fetal liver-
derived hematopoietic progenitor cells (FL-HPCs) resulted in prolonged clonogenic 
replating capacity. Furthermore, loss of BTG1 combined with ETV6-RUNX1 in NALM6 
cells resulted in an upregulation of BCL6 expression. By co-immunoprecipitation we 
found that PRMT1 was recruited to an ETV6-RUNX1 containing complex, whereas 
this interaction is lost in absence of Btg1, demonstrating that Btg1 is required for the 
interaction between PRMT1 and ETV6-RUNX1. The functional implications of these 
interactions and their effect on leukemic transformation remain to be established.
BTG1 has been identified as potential tumor suppressor gene, as deregulated 
expression of this gene is associated with various types of cancer (Chapter 1). Our 
observation that loss of Btg1 enhances ETV6-RUNX1-induced self-renewal of FL-
HPCs is in agreement with its function as tumor suppressor (Chapter 5). In addition, 
BTG1 gene deletions co-occur with other genetic aberrations in BCP-ALL, such as 
IKZF1 gene deletions [20]. In Chapter 6, we demonstrated that single copy loss of 
BTG1 is significantly enriched in IKZF1-deleted BCP-ALL. Moreover, the combined 
presence of BTG1 and IKZF1 deletions is associated with a markedly lower event-free 
survival and higher cumulative incidence of relapse in pediatric BCP-ALL patients. 
We provided further evidence for the leukemia suppressive function of Btg1 showing 
that Btg1-deficient mice develop T-cell leukemia, albeit with a low incidence and after 
a long latency period. Furthermore, we showed that T-cell leukemia in Ikzf1+/- mice is 
strongly accelerated by the loss of either one or two copies of the Btg1 gene. These 
data provide in vivo evidence that Btg1 acts as a bona-fide leukemia suppressor gene 
and cooperates with Ikzf1 in leukemia development. 
Similar to BTG1, the tumor suppressor gene BTG2 is also found to be deregulated 
in solid tumors whereas missense mutations are found in B-cell lymphomas (Chapter 
1). Our data demonstrated that similar to Btg1-deficient mice, Btg2-/- as well as Btg1-/-
;Btg2-/- mice developed T-cell leukemia, but still with a very low incidence and after a long 
latency period. Moreover, our data revealed no cooperation in leukemia development 
between the tumor suppressors Btg1 and Btg2. 
Several genes involved in hematological malignancies also play a key role in skeletal 
development, such as the Hox and polycomb group (PcG) genes [21, 22]. Previously, 
it was shown that loss of Btg2 gives rise to posterior homeotic transformations of the 
axial vertebrae which has been attributed to impaired BMP/Smad signaling [23]. In 
Chapter 7, we not only confirmed these findings, but also demonstrated that Btg1-
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/- mice display similar posterior homeotic transformation, which was evident by an 
identity shift of the seventh cervical vertebra (C7) into the first thoracic rib (T1) as has 
been observed in Btg2-deficient mice. However, Btg1-/- mice showed no evidence of 
posterior transformation at the transition from the thoracic to lumbar vertebra as present 
in Btg2-/- mice. On the other hand, there was a partial transformation of the sixth lumbar 
vertebra (L6) to the first sacral vertebra (S1), which was even more pronounced in the 
Btg1-/-;Btg2-/- double knockout mice. Overall, these data demonstrate that both Btg1 
and Btg2 fulfill a role in specifying the regional identity of the axial skeleton. 
General discussion 
Acute lymphoblastic leukemia is the most frequently observed cancer in children. 
Although cure rates are approaching 90%, relapse and associated therapy resistance 
remain a major clinical problem [17, 24]. Monoallelic deletions affecting the BTG1 gene 
are found in about 9% of BCP-ALL patients [7, 18]. In addition, BTG1 and its closest 
relative BTG2 are also subject to genetic aberrations in DLBCL [11, 12]. Although 
a number of studies have provided insight into the function of BTG1 and BTG2 in 
their ability to regulate proliferation and differentiation, their role during normal and 
malignant B-cell development had not been determined. In this thesis we have used 
Btg1 and Btg2 single and double knockout mice to study their function during normal 
hematopoiesis and specification of the axial skeleton. Apart from their role in neuronal 
stem and progenitor cell proliferation and differentiation, little is known about the effects 
of Btg1 and Btg2 loss on normal development [25-27]. In addition, we have studied the 
effects of BTG1 loss on proliferation and therapy response using knockout mice as well 
as human ALL cell models. Finally, we have investigated if and how Btg1-deficiency 
synergizes with other cooperating genetic events during leukemic transformation.  
Role of BTG1 in GC-induced apoptosis 
Resistance to glucocorticoids is a major clinical problem in the treatment of children 
with ALL, but the underlying mechanisms are not well understood [28, 29]. Although 
in vitro studies revealed that mutations in the glucocorticoid receptor (GR) can give 
rise to therapy resistance [30-32], acquired somatic mutations are rarely found in 
ALL patients [33]. We reported in Chapter 3 that BTG1 is a novel determinant of GC-
induced therapy responses that acts by regulating GR-mediated gene expression as 
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well as GR autoinduction. Although these experiments would suggest that BTG1 copy 
number losses are associated with (GC) therapy resistance in the patient, this appears 
to be highly dependent on the genetic context. Whereas in most patient groups, BTG1 
losses are not associated with an unfavorable outcome, patients carrying a (single 
copy) deletion of both BTG1 and IKZF1 at diagnosis, have an extremely high relapse 
probability (Chapter 6). Consistent with these findings, preliminary data show that 
the combined loss of BTG1 and IKZF1, both in mouse primary B-cells and human 
leukemia cell line models, renders these cells highly resistant to GC-induced apoptosis 
(R.Marke, unpublished data).
BTG1 interacts with and regulates the activity of protein arginine methyltransferase 
PRMT1 [3, 4]. PRMT1 is a global regulator of gene expression, and it was shown 
that disruption of PRMT1 function can contribute to leukemia formation [34]. PRMT1 
specifically methylates arginine residues on histone 4 (H4R3) [35] and is a coactivator 
of several nuclear receptors, such as HNF4 [36, 37], ER [38] and FXR [39]. Moreover, 
our laboratory recently showed that BTG1 promotes PRMT1-mediated ATF4 function in 
response to cellular stress [6]. Consistent to these findings, we describe in Chapter 3 that 
PRMT1 associates with the promoter regions of BTG1 and the GR in a BTG1-dependent 
manner. In conclusion, our data show that the BTG1/PRMT1 complex is involved in 
GR-mediated gene expression and that deregulation of this nuclear receptor coactivator 
complex can give rise to GC resistance. We are currently performing experiments 
involving RNA sequencing, to study the molecular mechanisms of glucocorticoid therapy 
resistance using peripheral B-cells of Btg1- and Ikzf1-deficient mice.  
Btg1 and Btg2 regulate normal B-cell development
Both Btg1 and Btg2 were shown to promote mouse B-cell differentiation displaying 
overlapping functions at multiple stages during B-cell development, while Btg1 regulated 
the proliferative expansion of IL-7 dependent B-cell progenitors in vitro by inhibition 
of apoptosis (Chapter 4). In line with these findings, Btg2 was found to regulate 
differentiation of neurons during hippocampal neurogenesis, whereas Btg1 in neuronal 
progenitors regulates self-renewal and quiescence of the pool of neural stem and 
progenitor cells by promoting cell cycle progression and survival through regulation 
of cyclin D1 expression [26, 27, 40-42] (Chapter 1). These in vivo studies seem to 
be in contrast with the original observations showing that BTG1 overexpression in 
NIH3T3 cells negatively affects cell proliferation [43] (Chapter 1), suggesting that the 
effects of BTG1 on cell function are dependent on cell type or stage of development. 
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Alternatively, supra-physiological concentrations of BTG1 may induce alternative cell 
biological effects as compared to normal endogenous BTG1 levels. In conclusion, our 
data show mostly overlapping functions for Btg1 and Btg2 during B-cell development 
in vivo. This is consistent with the observation that deletions or mutations affecting 
these tumor suppressor genes are a frequent event in B-cell malignancies like BCP-
ALL and lymphomas [7, 11, 12, 18, 44, 45]. Similar to BTG1, B-cell transcription 
factors such as EBF1 and PAX5 are also commonly found mutated or deleted in B-cell 
malignancies [7, 18]. 
It has become evident that cross-regulatory networks among the transcription factors 
E2A, EBF1 and PAX5, rather than a simple one-directional hierarchy, contribute to 
imprinting the B-lymphoid signature and regulating B-cell differentiation [46]. Early 
B-cell factor 1 (EBF1) is a key transcription factor driving expression of genes required 
for B lineage specification and commitment, whereas it antagonizes the expression of 
genes that specify alternative lineages [47, 48]. At later stages of B-cell differentiation, 
EBF1 is essential for the development of the B-1 and marginal zone B-cells and 
maintenance of follicular B-cells [49, 50]. Recently, the Runx1-Cbfβ complex was 
found to facilitate B-lineage specification, in part by epigenetic activation of the Ebf1 
gene [14]. The experiments described in Chapter 4 suggest that Btg1 and Btg2 
regulate B-cell differentiation possibly by modulation of EBF1 or PAX5 activity, since 
expression of Pax5 and Ebf1 itself was not inhibited, while their known target genes 
like Cd4, Ikzf2, Tcf7, Gata3 and Notch1 in progenitor B-cells derived from Btg1-/-;Btg2-/- 
mice were derepressed. This finding supports the notion that Btg1 and Btg2 function 
as transcriptional cofactors that probably act through recruitment of other effector 
molecules. Btg1- and Btg2-deficient mice showed a moderate reduction in B-cell 
numbers in bone marrow and spleen (Chapter 4), which is similar to Ebf1 haplodeficient 
mice that display a moderate decrease in B-cells [51] (Chapter 1). However, more 
experiments are required to determine the molecular mechanism by which BTG1 
and BTG2 modulate EBF1 function, which will include arginine methylation assays 
and ChIP-Seq experiments to assess whether EBF1 becomes directly methylated by 
PRMT1 and BTG1/PRMT1 complex is recruited to EBF1 target sites. 
  
Tumor suppressive functions of Btg1 and Btg2 in lymphoid malignancies
Deregulated expression of human BTG1 and BTG2 is observed both in solid tumors 
as well as in hematological cancers. In solid tumors, reduced expression of BTG1 and 
BTG2 has been correlated with the pathogenesis and prognosis of various cancers 
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[8, 10, 52] (Chapter 1), suggesting that induction or stabilization of BTG1 or BTG2 
expression may be an effective anti-tumor strategy. However it was not well understood 
whether loss of BTG1 and BTG2 actively contributed to malignant transformation in 
these neoplasms. 
The studies described in this dissertation demonstrate that loss of Btg1 indeed 
contributes to enhanced self-renewal and leukemic transformation (Chapter 5 and 
6), supporting its role as leukemia suppressor gene. In line with the finding that BTG1 
deletions are enriched in ETV6-RUNX1-positive BCP-ALL [20], we reported in Chapter 
5 that Btg1-deficiency, combined with ETV6-RUNX1 expression, results in enhanced 
self-renewal of primitive fetal-liver derived hematopoietic progenitor cells (FL-HPCs) by 
upregulation of the proto-oncogene Bcl6. During normal B-cell development, regulation 
of Tp53 by BCL6 is a key step in the control of DNA damage repair and apoptosis, 
whereas feedback regulation of BCL6 by Tp53 ensures that BCL6 does not interfere 
with p53 function [53]. Our data show that the tumor suppressors Tp53 and p19Arf 
are repressed in the ETV6-RUNX1 expressing FL-HPCs, resulting in uncontrolled 
cell growth. Expression of BCL6 in FL-HPCs leads to a similar increase in clonogenic 
replating capacity. Validation of known BLC6 target genes reveal similar regulation of 
Tp53, p19Arf and Bcl2 genes. In addition to its function as a determinant of leukemic 
stem cell survival in CML and BCR-ABL1 positive ALL [54, 55], our findings identify 
BCL6 as a potentially important driver of ETV6-RUNX1-induced self-renewal. It was 
shown that BCL6 expression is dependent on signaling by the PI3K/AKT and JAK/
STAT pathways in BCR-ABL1-positive ALL [54], which remains to be established for 
ETV6-RUNX1 positive ALL. In agreement with our findings in FL-derived cells, loss 
of BTG1 combined with ETV6-RUNX1 in NALM6 cells resulted in increased BCL6 
expression. Future studies should reveal whether BCL6 inhibitors are effective in the 
treatment of ETV6-RUNX1 positive BCP-ALL or other BCP-ALL subtypes. Moreover, 
it will be important to study whether ETV6-RUNX1 binds directly to BCL6 promoter 
by performing ChIP-Seq experiments. In line with this, the effect of ETV6-RUNX1 on 
BCL6 expression can be further examined by silencing ETV6-RUNX1 expression in the 
NALM6 BTG1-knockdown cells as well as ETV6-RUNX1-positive leukemia cell lines. 
To further establish cooperation between Btg1 loss and ETV6-RUNX1 in leukemia 
development, transplantation experiments were performed in which wild-type and Btg1-
deficient FL-HPCs were transduced with either control or ETV6-RUNX1 retrovirus into 
lethally irradiated recipient mice. Unfortunately, these experiments were uninformative, 
due to low levels of donor cell engraftment. These problems may be circumvented 
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by intercrossing Btg1-deficient mice with ETV6-RUNX1 transgenic knock-in mice. 
Surprisingly, Btg1-deficiency resulted in recipient-derived T-cell malignancies in some 
of the mice, suggesting that loss of Btg1 may produce non cell-autonomous effects. 
This observation is similar to previous studies investigating the role of the oncogene 
Notch1 and loss of the tumor suppressor p53 in development of leukemia/lymphoma 
in mice, demonstrating that tumor development may be induced through modification 
of neighboring cells [56, 57]. Although this is an interesting observation, future studies, 
e.g. transplantation of wild-type and Btg1-deficient FL-HPCs are necessary to exclude 
that the leukemia phenotype and the non cell-autonomous effects are caused by 
integrations of the retroviral vectors used. 
ETV6-RUNX1 has been identified as a constitutive repressor of transcription [58, 59], 
but despite extensive research, the exact mechanism by which it promotes leukemic 
transformation remains poorly understood. Our findings suggest that regulation of ETV6-
RUNX1 function involves the arginine methyltransferase PRMT1, which is recruited 
to the ETV6-RUNX1 complex in a Btg1-dependent manner (Chapter 5). In previous 
studies, it was shown that PRMT1 methylates RUNX1, abrogating the interaction 
between RUNX1 and co-repressor Sin3A, favoring transcriptional activation of RUNX1 
target genes [60]. More recently, the role of PRMT1 in regulation of AML1-ETO fusion 
protein was investigated, showing recruitment of PRMT1 to AML1-ETO target genes, 
promoting transcriptional activation. Moreover, knockdown of PRMT1 was found to 
suppress the self-renewal capacity of AML1-ETO [61]. Based on these observations, 
we postulate that PRMT1 methylates the oncogenic ETV6-RUNX1 fusion protein, 
which may alter the transcriptional repression properties of ETV6-RUNX1, although 
the exact functional consequences of this modification remain to be established. 
It will be important to investigate how ETV6-RUNX1 is regulated by PRMT1 using 
in vitro methylation assays and by generating ETV6-RUNX1 methylation mutants. 
Furthermore, PRMT1 inhibitors may be used to assess the effects of methylation on 
ETV6-RUNX1-mediated target gene regulation. These studies will demonstrate if 
and how manipulating PRMT enzymes can be used to block ETV6-RUNX1 activity 
in BCP-ALL. 
Gene deletions affecting transcriptional regulators of B-cell differentiation like E2A, 
PAX5 and IKZF1, frequently occur in B-cell malignancies, and co-occur with other 
genetic events before overt leukemia develops (Chapter 1 and 2) [7, 18]. In agreement 
with previous findings, we found that single copy losses of BTG1 co-occur with IKZF1 
deletions across different cytogenetic subgroups (Chapter 6) [20, 62]. Furthermore, we 
Chapter 8
226
observed that BTG1 and IKZF1 deletions are associated with lower event-free survival 
and higher cumulative incidence of relapse (Chapter 6). Earlier observations identified 
the presence of these lesions in such distinct BCP-ALL subgroups may relate to the 
fact that both deletion of IKZF1 and BTG1 appears to be the result of from illegitimate 
RAG-mediated recombination [20] and AID [63]. In agreement with the findings of 
Moorman et al. showing that the combined presence of specific deletions affect the 
outcome of BCP-ALL, we found that only BTG1 worsens the outcome of IKZF1-deleted 
ALL in contrast to other common copy number losses such as CDKN2A/B, PAX5, 
EBF1 and RB1 [64].  
Knockout mouse models for B-cell specific tumor suppressor genes have provided 
insights into their roles during normal and malignant B-cell development. However 
these mouse models do not consistently reflect the human phenotype, for example 
E2a-/- [65] and Ikzf1+/- [66] mice develop T-cell malignancies, while in humans deletions 
in these genes predominantly are associated with BCP-ALL (Chapter 2). As BTG1 
regulates normal B-cell differentiation and deletions affecting this gene specifically 
occurs in B-cell malignancies (Chapter 1 and 4) [7, 18], we hypothesized that loss of 
Btg1 in mice might lead to B-cell neoplasms. However, similar to E2a-/- and Ikzf1+/- mice, 
we observed T-cell leukemia in the Btg1-deficient mice, although with a low incidence 
(Chapter 6). As mentioned previously, BTG1 deletions co-occur with IKZF1 deletions 
(Chapter 6), suggesting that these genes cooperate in leukemia development. We 
observed tumors with only a low incidence in heterozygous Ikzf1 mice (Chapter 6). 
This is in contrast with transgenic Ikzf1 mouse models expressing dominant negative 
isoforms, which were reported to be highly susceptible for T-cell malignancies [67-
69]. Further evidence for the tumor suppressive function of Btg1 is provided by the 
enhanced leukemia development observed in Btg1+/-;Ikzf1+/- and Btg1-/-;Ikzf1+/- mice. 
These compound mice not only displayed increased tumor incidence but also an 
accelerated onset of disease in a Btg1 dose dependent manner, indicating that the 
Btg1 and Ikzf1 tumor suppressor genes cooperate during leukemia development 
(Chapter 1, 2 and 6). It will be important to study the molecular mechanisms by which 
combined loss of Btg1 and Ikzf1 affects gene expression programs and/or signaling 
pathways leading to malignant transformation, for instance by performing extensive 
gene expression analysis using RNA sequencing. 
Similar to BTG1, point mutations affecting the BTG2 gene are identified in DLBCL, and 
missense mutations in BTG2 were also identified in Burkitt and follicular lymphoma [11, 
12, 44, 45]. Both BTG1 and BTG2 appeared to be targets of AID, which is responsible 
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for mutating these genes [70]. We followed the Btg2 knockout mice till the age of 18 
months for the development of hematological malignancies. Similar to Btg1-/- and 
Ikzf1+/- mice, we observed T-cell leukemia in the Btg2-deficient mice, albeit with a low 
incidence and after a long latency (Chapter 6 supplement).  
 
A role for Btg1 and Btg2 in axial patterning of the skeleton
Hox and Runx genes play an important role in the differentiation of hematopoietic 
cells, and also determine the identity of the axial skeleton and axis extension [71, 72]. 
Deregulation of these gene families is frequently observed in hematological malignancies 
[71, 73]. Moreover it was found that children with hematological malignancies show 
an increased incidence of congenital abnormalities affecting the expression of Hox 
genes. An association between skeletal abnormalities and leukemia is suggested by 
the observation that children with ALL show an increased incidence of an extra rib at 
the seventh cervical vertebrae [74, 75]. Although we have no formal proof that Btg1 
regulates Hox gene expression, the cervical rib abnormalities observed in Btg1 and 
Btg2 knockout mice are highly similar to those found in Hox mutant mice as well as 
mice carrying mutations in PcG and trithorax group genes, which are critical regulators 
of Hox gene expression [76-81].
Consistent with previous findings that suggest a role for Btg2 in vertebral patterning, 
we demonstrated in Chapter 7 that both Btg1 and Btg2 fulfill unique and overlapping 
functions in specification of the axial vertebrae. While the previously described posterior 
homeotic transformations in Btg2-deficient mice have been attributed to impaired 
BMP/Smad signaling [23], we interpret that the phenotypes observed in Btg1- and 
Btg2-deficient mice are more similar to those seen in PcG knockout mice [80, 82-84]. 
As the PcG proteins regulate expression of Hox genes [85-87], we postulate that 
Btg1 and Btg2 may either directly or indirectly affect the expression of Hox genes, 
perhaps by regulating the function of PcG or their antagonists, such as the MLL protein 
complex. Alternatively, it has been reported that BTG1 and BTG2 can directly interact 
with HoxB9 to enhance its transcriptional activation, whereas BTG2 also associates 
with HoxC8 [88] (Chapter 1). Hence, it cannot be excluded that Btg1 or Btg2 directly 
affect the function of multiple Hox proteins. In situ hybridization studies may provide 
more insights into Hox gene regulation by Btg1 and Btg2 during axial patterning of 
the skeleton. 
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Overall conclusion  
The data described in this thesis provide a detailed insight into the roles of Btg1 and 
Btg2 during normal hematopoiesis and axial patterning of the skeleton. We show that 
Btg1 and Btg2 predominantly regulate B-cell differentiation, which is consistent with 
the fact that genetic aberrations affecting the BTG1 and BTG2 gene specifically occur 
in B-cell malignancies. Furthermore, we show that BTG1 regulates the glucocorticoid 
receptor by modulating GR-mediated gene expression, and deregulation of the BTG1 
gene can give rise to glucocorticoid resistance. Moreover, we provide evidence for 
the tumor suppressive function of Btg1 in the development of T-cell leukemia and 
demonstrate that it impact the outcome of IKZF1-deleted BCP-ALL, although the exact 
molecular mechanism remains to be established. 
BTG1 and BTG2 may suppress leukemogenesis in BCP-ALL and DLBCL by regulating 
EBF1 function, but also deregulation of other molecular pathways could be involved, 
such as the BCL6 pathway. BCL6 is the most frequently affected oncogene in DLBCL 
and a critical determinant of leukemic stem cell survival in CML and BCR-ABL1 positive 
ALL. Our finding that the proto-oncogene BCL6 is strongly upregulated in Btg1-defcient 
FL-HPCs expressing ETV6-RUNX1 suggests that inhibition of BCL6 could be effective 
in eradication of leukemia-initiating cells in ETV6-RUNX1 positive ALL. In mouse 
preclinical models inhibition of BCL6 by the peptide inhibitor RI-BPI was shown to be 
effective in the eradication of leukemia-initiating cells [54, 55]. 
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B cel translocatie gen 1 (BTG1) en BTG2 behoren beiden tot de familie van antiproliferatie 
genen. Op eiwitsequentie niveau zijn deze twee eiwitten voor 74% gelijk, wat suggereert 
dat deze overlappende functies hebben. BTG1 en BTG2 zijn zogenaamde transcriptie co-
factoren die de mRNA transcriptie beïnvloeden door het recruteren van specifieke effector 
moleculen, zoals het eiwit arginine methyltransferase 1 (PRMT1), naar transcriptie 
factor complexen. Zowel BTG1 als BTG2 zijn betrokken bij belangrijke processen in de 
cel, zoals proliferatie, differentiatie en apoptose waarbij een verstoring in de regulatie 
van deze genen geassocieerd is met verschillende vormen van kanker (Hoofdstuk 
1). BTG1 deleties worden frequent gedetecteerd in voorloper-B-cel acute lymfatische 
leukemie (voorloper-B-cel ALL), terwijl mutaties in zowel BTG1 als BTG2 zijn gevonden 
in diffuus grootcellig B-cellymfoom. Hematopoiëtische stamcellen differentiëren in B-cel 
voorlopers door het samenspel van essentiële transcriptiefactoren, zoals RUNX1, 
IKZF1, E2A, EBF1 en PAX5. Ontregeling van deze essentiële B-cel transcriptiefactoren 
wordt vaak waargenomen in B-cel maligniteiten, o.a. voorloper B-cel ALL (Hoofdstuk 
1 en 2). Voorloper B-cel ALL is een heterogene ziekte die wordt gekenmerkt door 
verschillende genetische afwijkingen, inclusief chromosomale translocaties, gendeleties 
en puntmutaties. De afgelopen jaren is steeds meer inzicht verkregen in de essentiële 
bijdrage van zogenaamde “driver”-mutaties en coöpererende genetische afwijkingen 
in voorloper B-cel ALL. Veel van deze chromosomale translocaties, zoals ETV6-
RUNX1 en BCR-ABL1, zijn “driver”-mutaties, wat betekent dat ze noodzakelijk zijn 
voor het ontstaan en voortbestaan van de leukemie, hoewel naast deze drivers vaak 
additionele mutaties nodig zijn voordat acute lymfatische leukemie zich ontwikkeld. 
Laatstgenoemde mutaties verstoren vaak de normale B-cel ontwikkeling en de functie 
van transcriptiefactoren betrokken bij de celcyclus, cytokine signalering en epigenetische 
regulatie. Daarnaast kan therapie-geïnduceerde selectie van specifieke sub-klonen 
leiden tot een therapieresistente recidieven. De mechanismen die bijdragen aan het 
ontstaan van leukemie, of het optreden van recidieven, zijn complex en daarom is 
het van belang om deze processen in detail te bestuderen, zodat nieuwe specifieke 
therapieën ontwikkeld kunnen worden (Hoofdstuk 1 en 2). 
Synthetische glucocorticoïden (GCs) zijn essentiële geneesmiddelen tijdens de 
behandeling van voorloper B-cel ALL. De prognose voor kinderen met een matige 
tot slechte GC therapierespons aan het begin van de behandeling is dan ook minder 
goed. Het is bekend dat BTG1 deleties vaak voorkomen in voorloper B-cel ALL en 
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dat leden van de BTG1/TOB familie betrokken zijn bij nucleaire receptor signalering. 
Om die reden hebben wij een mogelijke betrokkenheid van BTG1 deleties bij GC 
therapieresistentie bestudeerd. De experimenten beschreven in Hoofdstuk 3 laten 
zien dat verlies van BTG1 expressie bijdraagt aan glucocorticoïd resistentie in voorloper 
B-cel ALL cellijnen. Verlies van BTG1 expressie in de voorloper B-cel ALL cellijn RS4;11 
resulteert in een sterke afname van de glucocorticoïd receptor (GR) expressie en als 
gevolg worden GR gereguleerde genen niet meer worden geïnduceerd na behandeling 
met GC. In overeenstemming met deze bevindingen zien we dat het verhoogd tot 
expressie brengen van BTG1 in REH voorloper B-cel ALL de GR expressie de respons 
op GC therapie herstelt. Daarnaast kon door middel van zogenaamde chromatine 
immunoprecipitaties (ChIP) worden aangetoond dat er een associatie is tussen PRMT1 
en de promoter regio’s van BTG1 en NR3C1 (GR), terwijl deze interactie niet meer 
aanwezig is in de BTG1 knockdown cellen. Globaal tonen deze data aan dat BTG1, 
door regulatie van GR-afhankelijke genexpressie een belangrijke effect heeft op GC 
geïnduceerde celdood.
Omdat er steeds meer bewijs is dat genetische afwijkingen van BTG1 en BTG2 
bijdragen aan de ontwikkeling van B-cel maligniteiten, hebben we de functie van deze 
genen bestudeerd tijdens normale B-cel ontwikkeling, door gebruik te maken van 
zogenaamde Btg1 en Btg2 ‘knockout’ muismodellen. In Hoofdstuk 4 wordt aangetoond 
dat een verlies van zowel Btg1 als Btg2 de vroege B-cel ontwikkeling beïnvloedt. 
Een verlies van Btg1 of Btg2 leidt tot een geringe afname in het aantal pro- en pre-B 
cellen, een effect dat sterker wordt in de afwezigheid van zowel Btg1 als Btg2. Btg1, 
maar niet Btg2-deficiëntie, resulteert in verminderde uitgroei van IL-7 afhankelijke 
lymfoïde voorlopers in celkweek met methylcellulose. Deze data tonen aan dat Btg1 
en Btg2 zowel unieke als overlappende functies hebben gedurende B-cel ontwikkeling. 
Daarnaast is doormiddel van gedetailleerde genexpressie analyses aangetoond dat 
het gecombineerd verlies van Btg1 en Btg2 in voorloper B-cellen aanleiding geeft tot 
de expressie van T-cel specifieke genen. Een soortgelijk fenotype wordt waargenomen 
in muizen die een deficiëntie hebben in de B-cel transcriptiefactoren Ebf1 of Pax5. 
Samenvattend, suggereren deze data dat verstoorde B-cel ontwikkeling in voorloper 
B-cel ALL een gevolg kan zijn van veranderingen in essentiële B-cel differentiatie 
genen, zoals BTG1, EBF1 en PAX5.
Naast deleties in EBF1 en PAX5, komen BTG1 deleties frequent voor in voorloper 
B-cel ALL. Laatstgenoemde deleties zijn verder verrijkt in specifieke cytogenetische 
subtypen, zoals ETV6-RUNX1 en BCR-ABL1-positive leukemie. De experimenten in 
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Hoofdstuk 5 tonen aan dat Btg1-deficiëntie de ETV6-RUNX1 afhankelijke prolongatie 
van vroege lymfoïde voorlopercellen versterkt door stimulatie van het proto-oncogen Bcl6 
en repressie van de tumorsuppressor genen p19Arf en Tp53, bekende transcriptionele 
targets van het BCL6 eiwit. In overeenstemming met deze bevindingen zorgt geforceerde 
expressie van BCL6 in hematopoiëtische voorloper cellen voor langduriger prolongatie 
van voorlopercellen. Bovendien leidt het verlies van BTG1, gecombineerd met ETV6-
RUNX1, in NALM6 cellen in een toename van BCL6 expressie. Door middel van 
co-immunoprecipitatie hebben wij vervolgens aangetoond dat PRMT1 gerecruteerd 
wordt naar het ETV6-RUNX1 complex, terwijl deze interactie niet kan plaatsvinden 
in afwezigheid van Btg1. Dit toont aan dat Btg1 nodig is voor de interactie tussen 
PRMT1 en ETV6-RUNX1. Hoe een verlies van deze interacties aanleiding geeft tot 
leukemische transformatie is vooralsnog onbekend.
BTG1 is een mogelijk “tumorsuppressor gen”, omdat een verlies van mRNA 
expressie of functie wordt gevonden bij verschillende vormen van kanker (Hoofdstuk 
1). Onze bevinding dat verlies van Btg1 ETV6-RUNX1-geïnduceerde prolongatie van 
vroege lymfoïde voorlopercellen versterkt, is in overeenstemming met een functie 
als tumorsuppressor (Hoofdstuk 5). Daarnaast komen BTG1 deleties vaak voor in 
combinatie met andere genetische afwijkingen in voorloper B-cel ALL, zoals IKZF1 
gendeleties. In Hoofdstuk 6 laten wij zien dat een verlies van een kopie van BTG1 vaker 
voorkomt in voorloper B-cel ALL met IKZF1 deleties. Daarnaast is het gecombineerde 
verlies van deze genen geassocieerd met een opvallend lage ziektevrije overleving en 
een hoog risico op het krijgen van een recidief. Bovendien tonen we aan dat Ikzf1+/- 
muizen versneld T-cel leukemie krijgen bij verlies van één of twee kopieën van het 
Btg1 gen. Deze data leveren in vivo bewijs dat Btg1 functioneert als een leukemie 
suppressorgen en samen met verlies van het Ikzf1 aanleiding geeft tot het ontstaan 
van leukemie.
Naast BTG1 wordt ook verstoorde regulatie van de tumorsuppressor BTG2 
waargenomen in solide tumoren, waarbij missense mutaties gevonden zijn in B-cel 
lymfomen (Hoofdstuk 1). Onze resultaten tonen aan dat net als Btg1-deficiënte muizen, 
Btg2-/- en ook de Btg1-/-;Btg2-/- muizen T-cel leukemie krijgen, maar met een lage 
incidentie en na een lange latentietijd. Verder hebben wij geen aanwijzingen gevonden 
voor coöperatie tussen beide genen tijdens leukemie ontwikkeling.
Een aantal genen betrokken bij hematologische maligniteiten zijn ook betrokken bij 
de ontwikkeling van het skelet, zoals Hox en polycomb groep (PcG) genen. Eerder 
is al aangetoond dat verlies van Btg2 aanleiding geeft tot posterior homeotische 
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transformaties van de axiale wervels wat een gevolg lijkt te zijn van verstoorde BMP/
Smad signalering. In Hoofdstuk 7 hebben we niet alleen deze bevindingen kunnen 
bevestigen maar ook aangetoond dat Btg1-/- muizen een vergelijkbare homeotische 
transformatie laten zien. Dit is onder andere zichtbaar door een verandering van 
de zevende cervicale wervel (C7) in de eerste thoracale rib (T1), zoals eerder is 
beschreven voor Btg2-deficiënte muizen. In tegenstelling tot Btg2-/- muizen, laten 
Btg1-/- muizen geen posterior transformatie zien tussen de overgang van thoracale 
naar lumbale wervels. Aan de andere kant is er een gedeeltelijke transformatie van 
de zesde lumbale wervel (L6) naar de eerste sacrale wervel (S1) zichtbaar, die het 
meest uitgesproken is in muizen deficiënt voor zowel Btg1 als Btg2. Samenvattend 
tonen deze resultaten aan dat zowel Btg1 als Btg2 een rol vervullen bij het bepalen 
van de regionale identiteit van het axiale skelet.
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Dankwoord  
Wat voelt het bijzonder om dit dankwoord te schrijven. Het afsluitende hoofdstuk van dit 
boekje dat zeker door iedereen gelezen wordt. Het was een aantal jaren hard werken, 
maar ik ben ontzettend trots op het eindresultaat. Een ding is zeker “promoveren doe 
en kan  je niet alleen”. Er zijn zoveel mensen die hun bijdrage hebben geleverd in 
welke vorm dan ook, zonder jullie steun was dit boekje niet tot stand gekomen. Dus 
laat ik maar snel beginnen met een paar persoonlijke woorden.
Beste Peter, onze eerste ontmoeting was tijdens mijn eindstage bij de afdeling 
kinderoncologie. Ik vond het bijzonder dat jij als kinderoncoloog zo nauw betrokken 
was bij het onderzoek. De kliniek stond zo dichter bij het onderzoek. Na mijn stage kon 
ik blijven als promovendus bij laboratorium kinderoncologie en werd jij mijn promotor. 
De werkbesprekingen leerden mij vooral om kritisch data te beoordelen en te bedenken 
wat een logische volgende stap was. Jouw visie op mijn onderzoek heeft daar zeker 
een bijdrage aan geleverd. Dank je wel voor alle input die je hebt gegeven tijdens 
mijn onderzoek en bij het schrijven van dit boekje. 
Het begon allemaal in 2008, ik was op zoek naar een plek voor mijn 2de masterstage. 
Op advies van Blanca kwam ik bij jou, Frank, op het laboratorium kinderoncologie 
terecht. Het projectvoorstel en de groep spraken mij direct aan en ik was dan ook 
jullie 1ste stagaire. Direct na mijn stage ben ik in januari 2009 begonnen aan mijn 
promotietraject bij jou op de afdeling. In deze jaren heb ik veel mogen leren van jouw 
kennis en gaf je vaak goede feedback, ik wil je daarvoor bedanken. Het project was 
uitdagend omdat het veel muizenstudies betrof. Het was veelal vallen en weer opstaan, 
maar als ik terug kijk op wat we bereikt hebben, mogen we daar zeker trots op zijn. 
Nu is het boekje af en kan ik mijn promotietraject echt afsluiten. Dat was zonder jouw 
adviezen en steun absoluut niet gelukt. Ik wil je bedanken voor de fijne samenwerking, 
ik heb altijd met veel plezier in je lab gewerkt.
Blanca, ik ontmoette jou eerst tijdens mijn stage bij de afdeling Moleculaire Biologie, 
waar jij mij tipte om stage te gaan lopen bij de afdeling kinderoncologie. Toen ik eenmaal 
begonnen was aan mijn promotietraject, kwam jij een jaar later bij het laboratorium 
voor kinderoncologie werken. Het was ontzettend fijn dat jij mij kon ondersteunen met 
de muisexperimenten, gezien jij daar veel ervaring mee had. Jij werd dan ook snel 
benoemd als mijn co-promotor. Ik heb ontzettend veel geleerd, zowel theoretisch als op 
het lab, maar soms krijg ik nog het gevoel dat ik maar 5% weet van al die kennis die jij 
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bezit, dus voorlopig ben ik nog niet klaar met leren. We hebben de onderzoeken weten 
te vertalen in mooie papers en uiteindelijk dit boekje, waar jij zeker een belangrijke 
bijdrage aan hebt geleverd. Blanca, bedankt voor de fijne samenwerking en alle input 
en steun die jij mij gegeven hebt tijdens het promotietraject. 
Hoe moet je dankbaarheid in woorden uitdrukken…dit boekje was er niet geweest 
zonder jullie bijdrage Liesbeth en Dorette. Ik ben dan ook erg trots dat jullie mijn 
paranimfen willen zijn. De afgelopen jaren hebben we veel samengewerkt om de 
hoofdstukken in dit boekje compleet te maken. Zelfs toen ik weg was, hebben jullie nog 
de laatste experimenten uitgevoerd zodat de papers gepubliceerd konden worden. Ik ben 
daar enorm dankbaar voor. De afgelopen jaren heb ik met veel plezier gewerkt, mede 
door de fijne samenwerking met jullie. We maakten lange dagen en de experimenten 
eisten vooral veel geduld. Maar ondanks dat, stonden jullie altijd weer klaar om mij te 
helpen (ik besef heel goed dat ik een luxe positie had tijdens mijn promotie). Zelfs op 
en neer naar de boerderij in Overasselt om onze muizen te halen was geen probleem 
voor jou Liesbeth, zodat we toch verder konden met onze experimenten. Bedankt 
voor jullie steun, hulp en de gezelligheid tijdens mijn promotie, jullie hebben een zeer 
belangrijke bijdrage aan dit boekje geleverd. 
Ook al zat het niet altijd mee in het onderzoek, ik ging met plezier weer naar het 
werk. De werksfeer was altijd top, dank jullie wel LKO collega’s Laurens, Yuni, Marc, 
Arthur, Jeroen, Hanneke en Rene voor de fijne samenwerking en jullie bijdrage in 
welke vorm dan ook. Laurens dank je voor de Bever koopavonden, deze waren ook 
zeer informatief en nuttig! Daarnaast wil ik ook graag de oudcollega’s Marloes, Jørn, 
Joost, Karin, Ricardo, Melanie bedanken voor de gezellige tijd op het lab. 
Tijdens mijn onderzoek heb ik veel samengewerkt met het CDL in Nijmegen en 
Overasselt daarom wil ik graag iedereen bedanken voor de prettige samenwerking. 
Ik heb ontzettend veel van jullie geleerd. Daarnaast wil ik ook WIL research bedanken 
voor hun expertise bij de analyse van de skeletafwijkingen in onze muismodellen.  
Verder dank ik de stagiaires, Marjolein, Elke-Joan en Mylene die meegewerkt hebben 
aan dit promotieonderzoek. Misschien is niet al jullie werk in dit boekje beland maar 
dat wil niet zeggen dat jullie geen belangrijke bijdrage hebben geleverd. Ik wens jullie 
heel veel succes met jullie promotie en carrière. We zien of spreken elkaar vast nog 
wel eens en Mylene we zetten de samenwerking voort!
Beste kamergenoten Stefan, Daan, Stan, Stefanie, Kirsten, Aldert, Job en Frederick 
het was ontzettend gezellig om als LKO’er met jullie het kantoortje te delen. Het was 
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er altijd prima werken, we hadden leuke gesprekken en soms konden we heerlijk 
klagen over onze PhD. Bedankt voor deze gezellige periode!
Ook dank aan alle collega’s van het LKI voor de prettige samenwerking en jullie hulp, 
de jaren zijn voorbij gevlogen. Fred, dank je wel voor je hulp met de muisexperimenten 
het skeletverhaal is een mooi paper geworden. Ada, jouw bijdrage aan dit boekje is 
bijzonder groot want zonder jouw inzet zijn we nergens. Dank je voor de fijne jaren. 
Ik wens je heel veel sterkte de komende tijd, hopelijk kom je de ziekte snel te boven.
Gezien ik alweer 2 jaar werkzaam ben op de afdeling Moleculaire Biologie wil ik ook 
graag mijn nieuwe collega’s bedanken. Joost, dank je wel voor de kans dat ik nu aan 
volwassenleukemie mag werken en je geduld en begrip betreffende mijn promotie, 
het is nu echt klaar. Dear group members, in particular Koen and Amit, thank you for 
helping me out with the bioinformatic analysis and new techniques. U-members, Tanya 
and Cheng, thank you for your support and the nice conversations we have during 
the day. I would like to thank all colleagues of the three departments for the nice and 
friendly working atmosphere. 
Lieve vrienden, Jurjen, Inge, Harald, Laura, Suzan, Gerben, Maartje, Stefan, Marleen, 
Nick, Marijke, Davey en Jolanda zonder jullie steun en begrip had ik het echt niet gered 
(jullie hebben een zeer belangrijke bijdrage aan dit boekje geleverd). Ik kon altijd mijn 
hart bij jullie luchten en het was fijn een luisterend oor te hebben. We hebben samen 
al heel veel meegemaakt en hopelijk gaan we nog heel veel leuke uitstapjes maken. 
Ik heb in ieder geval weer tijd in de weekenden, geen promotiewerk meer voor mij! 
En vanaf oktober kan ik ook doordeweeks een keer op de koffie komen, dat lijkt me 
namelijk erg gezellig!
Beste schoonouders, Jeroen en Adriette graag wil ik jullie bedanken voor jullie 
gezelligheid en steun de afgelopen jaren!  
Lieve oma, bij ieder bezoek vroeg u altijd aan mij wanneer het feestje ging komen, 
een goede motivatie om mijn promotie af te ronden, maar helaas kunt u dit niet meer 
meemaken. Dank u wel voor alle fijne jaren.
En dan nog mijn ouders, lieve papa en mama, zonder jullie steun en begrip had 
ik het zeker niet gered. Het was voor jullie soms moeilijk voor te stellen waarom het 
allemaal zo lang duurde, maar ondanks dat bleven jullie mij motiveren om uiteindelijk 
mijn promotie af te ronden (ik neem aan dat jullie dit boekje wel helemaal gelezen 
hebben). Tja en het blijkt wel dat ik niet heel erg goed ben in plannen! Sanneke, 
zonder jou had dit boekje geen kaft, ik ben er ontzettend trots op dat je dit voor mij 
hebt willen doen. Nu heb ik echt weer meer tijd voor Roos en Cas, het logeerbed is 
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inmiddels opgebouwd! En natuurlijk Roel, dank je dat je hebt mee willen denken over 
een metafoor voor mijn lekenpraatje. Lieve Roos en Cas, jullie zijn twee toppers die 
soms wat te weinig aandacht hebben gekregen doordat ik altijd moest werken. De 
logeerkamer is klaar dus kom maar snel een keer logeren! Dank jullie wel voor de 
super mooie “bijtjes” die jullie hebben getekend op dit boekje. 
Lieve Johan, het laatste dankwoord is voor jou omdat jij dit het meest verdient. Door 
jou heb ik het volgehouden om mijn promotie af te ronden. Ik geloof dat je het woordje 
“promotie” niet meer wil horen, maar dat komt goed, dat beloof ik. Je bent een enorme 
steun voor me geweest de afgelopen jaren, het was altijd weer fijn om na het werk 
naar huis te gaan. Ik heb erg genoten van de mooie reizen die we gemaakt hebben en 
hopelijk komen er nog veel meer van die mooie vakanties bij. Het afgelopen jaar was 
behoorlijk zwaar maar we hebben gezegd dat we van 2016 een mooi jaar gaan maken 
en dat dit ons gaat lukken! We hebben eindelijk de sleutel van ons nieuwe huis, ik krijg 
te horen dat ik mag promoveren en worden we papa en mama in oktober. Ik geniet 
van al deze mooie momenten samen met jou. Je bent geweldig…..Love you HDXXX
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Esther Jozefina Henrica Tijchon werd op 12 november 1984 geboren te Wijchen. Na 
het behalen van haar HAVO diploma aan het Maaswaal College in Wijchen, startte zij 
in 2002 met de opleiding Biologie en Medisch Laboratorium Onderzoek aan het Hoger 
Laboratorium Onderwijs van de Hogeschool van Arnhem en Nijmegen. Tijdens deze 
studie liep zij stage bij de afdeling Fungal Genomics van de Wageningen Universiteit 
en bij de afdeling Synthetic Biology van de ETH in Zürich (Zwitserland). Na het behalen 
van haar bachelorsdiploma in 2006 startte zij met de masteropleiding Medische Biologie 
aan de Radboud Universiteit te Nijmegen. Tijdens deze studie liep zij stage bij de 
afdeling Moleculaire Biologie van de Radboud Universiteit Nijmegen (dr. A. Costessi 
en prof. dr. H.G. Stunnenberg) en op het Laboratorium voor Kinderoncologie van het 
Radboudumc te Nijmegen (dr. J.C. van Galen en dr. F.N. van Leeuwen). Na het behalen 
van haar masterdiploma in 2009, startte zij als promovendus op het Laboratorium 
voor Kinderoncologie van het Radboudumc te Nijmegen. Onder begeleiding van dr. 
F.N. van Leeuwen, dr. B. Scheijen en prof. dr. P.M. Hoogerbrugge werkte zij aan het 
promotieonderzoek waarvan de resultaten zijn beschreven in dit proefschrift. Vanaf 
september 2014 werkt zij als Post-doc aan de moleculaire mechanismen die betrokken 
zijn bij het ontstaan van acute myeloïde leukemie. Dit onderzoek wordt uitgevoerd bij 
de afdeling Moleculaire Biologie onder leiding van dr. J. Martens, Radboud Universiteit 
te Nijmegen. 
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